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Prostate cancer
In developed countries, prostate cancer is the most common malignancy in men and a 
major cause of cancer-related death (1). In The Netherlands 93 new cases per 100,000 
men were detected in 2003 (The Netherlands Cancer Registry). Prostate cancer inci-
dence varies between different ethnic groups. African-American men have the highest 
incidence rates, followed by Caucasian-American men and men in Western Europe 
and Australia. The lowest incidence rates are observed in the Asian population. These 
differences may be explained by environmental and dietary factors. However, genetic 
factors, i.e. polymorphisms in genes that can predispose to cancer, may also play a role 
in prostate cancer development. A major risk factor of prostate cancer is age, since it is 
predominantly a disease of the senior adult (i.e. men over the age of 65 years). Below the 
age of 55 the incidence of prostate cancer is very low (2, 3).  
During recent years our knowledge of the molecular mechanism underlying prostate can-
cer development and progression has rapidly increased. However, there are still many gaps 
in our knowledge that remain to be filled. Genetic analyses of different stages of prostate 
cancer will increase our knowledge of the molecular background of the development and 
progression of prostate cancer. The identification of novel biomarkers will help to predict the 
clinical course of the disease. Furthermore, a better understanding of the molecular mecha-
nism of prostate tumorigenesis is essential for development of novel targeted therapies.
Androgen signalling mediated by the androgen receptor (AR) is essential for devel-
opment and maintenance of the normal prostate (4). The majority of prostate cancers 
also depend on a functional AR. The AR is a member of the steroid hormone receptor 
transcription factor family. It is activated by binding of androgens (testosterone or 
dihydrotestosterone (DHT)). The AR regulates the transcription of many target genes 
by binding to androgen response elements in the promoter or enhancer regions. The 
AR recruits specific cofactors to either activate or repress a specific target gene. In the 
normal prostate there is a balance of expression of androgen-regulated genes involved 
in differentiation, proliferation, function and survival. This balance is moved towards 
proliferation and survival in prostate cancer cells (Figure 1).
Hoofd tuk 1
Figuur 1
Figure 1. Model of androgen receptor function in the normal adult prostate (A) and in prostate cancer (B)
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A well-known androgen-regulated and prostate-specific gene is Prostate Specific 
Antigen (PSA). The PSA protein is secreted by the prostate. In prostate cancer patients 
PSA levels can be measured in serum. Elevated serum PSA levels are a first indication 
of prostate cancer, however, elevated PSA might also be caused by benign prostatic 
hyperplasia (BPH) or prostatitis. Introduction of the PSA test in the 1980’s has increased 
prostate cancer incidence considerably. However, a proportion of the detected cancers 
will never become life threatening. Consecutive procedures currently used for prostate 
cancer diagnosis include:  serum PSA detection, digital rectal examination, transrectal 
ultrasonography and histopathological examination of biopsy specimens (5). The histo-
logical grade, the tumour stage and PSA level at diagnosis are used to predict prostate 
cancer progression. Yet, at present, it is impossible to accurately discriminate between 
patients with clinically significant and more indolent disease (6). 
In Figure 2, a schematic representation of the different stages of prostate cancer 
development and progression is depicted. Prostatic intra-epithelial neoplasia (PIN) is 
considered to represent the precursor lesion of prostate cancer, because similar genetic 
alterations are found both in PIN and in primary prostate cancer.
Tumours confined to the prostate can either be treated by surgical removal of the pros-
tate or by local radiation therapy. A third option is active surveillance, i.e. a patient is not 
treated, but instead is closely monitored for disease progression. Because the AR plays a 
critical role in overall function of the normal prostate as well as in growth and survival of 
malignant prostate cells, primary therapy of metastatic disease is androgen-deprivation 
(endocrine therapy). This therapy is based on inhibition of AR transcriptional activity, by 
either inhibiting androgen production or by blocking AR function with anti-androgens, 
such as hydroxy-flutamide or bicalutamide. Initially endocrine therapy results in regres-
sion of the tumour. However, eventually all tumours become resistant to hormonal abla-
tion therapy and progress to androgen-independent disease. In most (> 80%) hormone 
refractory tumours the AR is still expressed and still plays a role in the disease (7). In 
Figuur 2
Figure 2. Overview of prostate cancer development and progression.
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part of these tumours the AR gene is amplified and the protein over expressed (8). In a 
small percentage the AR is mutated (9), turning antagonists into agonists. Other factors 
that may contribute to an active AR in endocrine resistant prostate cancers are over 
expression of cofactors or inhibition of corepressors (10). Recently, evidence has been 
provided that expression of enzymes that convert adrenal androgens to DHT or even 
synthesize DHT from cholesterol, is induced in prostate cancer (11). In a small propor-
tion of prostate cancers the AR is bypassed (7). In these tumours other pathways have 
taken over the function of the AR pathway. Currently, there are no curative therapies for 
endocrine therapy resistant disease.
Prostate cancer Genetics
It is generally accepted that tumours develop from a single cell that acquires a genetic 
or epigenetic alteration, however, the process from a normal cell to a cancer cell involves 
a multi-step model, which is driven by the accumulation of genetic and epigenetic 
changes (12).
Like in many other tumours, a small proportion (5-10%) of prostate cancer is thought 
to be of hereditary origin (13, 14). Hereditary prostate cancer is associated with an early 
onset (younger than 55 years) of the disease and family history of prostate cancer preva-
lence. For identifying genes involved in hereditary cancer high-throughput genotyping 
techniques and linkage analysis of cancer-prone families are being used to fine map the 
location of familial cancer genes.
Genome-wide linkage analyses of prostate cancer families have implicated many loci, 
however, no definitive gene that causes a significant proportion of the familial prostate 
cancers has been identified. Identified susceptibility loci, which are associated with 
hereditary prostate cancer are: hereditary prostate cancer 1 (HPC1) on chromosome 
1q24-q25 (15), predisposing to prostate cancer (PCaP) on chromosome 1q42.2-q43 
(16), CAPB on chromosome 1p36 (17), a locus on chromosome 8p22-23 (18), HPC2 on 
chromosome 17p11 (19), HPC20 on chromosome 20q13 (20), and HPCX on chromosome 
Xq27-q28 (21). For these loci only a few candidate genes have been identified so far. 
Ribonuclease L (RNASEL) has been identified as the candidate gene of the HPC1 locus 
(22).  RNASEL mediates the antiviral and apoptotic activities of interferons. Inactivating 
mutations have been detected in a few prostate cancer families. For the HPC2 locus 
ELAC2 has been identified as the candidate gene (19). In two families mutations affect-
ing the coding region have been detected. 
More recently, genome-wide SNP association studies of individuals with familial 
prostate cancer and a study on 23,000 Icelanders identified multiple prostate cancer 
susceptibility loci. These loci include regions on chromosome 8q24, 2p15, Xp11.22 and 
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17q (23-25). Proposed susceptibility genes, based on genetic variations, are MSR1 (26), 
BRCA2 (27, 28), PALB2 (29), CHEK2 (30), and more recently HNF1B, CTBP2, MSMB, LMTK2 
and JAZF1 (23, 25). So, to date multiple loci and genes with moderate effects associated 
with susceptibility to prostate cancer have been identified, but none account for a large 
proportion of susceptibility to the disease.
A standard genetic strategy to identify novel tumour suppressor genes and oncogenes 
involved in sporadic tumours starts with a genome-wide screen of tumour samples for 
DNA loss (possible location of a tumour suppressor gene) or DNA gain (possible location 
of an oncogene). Next, the genes in the lost or gained chromosomal regions are identi-
fied. This is followed by mRNA expression analysis, mutation analysis of candidate genes 
and functional analysis of selected candidate gene(s).
Molecular techniques used to identify genome-wide genomic alterations over the last 
decades are:  karyotyping, multicolour spectral karyotyping (SKY), allelotype analysis, 
fluorescence in situ hybridisation (FISH), chromosome comparative genomic hybridisa-
tion (CGH), and more recently genome-wide array CGH. 
A powerful tool for detailed genome-wide screening is CGH. In CGH, labelled tumour 
and reference (normal) DNAs are hybridised to normal human metaphase chromosomes 
to detect DNA gains and losses (31).  The resolution of chromosome CGH is limited 
(~5-10 Mbp) therefore more sophisticated hybridisation targets have been developed 
(32). DNA sequences (BACs, oligonucleotides or oligonucleotides containing SNPs) are 
spotted in an array on slides to which the labelled tumour and/or reference DNA can be 
hybridised (array CGH). Depending on the distance between the DNA sequences a very 
high resolution can be obtained. Other advantages of this technique are that it maps 
losses and gains more precisely and homozygous deletions and high level amplifica-
tions can be identified (33, 34). Oligo arrays containing SNPs have an extra advantage in 
that they also provide allelotypic information. These SNP arrays are nowadays used to 
identify detailed genome-wide genetic alterations in tumour samples (35, 36).
Genome-wide search for chromosomal alterations in sporadic prostate cancer resulted 
in the identification of several common regions of DNA loss or DNA gain. In sporadic 
prostate cancer most frequent regions of DNA loss are part of chromosome arm 6q, 8p, 
13q and 16q, and less frequently lost regions are 2q, 5q, 10q, 17p, and 18q. Most fre-
quent regions of DNA gain are on chromosomes 7 and 8q, less frequently gained regions 
involve: 3q, 17q and Xq (37, 38). However, no clear classical tumour suppressor genes or 
oncogenes have been identified to date for most of these regions. A small region of loss 
is frequently found on chromosome 10q23 (see also Chapters 2 and 3). In this region the 
tumour suppressor gene PTEN (39, 40) is located, which will be described in more detail 
in the next section. Furthermore, we identified N-COR as a novel tumour suppressor 
gene located on chromosome 17p (Chapter 2). More recently, a small region of loss on 
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chromosome 21q was described. This interstitial deletion results in the recurrent gene 
fusion of TMPRSS2 to ERG (41), which will be described in more detail below.
PTEN in cancer
Germ line mutations of PTEN are found in Cowden syndrome, Lhermitte-Duclos disease 
and Bannayan-Zonana syndrome (42, 43). These rare diseases are autosomal dominant, 
familial cancer predisposition syndromes. They are characterized by multiple hamar-
tomas and predisposition to neoplasms of thyroid, breast and skin.
PTEN is most frequently inactivated in several sporadic human cancers including, 
gliobastomas, endometrial cancer, and prostate cancer, either by mutation, homozygous 
deletion or promoter methylation (44, 45). 
Loss of one PTEN allele without inactivation of the second allele is also found in pros-
tate cancer. This suggests that PTEN haplo-insufficiency plays a role in tumorigenesis. 
Loss of PTEN is detected, in 39-68% of primary prostate cancer samples and in 23% of 
PIN lesions (46, 47). Loss of one copy of the 10q region, where PTEN maps, might also be 
explained by the presence of a second tumour suppressor gene located nearby PTEN. We 
have screened 14 genes mapping in a ~3 Mbp region around PTEN for mRNA expression 
alterations in prostate cancer xenografts and cell lines (Chapter 3) (48). 
The frequency of complete PTEN inactivation reported in clinical prostate cancer is 
highly variable (49-55). This might partially be due to the different techniques used to 
detect complete inactivation of PTEN and to the different stages of disease analysed. 
The major mechanism of complete PTEN inactivation is by homozygous deletion. Most 
common point mutations produce a premature stop codon. Other frequent mutations 
are point mutations in the active site of the phosphatase domain of PTEN. Complete 
inactivation of PTEN is most often detected in metastatic prostate cancer, up to 60%, 
and less frequently in primary tumours, in ~15%. In prostate cancer PTEN is the most 
frequently mutated tumour suppressor gene found to date.
Function of PTEN
PTEN consists of nine exons encoding a 403 amino acid protein that functions as a lipid 
phosphatase and as a dual specific protein phosphatase. PTEN is a negative regulator 
of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, by dephosphorylating phos-
phatidylinositol (3,4,5)-trisphosphate (PIP3). In this way PTEN counteracts PI3K (Figure 
3). The PI3K/AKT pathway regulates signalling of multiple biological processes including 
cell survival, cell proliferation, cell growth, metabolism and migration. Activation of the 
PI3K/AKT pathway results in phosphorylation of AKT. AKT on its turn phosphorylates 
many substrates, including the pro-apoptotic proteins BAD and caspase-9, forkhead 
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transcription factors FOXO1, FOXO3A and FOXO4, cell cycle regulator MDM2, glycogen 
synthase kinase 3 (GSK-3), and mTOR (56, 57). 
Hyper-activation of AKT can not only be due to PTEN inactivation, but also be the result 
of oncogenic point mutations in PI3K (58). These mutations occur frequently in the 
kinase domain, the adjoining helical domain of the p110α subunit and the PH domain. 
Mutations are frequently detected in ovarian, breast, endometrial and colon cancer (59), 
however no mutations have been detected in prostate cancer (60). At low frequency, 
AKT1 is activated by mutation (E17K) (61) or overexpression. AKT1 mutations are de-
tected in breast, colon, ovarian, lung and prostate cancer (61-64). 
PTEN mouse cancer models
Several groups have analysed PTEN function in vivo by constitutive Pten inactivation or 
by generation of conditional Pten-deficient mice, using the Cre-LoxP system (65-70). Pten 
null mice are embryonically lethal and die at embryonal day 7-9.5. Pten+/- mice develop a 
broad range of tumours, including thyroid, mammary, endometrial and prostate cancers 
and T-cell lymphomas. This spectrum closely resembles the neoplasias developed in 
humans with PTEN mutations. 
To elucidate the role of PTEN in specific tumours, a series of conditional knock-out 
(Cre-LoxP system) mice have been generated, by using tissue-specific promoters to 
express the Cre-recombinase. For prostate tumorigenesis either the probasin promoter, 
the PSA promoter or the MMTV promoter have been used for prostate-specific knock-
out of Pten. Complete loss of Pten results in invasive prostate cancer, however, tumour 
latency differed between different mouse models, from 9-29 weeks to 10-14 months. 
This can be due to the different genetic background of mouse strains used or the differ-
ent promoters used to transcribe the Cre-recombinase. Depending on the mouse model 
used, homozygous deletion of Pten leads to metastatic prostate cancer. Heterozygous 
Figuur 3
Figure 3. PI3K/AKT signalling activates multiple pathways relevant to cancer.
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loss of Pten results in the development of hyperplasia and mPIN, with a latency of 12-16 
months. Progression to invasive cancer has not been detected in these mice. However, 
mono-allelic inactivation of Pten, in combination with Tp53 inactivation can induce 
prostate cancer (Korsten et al, unpublished).
recurrent ets Gene fusions in Prostate cancer
In 2005 Petrovics et al (71) reported frequent overexpression of the ETS transcription fac-
tor ERG mRNA in clinical prostate cancer (62% of 114 prostate cancer samples). They as-
sociated high levels of ERG expression with a favourable prognosis, based on longer PSA 
recurrence-free survival, lower pathological stage, well and moderately differentiated 
grade, and negative surgical margins status. Later that year, Tomlins et al (41) showed 
that ERG overexpression in prostate cancer was caused by a recurrent gene fusion of 
the TMPRSS2 gene to the ERG gene. In their first experiments they detected overexpres-
sion of ERG by a novel bioinformatics approach, denoted cancer outlier profile analysis 
(COPA). COPA was used to identify outlier profiles in gene-expression data sets, to search 
for genes with marked overexpression in a subset of samples. It successfully identified 
outlier profiles for genes in specific tumour types in which high-level gene amplification 
or gene rearrangement was known to occur, like ERBB2 in breast cancer and RUNX1T1 in 
leukaemia. ERG was scored as high outlier gene in several independent prostate cancer-
profiling studies. Actually, ERG is not a standard outlier, because it is overexpressed in a 
large proportion of prostate cancers.
An exon-walking quantitative PCR (QPCR) strategy of samples with ERG overexpres-
sion revealed overexpression of the last exons of ERG and not the first exons, suggestive 
for gene rearrangement. To characterize the 5’ end of the ERG transcripts, 5’ RNA ligase 
rapid amplification of cDNA ends (RLM-RACE) was performed. This led to the discovery 
of fusion of the first exon(s) of TMPRSS2 (transmembrane protease, serine 2) to ERG. TM-
PRSS2 is a prostate-specific and androgen-regulated gene (72) and ERG is a well-known 
oncogene. Thus, as a result of this fusion TMPRSS2 donates the prostate-specific and 
androgen-regulated transcription regulating sequences to the coding sequences of 
ERG, leading to altered overexpression of ERG.
TMPRSS2 and ERG are located in the same orientation on chromosome band 21q22, ~3 
Mbp apart (Figure 4). Array CGH and FISH analysis have shown that there are two mecha-
nisms for this gene fusion. In approximately 60% of tumour samples with TMPRSS2-ERG 
fusion transcripts the region between ERG and TMPRSS2 is lost. In the other samples with 
TMPRSS2-ERG fusion transcripts this region is retained, here the mechanism is a more 
complex genomic reallocation (73, 74). 
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Using COPA, ETV1 (41) and later, two other ETS family members, namely ETV4 (75) and 
ETV5 (76), have been discovered as outliers in prostate cancer samples. Further character-
ization showed that ETV1, ETV4 and ETV5 all are involved in gene fusions with TMPRSS2, 
but also with other genes. Overexpression of the ETS genes is mutually exclusive.
ETS transcription factors
The founding member of the ETS family, v-ets, was originally discovered as part of gag-
myb-ets fusion protein of the avian transforming retrovirus E26. This v-ets oncogene 
induces both erythroblastic and myeloblastic leukaemias in vivo. The ETS transcription 
factor family consists of ~30 family members, which is one of the largest families of 
transcriptional regulators (77, 78). All ETS proteins share an evolutionary conserved ETS 
domain. This 85 amino acid region forms the helix-turn-helix DNA binding domain, which 
recognises a central GGAA/T core consensus sequence (ETS binding site) in promoter 
regions of target genes. A second conserved domain is the pointed domain that is pres-
ent in a subset of ETS genes. This 65-85 amino acid helix-loop-helix domain functions in 
protein-protein interactions. Based on their structural composition and their homology 
in the ETS domain, ETS genes are divided into several subfamilies (Table 1). 
Besides the ETS domains and PNT domains, also activation and repression domains have 
been postulated in most ETS factors. For example the PEA3 subfamily has an N-terminal 
transactivation domain (79).
ETS proteins can function as transcription activators or repressors. They are known to 
play crucial roles in cellular proliferation, differentiation, apoptosis, tissue remodelling, 
angiogenesis, metastasis and transformation. To date, over 400 ETS target genes have 
been defined based upon the presence of ETS binding sites in their regulatory regions. 
Well-known ETS target genes are matrix metalloproteinases (MMPs) and uPA/uPAR. 
Deregulated expression patterns of ETS genes have been observed in leukaemias and 
solid tumours. Overexpression of wild type ETS genes, most commonly ETS1, ETS2, ETV4, 
Figuur 4
Figure 4. Schematic representation of chromosome 21q region. ERG and TMPRSS2 are indicated, the distance is in Mbp.
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and ETV1, is found in breast, colon, lung and prostate cancer. In general, overexpression 
of wild type ETS genes is associated with advanced stages of disease. 
Also, ETS genes are frequently involved in chromosomal translocations, resulting in fu-
sion proteins or in altered expression of the ETS gene. These ETS fusion genes have been 
detected in Ewing’s sarcoma and leukaemia, and more recently in prostate cancer. FLI1, 
ERG, ETV1, ETV4 and FEV are known to be involved in gene fusion in Ewing’s sarcomas 
(80). Fusion of the 5’ part of Ewing sarcoma breakpoint region 1 (EWSR1) to the 3’ part of 
an ETS family member (FLI1/ERG/ETV1/ETV4/FEV) is a hallmark of Ewing’s sarcoma. These 
gene fusions lead to the production of a fusion protein, linking the N-terminal region 
of EWSR1 to the ETS domain. The most frequent translocation is a fusion of EWSR1 to 
FLI1, detected in 90-95% of cases, followed by EWSR1-ERG (~5%). The other fusions are 
detected in less than 1% of cases. EWSR1-ETS fusions are mutually exclusive. EWSR1 is 
a ubiquitously expressed gene and the first exons of EWSR1 encode for a strong trans-
activation domain. The fusion proteins modulate the expression of target genes in a 
sequence-specific manner that is determined by the ETS component.
In leukaemias many different fusion genes involving the ETS gene TEL have been 
described (81). Three types of TEL rearrangements can be discriminated. 1) TEL is jux-
taposed to several tyrosine kinase genes, resulting in chimeric proteins. These proteins 
often possess the N-terminal PNT domain of TEL and the intact protein tyrosine kinase 
domains from the partner proteins. 2) The N-terminal PNT domain and the central re-
pressor domain of TEL is linked to the nearly complete AML1 protein (82). 3) In MN1-TEL 
fusions, the N-terminal region of MN1 is juxtaposed to the C-terminal region, including 
the ETS domain, of TEL (83, 84). In several types of myeloid leukaemia fusion of TLS/FUS 
Table 1. Overview of ETS subfamilies with schematic protein structure of the members. Pointed domains (PNT) and ETS 
domains are indicated.
ets (ets1, ets2)
erG (erG, fLi1)
feV 
teL (etV6 (teL), teL2)
GaBPα
Pea3 (Pea3 (etV4), etV1 (er81), 
etV5 (erm), er71)
eLf (eLf1, eLf2, eLf4)
ese (eLf3, ese2/3)
PDef
sPi (Pu.1, spi-B, spi-c)
erf (mets, erf)
tcf (eLK1, saP1, net, netb)
 PNT ETS
 PNT  ETS
 ETS
 ETS PNT
 PNT  ETS
 ETS
 ETS
 PNT  ETS
 PNT  ETS
 ETS
 ETS
 ETS
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to ERG has been found. Here, the weakened transcriptional activity, compared to wild 
type ERG, is believed to play a role in transformation of cells (85, 86).
ETS gene fusions in prostate cancer
Besides the initial discovery of TMPRSS2-ERG fusion gene in prostate cancer, several other 
ETS fusion genes have been detected, as stated above. Table 2 shows an overview of all 
ETS fusion genes known in prostate cancer to date. TMPRSS2 is not only rearranged with 
ERG, but also with ETV1, ETV4 and ETV5. Moreover, whereas ERG is exclusively rearranged 
with TMPRSS2, ETV1, ETV4 and ETV5 all have multiple fusion partners (Table 2) (41, 75, 76, 
87-91).  The most likely explanation for the high frequency of ERG to TMPRSS2 fusion is 
that both TMPRSS2 and ERG are located on chromosome 21q in close proximity (Figure 
3), whereas ETV1 is located on 7p, ETV4 on 17q and ETV5 on 3q. The fusion partners of 
ETV1, ETV4 and ETV5 are located on different chromosomes (Table 2). As shown in Table 
2, none of the other fusion genes is detected as frequently as the TMPRSS2-ERG fusion 
gene. The TMPRSS2-ERG fusion gene is detected in 40-70% of clinical prostate cancer 
samples and in ~20% of high-grade PIN lesions (HGPIN) (92, 93). 
Table 2. Overview of 5’ and 3’ fusion partners in prostate cancer
5’ fusion partner Prostate-specific Androgen-regulated 3’ fusion partner Present
TMPRSS2 (chr 21q) + + ERG (chr 21q) ~60%
TMPRSS2 (chr 21q) + + ETV1 (chr 7p) <1%
FOXP1 (chr 3p) ND ND <1%
EST14 (chr 14q) + + <1%
HERVK17 (chr 17p) + + <1%
SLC45A3 (chr 1q) + + <1%
HERV-K_22q11.23 + + <1%
C15orf21 (chr 15q) + + (down) <1%
HNRPA2B1 (chr 7p) - - <1%
ACSL3 (chr 2q) ND + <1%
Chr 14q13.3-q21.1* + + ETV1 (chr 7p) <1%
TMPRSS2 (chr 21q) + + ETV4 (chr 17q) <1%
KLK2 (chr 19p) + + <1%
CANT1 (chr 17q) + + <1%
DDX5 (chr 17q) - - <1%
TMPRSS2 (chr 21q) + + ETV5 (chr 3q) <1%
SLC45A3 (chr 1q) + + <1%
* Full length ETV1     
ND: not determined
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Like TMPRSS2, most other fusion partners (EST14, HERVK17, SLC45A3, HERV-K_22q11.23, 
KLK2, and CANT1) have a prostate-specific and androgen-upregulated expression 
pattern. One gene (C15orf21) has a prostate-specific and androgen-downregulated 
expression pattern, HNRPA2B1 and DDX5 have a ubiquitously expression pattern and are 
not regulated by androgens. The recently identified ETV1 fusion partner ACSL3 is also a 
strongly androgen-upregulated gene (89). Tissue-specificity of this gene has not been 
determined yet.
Noteworthy, two of the ETV1 fusion partners involve endogenous retroviral repeat 
sequences of the HERVK subfamily (HERVK17 and HERV-K_22q11.23). Retroviral repeat 
sequences comprise ~8% of the human genome. They are divided over many subfami-
lies, one of these subfamilies is the HERVK family (94, 95). Some members of the HERVK 
retroviral subfamily possess active promoters, and previously one similar gene fusion, 
HERVK19-FGFR1, has been reported in a myeloproliferative disorder (96). This makes the 
finding of particular interest for further investigations of the role of apparent defective 
retroviral sequences in prostate tumorigenesis. 
Two prostate cancer cell lines, LNCaP and MDA Pca 2b, have a rearrangement of the 
whole ETV1 locus to the same region on chromosome 14q13.3-q21.1. In this region two 
known genes are located, MIPOL1 and FOXA1. FOXA1 has a prostate-specific expression 
pattern, and MIPOL1 is ubiquitously expressed. Whether these genes are androgen-
regulated is less clear. In LNCaP cells the whole ETV1 locus is integrated in the last intron 
of MIPOL1. MDA Pca 2b cell line harbours a (7;14) chromosomal translocation. FISH 
analysis using probes on ETV1 and on the chromosome 14q13.3-q21.1 region showed 
a fusion of these loci in the MDA Pca 2b cell line. Interestingly, the ETV1 fusion partner 
EST14 is located in the same region. EST14 is a two-exon gene that flanks MIPOL1 (Figure 
5). Like FOXA1, EST14 also has a prostate-specific expression pattern. Moreover, EST14 
is weakly androgen-regulated. Thus, this unique region is both involved in ETV1 gene 
fusions and in integrations and rearrangements of full length ETV1. Further investigation 
of the chromatin structure of this region may help to elucidate the mechanism of gene 
rearrangements in prostate cancer.
36.7 37.3FOXA1
EST14
MIPOL1
Chr 14
C14orf25
Figuur 5
Figure 5. Schematic representation of genomic region on chromosome 14q13.3-q21.1. Distance from the top of chromosome is 
indicated in Mbp. Grey arrows indicate direction of transcription, black arrows indicate positions of ETV1 integrations.
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Clinical association with TMPRSS2-ERG fusion status
TMPRSS2-ERG fusion transcripts are the most frequently, up to 70%, detected fusion 
transcripts in clinical prostate cancer. To date, many different splice variants of the 
TMPRSS2-ERG fusion gene have been described. Almost all of these fusion transcripts 
encode N-truncated ERG proteins, however, sometimes a small part of TMPRSS2 is pres-
ent in a TMPRSS2-ERG chimeric protein. The most frequently detected splice variant is 
a fusion of TMPRRS2 exon 1 to ERG exon 4, followed by a fusion of TMPRSS2 exon 0, 
an alternative first exon of TMPRSS2, located 4 kbp upstream of exon 1, to ERG exon 4 
and TMPRSS2 exon 1 and 2 to ERG exon 4. Other splice variants were identified at low 
frequency. Most splice variants involve multiple exons of TMPRSS2 fused to exon 4 of 
ERG or TMPRSS2 exon 1 fused to different exons of ERG. Of note, multiple splice variants 
can be detected in a single sample.
Several groups have tried to associate TMPRSS2-ERG fusion status with clinical data. 
The most relevant studies are listed in Table 3. Demichelis et al (97) observed in 15% 
Table 3. Studies that reported on the correlation between TMPRRS2-ERG fusion gene and clinical outcome of prostate 
cancer.
a. cancer-specific (css) and overall survival (os)
reference n samples technique TMPRSS2-ERG follow-up 
(median)
fusion-positive versus 
fusion-negative cases
Attard et al
(104)
445 TUR-P /
Biopsies
FISH 30% 7.5 yr Shorter CSS and OS 
(multivariate level)
Demichelis et 
al (96)
111 TUR-P /
prostatectomy
FISH 15% 9.1 yr Shorter CSS (univariate level)
B. Biochemical progression-free survival (Bfs)
Petrovics et 
al (71)
114 RP Q-PCR 62%* n.s. Longer BFS (univariate level)
Saramäki et al 
(102)
150 RP FISH 33% 5.5 yr Longer BFS (multivariate 
level)
Nam et al (97) 165 RP RT-PCR 42% 1.7 yr Shorter BFS (multivariate 
level)
Perner et al (74) 118 RP FISH 49% n.s. **
Wang et al 
(105)
59 RP RT-PCR 59% n.s. ***
Hermans et al 
(chapter 5)
67 RP Q-PCR 66% 10.2 yr No difference in BFS ****
* ERG overexpression
** Higher recurrence rate, no survival analysis
*** More early recurrences in patients with variant TMPRSS2-ERG fusion, no survival analysis
**** Longer BFS for TMPRSS2(exon0)-ERG (multivariate level)
N: number of patients
n.s.: not specified
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of the tumours from a watchful waiting cohort of 111 men with localized prostate 
cancer TMPRSS2-ERG fusion by FISH analysis. They associate TMPRSS2-ERG fusion with a 
higher frequency of metastasis and cancer-specific death. However, genefusion-positive 
samples have higher Gleason scores, and after adjusting for Gleason score, the outcome 
is no longer significant. Nam et al showed, in a cohort of 165 patients, association of 
TMPRSS2-ERG fusion with earlier biochemical recurrence after radical prostatectomy 
(98). This was independent of stage and grade, however median follow-up was short 
(20 months). 
Most groups do not find a strong association with prognostic factors (Gleason score, 
pathological stage, surgical margins) or clinical outcome (99-102). Initially, before the 
discovery of the TMPRSS2-ERG gene fusions, Petrovics et al (71) associated prostate can-
cers overexpressing ERG mRNA with a favourable prognosis (longer PSA recurrence-free 
survival, negative surgical margins, lower pathological stage and well and moderate dif-
ferentiation grade). Two other groups recently made similar observations for TMPRSS2-
ERG fusion positive cancers (103, 104). 
Other studies reported on the association of clinical data with specific characteristics of 
TMPRSS2-ERG gene rearrangements or TMPRSS2-ERG fusion transcript splice variants. In 
a study of a watchful waiting cohort of 445 patients, a small subset of the cancers shows 
a duplication of TMPRSS2-ERG in combination with deletion of 5’ ERG (2+Edel) (105). This 
genomic alteration is associated with poor cancer-specific survival and worse overall 
survival. In this study, two+Edel seems a predictor of poor clinical outcome, independent 
of Gleason score, baseline PSA and age as determined by multivariate analysis. No differ-
ence in survival was observed between patients with fusion gene negative tumours and 
patients with tumours containing TMPRSS2-ERG fusion with translocation as mechanism 
of rearrangement. In a high-risk cohort of 118 patients (50% Gleason score >7, 49% 
pT3b tumours, 72% positive surgical margins and 56% node-positive disease), Perner 
et al (74), report presence of TMPRSS2-ERG fusion in 49% of the samples as detected by 
FISH. For patients with TMPRSS2-ERG fusion by interstitial deletion a trend for higher PSA 
recurrence rate was observed as compared to patients without gene fusion. In a cohort 
of 59 patients, Wang et al (106) observe that presence of TMPRSS2(exon 2)-ERG(exon 
4) fusion transcripts was associated with aggressive disease. Also, they describe that 
splice variants of TMPRSS2 exon 1 to either ERG exon 2 or exon 3 are associated with 
seminal vesicle invasion, which is correlated with poor clinical outcome after radical 
prostatectomy. All these splice variants contain a native translation initiation codon (in 
TMPRSS2 exon 2 or ERG exon 3) as translation start codon. In our study (chapter 5) we 
observed no association of prognostic factors with TMPRSS2-ERG gene fusion. Recently, 
a novel TMPRSS2-ERG fusion transcript, starting at TMPRSS2 exon 0, has been described 
(99). We have separated the fusion gene-positive group in samples with expression of 
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TMPRSS2(exon 0)-ERG transcripts or without expression of these transcripts. This results in 
an association of longer time to biochemical recurrence in the group with TMPRSS2(exon 
0)-ERG expression. Moreover, multivariate analysis identifies expression of TMPRSS2(exon 
0)-ERG as an independent predictor of longer biochemical recurrence-free survival after 
radical prostatectomy. More extensive studies, with larger patient cohorts and long 
clinical follow up, are needed to help resolve the specific prognostic association with 
gene fusion status.
Recently, Yoshimoto et al (107) reported that presence of both TMPRSS2-ERG gene fu-
sion and PTEN deletion is associated with earlier biochemical recurrence. Three groups of 
differential patient outcome were discriminated: (1) a poor prognosis group when both 
TMPRSS2-ERG fusion gene and PTEN deletion are present, (2) an intermediate group with 
either TMPRSS2-ERG fusion gene or PTEN deletion and (3) a favourable prognosis group 
with neither TMPRSS2-ERG fusion gene nor PTEN deletion. 
Specific morphological features have been identified in most TMPRSS2-ERG fusion 
positive prostate tumour samples, these are blue-tinged mucin, cibriform growth pat-
tern, macronuclei, intraductal tumour spread, and signet-ring cell (108, 109). Most of 
these characteristics are indications of more aggressive disease.
Prostate cancer is a molecular and histological heterogeneous disease, which can be 
composed of multiple foci within the same gland (110, 111). Analysis of TMPRSS2-ERG 
gene rearrangements in multifocal prostate cancer samples showed that individual foci 
can have different rearrangements (112-115). Mehra et al. (116) reported that TMPRSS2-
ERG rearrangement at metastatic sites always occurs through interstitial deletion. More-
over, all metastatic sites in an individual patient display an identical ETS rearrangement 
status (fusion gene positive or fusion gene negative), pointing to clonal expansion of 
tumour cells from the same primary focus.
Two studies have applied array CGH analysis on prostate cancer samples and searched 
for common genomic alterations in ETS fusion-positive and ETS fusion-negative cancers 
(117, 118). Lapointe et al (118) divided their samples in three subtypes based on expres-
sion profiling. Subtype two and three tumours showed a more aggressive phenotype 
compared to tumours of subtype one. Subtype two harbours tumours with TMPRSS2-ERG 
fusion, whereas in subtype one, an ETS fusion-gene negative group, loss of chromosome 
band 6q15 was detected. Subtype three was also a TMPRSS2-ERG fusion-negative group. 
This group had in general more chromosomal alterations. Kim et al (117) distinguished 
a subgroup with low expression of ETS mRNAs with loss of chromosome band 6q21. 
Moreover, Tomlins et al detected distinct expression signatures for ETS-positive and ETS-
negative tumours, including a relative underexpression of genes located on 6q21 in the 
ETS-negative group (119). 
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Recently, it has been reported that in ~10% of the ETS fusion gene negative tumours 
overexpression of SPINK1 was associated with a shorter time to biochemical recurrence 
(120).
TMPRSS2-ERG fusion and prostate cancer diagnosis
The serum PSA test is currently used as a first step in prostate cancer diagnosis. Although 
it is a sensitive and simple test, it lacks specificity, because elevated serum PSA levels can 
also be measured in case of benign alterations of the prostate. Therefore, there is need 
for a sensitive and more specific prostate cancer-screening test, preferentially using 
non-invasive conditions, like a blood or urine test.
For this reason presence of TMPRSS2-ERG fusion transcripts in urine sediments, ob-
tained after digital rectal examination (DRE) of prostate cancer patients, was evaluated 
(121-123). A PCR-based assay resulted in a sensitive and specific detection of TMPRSS2-
ERG fusion transcripts in urine sediments. However, not all prostate cancer samples 
harbour TMPRSS2-ERG fusion genes, therefore additional biomarkers, PCA3, GOLPH2 and 
SPINK1, were analysed. Although, the combination provided a promising high sensitivity 
and specificity, data are still preliminary and cannot replace the currently used PSA test. 
Further refinement and testing of large patient cohorts are needed before routine clini-
cal application, supplementary to or instead of serum PSA detection.
Recently, it has been reported that the TMPRSS2-ERG fusion gene can be detected in 
circulating tumour cells isolated from blood for its potential to monitor tumour metasta-
sis (124). Although TMPRSS2-ERG fusion was detected at the genomic level, this was not 
possible at transcript level. This might be due to the limiting sensitivity of the test or by 
downregulation of fusion gene expression in circulating cells.
Functional studies of ETS fusion genes in prostate cancer
To characterize the functional role of ETS fusion genes in prostate cancer several in vitro 
and in vivo studies have been performed. First the role of ETS fusion genes in prostate 
cancer cell lines was investigated. The VCaP prostate cancer cell line, that expresses the 
TMPRSS2-ERG fusion gene, has been used to downregulate ERG expression by siRNA. 
The effect on cell biological and tumorigenic properties was evaluated. Tomlins et al. 
(125) showed that ERG downregulation inhibited cell invasion, but did not affect cell 
proliferation. Sun et al. (126) reported that ERG downregulation resulted in cell mor-
phological changes, slow growing and clumped cells, after 6-8 days. Injection of VCaP 
cells, transfected with ERG siRNA, in severe combined immune-deficient (SCID) mice, 
showed that these cells were less tumorigenic than parental VCaP cells (126). Both stud-
ies also indicated that ERG knockdown induced a transcriptional program consistent 
with prostate differentiation.
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The prostate cancer cell line LNCaP overexpresses ETV1. In this cell line the complete 
ETV1 locus is inserted in the last intron of MIPOL1, as described above. Downregulation 
of ETV1 expression by siRNA resulted in inhibition of invasive properties of the LNCaP 
cells (88, 127). Moreover, ETV1 downregulation reduced the expression of MMPs, which 
are known to be involved in cell invasion. In addition, Cai et al (127) reported that down-
regulation of ETV1 protein inhibited cell proliferation.
Another approach that has been used to determine the role of the ETS fusion genes in 
prostate cells, was infection of non-tumorigenic, immortalized, benign prostate epithe-
lial cells with viruses expressing ETS factors (N-truncated ERG and ETV1, and full length 
ETV1 and ETV5) (76, 88, 91, 125) or nucleoporation of immortal, non-tumorigenic BPH1 
cells with N-truncated ERG expression constructs (128). The full length forms of these ETS 
transcription factors have an N-terminal transactivation domain (TAD). In case of gene 
fusion this N-terminal part is lost. Most studies showed that transient or stable overex-
pression of these ETS genes have no effect on cell proliferation, although Klezovitch et 
al (128) detected increased rates of cell accumulation. In all studies, ETS overexpression 
increased cell invasion. Klezovitch et al (128) detected little effect on cell migration in 
BPH1 cells over expressing N-truncated ERG. In contrast, we found that both full length 
and N-truncated ETV1 stimulated cell migration in PNT2C2 cells (91). Interestingly, over 
expression of full length ETV1 stimulated anchorage-independent growth, whereas over 
expression of N-truncated ETV1 or ERG had no effect (88, 91, 125). Moreover, we have 
shown that N-truncated and full length ETV1 possesses different transcription regulation 
functions in an ETS reporter assay. Both N-truncated and full length ETS factors induce 
an invasion-associated transcriptional program, including induction of MMPs and uPAR/
uPA, but comparing full length and truncated ETV1 we found a difference in stimulation 
of genes involved in integrin-signaling (ITGB3 and ITGAV).
To elucidate the functional properties of the ETS fusion genes in prostate epithelium 
in vivo, transgenic mouse models overexpressing N-truncated ERG or N-truncated ETV1 
have been generated, under control of a modified prostate-specific and androgen-
regulated probasin (PB) promoter (88, 125, 128). The transgenic mice, PB-ERG and PB-
ETV1, do not develop prostate tumours. However, most PB-ETV1 mice do develop mPIN 
foci by 12-14 weeks in all three prostate lobes (anterior, ventral and dorsolateral) (88). In 
PB-ERG mice mPIN lesions were found in the ventral lobe after 12-14 weeks (125) or 5-6 
months (128).
In vitro and in vivo studies indicate that the N-truncated ETS factors are important 
in earlier stages of prostate cancer, but this might not be sufficient for development 
of prostate tumours. Additional genetic alterations, like loss or mutation of a tumour 
suppressor gene like PTEN, seem needed to develop prostate cancer. Moreover, we 
have shown that in prostate cancer xenografts, overexpression of wild type ETS factors 
is found in AR negative, late stage disease, whereas expression of TMPRSS2-ERG fusion 
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genes is downregulated (73). This points to different roles of N-truncated and full length 
ETS factors in prostate cancer.
outLine of tHis tHesis
The aim of this thesis is to characterize the major genetic defects underlying prostate 
cancer development and progression. In chapter 2, a genome-wide screen for genomic 
alterations by array CGH is performed in DNA from eleven human prostate cancer xeno-
grafts. Our focus was on identification of homozygous deleted regions, because these are 
reliable landmarks of tumour suppressor genes. Homozygous deletions were confirmed 
by PCR analysis and genes within these regions were tested on mRNA expression. Most 
interesting regions were subjected to further structural and functional analysis. In chap-
ter 3, we studied chromosome 10 alterations in more detail in the same xenograft DNAs. 
PTEN and surrounding genes were subjected to expression and structural analysis. 
chapter 4 describes the identification and characterization of the TMPRSS2-ERG and 
TMPRSS2-ETV1 fusion genes in human prostate cancer xenografts. By array CGH, FISH 
and QPCR analysis we detected TMPRSS2-ERG fusion transcripts in five AR positive xeno-
grafts. However, these transcripts were absent in late stage AR negative prostate cancer, 
although the fusion gene was present. 
TMPRSS2 transcription can start at two alternative first exons, exon 0 and 1. In chapter 
5 we determined the specific characteristics of transcripts starting at these two alterna-
tive first exons of TMPRSS2 in normal tissues, and in prostate cancer xenografts and cell 
lines. Next, we investigated presence of TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG 
fusion transcripts in prostate cancer xenografts and in clinical prostate cancer samples. 
In addition, we correlated expression of TMPRSS2(exon 0)-ERG with clinical outcome in a 
cohort of primary prostate cancers to investigate whether it was of prognostic value.
Besides the initial discovery of TMPRSS2 to ETS fusion genes, other ETS fusion partners 
have been described. In chapter 6 the identification of two novel unique ETV4 fusion 
genes in clinical prostate cancer samples is described. Moreover, we determined the 
specific characteristics of these novel ETV4 fusion genes and of both fusion partners. In 
chapter 7, we investigated overexpression of ETV1 in clinical prostate cancer specimens 
by QPCR analysis. We identified overexpression of novel ETV1 fusion genes and of full 
length ETV1. First, we determined specific characteristics of these novel fusion partners. 
Next, we assessed the biological properties of both full length and N-truncated ETV1 
proteins. Finally, in chapter 8 the results described in this thesis are discussed and sug-
gestions for further research are offered.
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aBstract
Prostate cancer is the most common malignancy in men in developed countries. Mo-
lecular mechanisms underlying prostate cancer development and progressive growth 
are not fully understood. Human prostate tumors propagated as xenografts on mice 
are perfect starting material to search for novel genes involved in prostate cancer. We 
analyzed genomic DNA of eleven xenografts by array-based comparative genomic 
hybridization. In eight xenografts eleven homozygous deletions were found: three on 
chromosome arm 10q, two on 13q, 16q, and 17p, and one on 2q and 8p. Part of these 
deleted regions contain genes previously implicated in tumorigenesis, including PTEN 
on 10q, BRCA2 and RB1 on 13q, and ATBF1 on 16q. One of the two homozygous deletions 
on 17p showed deletion of MKK4, and the other had lost both copies of N-COR. Further 
analysis identified a second homozygous deletion of both genes in other xenografts. In 
two more xenograft DNAs one copy of MMK4 was lost. Mutation or loss of one copy of 
N-COR was detected in four more xenografts. Downregulation of N-COR, using specific 
siRNA, demonstrated stimulated in vitro growth of LNCaP prostate cancer cells. These 
results strongly indicate N-COR as a novel tumor suppressor in prostate cancer.
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introDuction
Prostate cancer is the most frequently diagnosed malignancy in men, and the second 
leading cause of cancer-related death in developed countries (Jemal et al., 2008). Lo-
cally confined prostate cancer can be cured by surgery or radiation therapy, however, 
for metastatic prostate cancer an adequate therapy is not available. Unraveling of the 
molecular mechanisms of prostate cancer development and progressive growth could 
provide novel targets for more effective therapies.
In tumor DNAs chromosomal gains indicate the localization of candidate oncogenes 
and chromosomal losses point to the localization of candidate tumor suppressor genes. 
Previous studies of chromosomal alterations in prostate cancer have identified multiple 
frequently affected regions (Saramaki et al., 2006; Sun et al., 2007). Commonly lost re-
gions involve chromosome arms 6q, 8p, 13q, and 16q, less frequently lost regions are on 
2q, 5q, 10q, 17p, and 18q. Frequently gained regions are on chromosome arms 7q, and 
8q; less frequently gained regions involve 3q, 17q and Xq. 
Comparative genomic hybridization (CGH) (Kallioniemi, 2008; Michels et al., 2007) on 
BAC arrays, cDNA microarrays, or oligonucleotide arrays allows a quantitative analysis of 
chromosomal copy-number changes at high resolution of the genome. Array CGH was 
recently used to study genomic alterations in clinical prostate cancer (Kim et al., 2007; 
Lapointe et al., 2007; Liu et al., 2006; Paris et al., 2004; Paris et al., 2007; Torring et al., 
2007; van Dekken et al., 2004; Verhagen et al., 2006; Yano et al., 2004) and in xenografts 
and cell lines (Clark et al., 2003; Saramaki et al., 2006; Wolf et al., 2004). 
Xenografts are powerful models to investigate genetic alterations, because they lack 
normal cells of human origin. This simplifies the detection of homozygous deletions, 
high-level amplifications and specific small regions of genomic losses. Previously, we 
described in xenograft DNAs frequent homozygous deletion of PTEN on 10q (Vlietstra 
et al., 1998; Hermans et al., 2004), and a homozygous deletion of WRN (Van Alewijk et 
al., 1999). In addition, we showed in three xenografts loss of a small region on 21q that 
linked TMPRSS2 to ERG in the TMPRSS2-ERG fusion gene (Hermans et al., 2006). 
In this study we screened the whole genome of prostate cancer xenografts by ar-
ray CGH for genomic gains and losses, and, more specifically, for novel homozygous 
deletions. We identified eleven homozygous deletions. Most of these seem to contain 
genes relevant for tumorigenesis. Three are the previously described deletions of PTEN 
(Vlietstra et al., 1998; Hermans et al., 2004). The eight new homozygous deletions are 
on 2q, 8p, 13q (two deletions), 16q (two deletions) and 17p (2 deletions). Three of these 
homozygous deletions contain known tumor suppressor genes, including BRCA2, RB1 
and ATBF1 (Agalliu et al., 2007; Kubota et al., 1995; Sun et al., 2005). The two homozygous 
deletions on 17p were subjected to further analysis, which resulted in the detection of 
additional homozygous deletions. This pointed to MKK4 and N-COR as candidate tumor 
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suppressor genes. Further structural and functional analyses indicate NCOR as the more 
frequent novel tumor suppressor gene in prostate cancer. 
resuLts
Array CGH analysis of human prostate cancer xenografts
We used 1Mb-spaced genome-wide BAC arrays (Fiegler et al., 2003) to detect altera-
tions in genomic DNA of eleven human prostate cancer xenografts: PCEW, PC82, PC133, 
PC135, PC295, PC310, PC324, PC329, PC339, PC346 and PC374. Figure 1 summarizes 
the frequencies of chromosomal regions of gains and losses found. In supplementary 
Table 1 the positions of the regions of gain and loss are indicated in detail. In total 332 
candidate genomic alterations were detected (179 regions of loss and 153 regions of 
gain, with a log2 T/N <-0.3 or log2 T/N >0.3, respectively, of at least two consecutive BAC 
clones). The most frequent genomic alterations detected by array CGH, as found in six or 
more xenograft DNAs, were gains of parts of chromosomes 7 and 8q and losses of part 
of 8p, 10q, 13q and 16q, reflecting the genomic alterations described in clinical prostate 
cancers (Saramaki et al., 2006; Sun et al., 2007). 
High level amplifications in prostate cancer xenograft DNAs 
High-level amplifications (log2 T/N >1.2) were rare in xenograft DNAs. Previously de-
scribed small, amplified regions on 8q in xenograft PC339 were confirmed (Van Duin 
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Figure 1. Overview of frequencies of chromosomal regions of gains (green) and losses (red) detected in eleven prostate cancer 
xenograft DNAs as plotted from 1p telomere to Yq telomere (Log2 T/N <-0.3 was taken as loss; Log2 T/N >0.3 was taken as 
gain).
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et al., 2005). Two small high-level amplifications (5-6 Mbp) were found in PCEW DNA on 
3q22.1-q22.3 and 3q29, respectively. PIK3CB and MRAS are candidate oncogenes located 
in the 3q22.1-q22.3 interval, in the other amplified region a candidate oncogene cannot 
be defined. 
Small regions of loss
The frequently lost regions of 8p, 13q and 16q mostly involve large parts of these chro-
mosome arms. However, losses of chromosome 10q in some samples concern a small 
region of ~2 Mbp, spanning three BAC clones, where the tumor suppressor gene PTEN is 
located (Supplementary Table 1).  Like for PTEN small   regions of loss might indicate the 
positions of other tumor suppressor genes, particularly in those chromosomal regions 
that show frequent loss of large fragments in the other xenografts DNAs. These small 
regions of loss might also add information to that obtained from homozygous dele-
tions.  Moreover, the loss of exactly the same genomic region might be indicative of an 
interstitial deletion resulting in a fusion gene, as previously described in the xenograft 
DNAs for the TMPRSS2-ERG fusion gene on 21q (Hermans et al., 2006).  
We found by array CGH 34 regions of loss that were smaller than 5 Mbp (two to 
five consecutive BACs with a Log2 T/N <-0.3) (Supplementary Table 1). Three of those 
involved loss of exactly the same four BACs, which fused the first part of TMPRSS2 to 
the last part of ERG on 21q, as previously described (Hermans et al., 2006). We could 
not detect another similar region of loss of exactly the same fragment in other parts 
of the genome of multiple xenografts. However, in two xenografts (PC82 and PC329) 
small partially overlapping regions of loss on 13q2.1-q22.2 were found. The common 
gene present in both genomic fragments was KLF5. Also, a small region of loss in PC82 
that overlapped with a homozygous deletion in PC310 on 13q14 in the BRCA2-DLC2 
Table 1. Characteristics of homozygous deleted regions detected in eleven prostate cancer xenografts
chromosome HD Size HD 
(Mbp)
Loss Candidate genes
2q37.1 1/11 0.8 1/11 COPS7B, NPPC, ALPP, ALPPL2, ALPI, ECEL1, CHRND, CHRNG,TIGD1,EIF4EL3
8ptel 1/11 1.5 4/11 ZNF596, FBXO25, INMO1, LOC286161, LOC157697, DLGAP2
10q23.3 3/11 0.7-1.2 5/11 PTEN and 13 other genes
13q13.1-q13.2 1/11 1.4 6/11 BRCA2, CG018, PFAAF5, APRIN, KL, DLC2
13q14.2 1/11 0.9 7/11 ITM2B, RB1, P2RY5, CHC1L, CYSTRL2
16q22.2-q22.3 1/11 0.6 8/11 ATBF1
16q23.1 1/11 0.4 7/11 WWOX
17p11.2-p12 1/11 1.0 2/11 MKK4, MYOCD, KIAA0672
17p11.2-p12 1/11 0.8 2/11 DNAH9, ZNF18, MKK4
17p11.2-p12 1/11 1.8 3/11 N-COR and eleven other genes
17p11.2-p12 1/11 0.7 3/11 N-COR and six other genes
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region was detected (Supplementary Table 1 and Figure 2). A similar combination was 
found for a region of loss and a homozygous deletion on 16q22, in PC329 and PC339, 
including ATBF1. Many small regions of loss are not located on chromosomes that are 
frequently lost in prostate cancer. Most promising candidate tumor suppressor genes in 
these fragments are MTSS1 (8q) (Loberg et al., 2005), KAI1 (11p) (Bouras and Frauman, 
1999), and ATM (11q) (Meyer et al., 2007).
Identification of homozygous deleted regions
We focused the analysis of the array CGH data on homozygous deletions as most reli-
able landmarks of tumor suppressor genes. Seventeen candidate regions with a log2 
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Figure 2. Mapping of eight novel homozygous deletions in the prostate cancer xenografts. Individual graphs of chromosomes 
with homozygous deletion (circled) are shown. Confirmation of the homozygous deleted region was by PCR analysis. PCR of 
xenograft DNA with homozygous deletion and a control are depicted.
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T/N ratio below -1.5, indicative of a homozygous deletion were detected. Eleven of 
these regions were confirmed as homozygous deletions by PCR with primers mapping 
in these genomic fragments. Graphs of the chromosomes with confirmed homozygous 
deletions and PCR data of eight homozygous deletions are depicted in Figure 2. More 
details of the homozygous deletions are given in Table 1. We excluded in the analyses 
three previously extensively described homozygous deletions of PTEN (Hermans et al., 
2004; Vlietstra et al., 1998). One of the novel homozygous deletions was on 2q, one on 
8p, two were on 13q, two on 16q, and two on 17p (Figure 2). Genes in the eight novel 
homozygous deletions were assayed by PCR in all other xenograft DNAs for overlapping 
homozygous deletions that were missed on the BAC arrays. However except for 17p, 
no additional overlapping homozygous deletions were found (see below). Moreover, all 
genes, except one-exon genes, located within the homozygous deleted regions were 
checked for mRNA expression in all xenografts to find substantial downregulation of 
candidate tumor suppressor genes by epigenomic mechanisms. Gene expressions were 
compared to mRNA expression in the normal prostate (Supplementary Table 2). 
On 2q37.1 a homozygous deletion of ~800 kbp was detected in PC329 DNA. Ten genes 
map in this region (Table 1). The homozygous deletion is located adjacent to a region 
of gene copy number gain. Only two out of the ten genes in the homozygous deletion 
were expressed in xenografts. The other eight genes showed no expression, and were 
also not expressed in the normal prostate (Supplementary Table 2). In xenograft PC295 
DNA a homozygous deletion of telomeric 8p was discovered (Figure 2). In this 1.5 Mbp 
region six genes are located (Table 1). Five genes were expressed in the prostate, but 
none of the genes was downregulated.  None of the genes in the homozygous deletions 
on 2q and 8p seems a candidate tumor suppressor gene. 
On 13q, two different homozygous deletions were found. The homozygous deletion 
on 13q13.1-q13.2 in PC310 DNA was ~1.4 Mbp, and was also part of large regions of 
genomic loss in six other xenograft DNAs. It contained seven genes (Figure 2 and Table 
1) with BRAC2, APRIN, KL and DLC2 as important candidate tumor suppressor genes. 
Except for KL, none of these genes was considerably downregulated in other xenografts 
(Supplementary Table 2). 
A homozygous deletion of 0.9 Mbp on 13q14.2 in PC135 contained five genes (Figure 
2). It was also part of a larger region of loss in seven other xenografts DNAs.  RB1 is the 
most important tumor suppressor gene in this fragment. None of the xenografts without 
a homozygous deletion for this region showed downregulation of the five genes.
Chromosome arm 16q contained two homozygous deletions. The first was on 16q22.2-
q22.3 in PC339 DNA (Figure 2). This ~600 kbp genomic fragment harbored ATBF1 as 
only gene. Loss of one copy of ATBF1 was detected in eight other xenografts. In PC329 
this region of loss is very small (~2 Mbp; see Supplementary Table 1). ATBF1 contains a 
highly polymorphic polypyrimidine tract (poly(T)n) in intron 8 near the splice acceptor 
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site of exon 9, which affects correct splicing (Sun et al., 2005). Sequencing of the poly(T)
n
 tract in all xenograft DNAs detected shortened poly(T)
n
, both 13Ts instead of 16Ts, in 
two xenografts (PC346 and PC374). This indeed resulted in alternative splicing of ATBF1 
mRNAs (data not shown). Both xenografts DNAs show also microsatellite instability and 
a defective mismatch repair system. Except for PC339, ATBF1 mRNA expression was 
detected in all other xenografts. 
A second homozygous deletion on 16q (~400 kbp) in PCEW was mapped on 16q23.1. 
This homozygous deletion is located in large intron 7 of the WWOX gene (Figure 2). Here 
also maps the fragile site FRA16D (Buttel et al., 2004; Palakodeti et al., 2004). In seven 
xenografts loss of one copy of WWOX was found. Expression analysis showed presence 
of WWOX mRNA in all xenografts (Supplementary Table 2).
Characterization of the homozygous deletions on chromosome 17p
In the genomic DNA of xenograft PC324 two homozygous deleted regions on 17p11.2-
p12 were detected (Figures 2 and 3), one of ~1.0 Mb and the other of ~1.8 Mbp. PCR 
analysis of the first deleted DNA fragment identified in the other xenografts one more 
homozygous deletion in xenograft PC295 (Figure 3a,b). This homozygous deletion (~0.8 
Mbp) was not detected by array CGH. One of the breakpoints of both homozygous dele-
tions in xenografts PC295 and PC324 is in intron 1 of the MKK4 gene, but the deletions 
do not overlap (Figure 3b). We detected loss of one copy of MKK4 in two additional 
xenografts (PCEW and PC82). Because MKK4 is the only gene deleted in both PC295 and 
PC324, we limited gene expression analysis to this gene. Expression analysis by QPCR 
confirmed absence of expression in the xenografts with the homozygous deletions, 
however, in all other xenografts MKK4 mRNA was present (Figure 3c). The eleven exons 
of MKK4 were sequenced in all xenograft DNAs, but no inactivating mutations were 
detected.
The second homozygous deletion in PC324 DNA on 17p11.2-p12 detected on the 
BAC arrays mapped very close to the first one. Again, PCR analysis of the DNAs of all 
xenografts resulted in the detection of an overlapping homozygous deletion, now in 
xenograft PC133 DNA (~0.7 Kbp, Figure 3b). This homozygous deletion, like the one in 
xenograft PC295 on 17p, was not detected by array CGH, because it was located between 
two BACs. The two homozygous deletions overlapped in N-COR. Three xenografts, PCEW, 
PC82 and PC295, showed loss of one copy of N-COR. mRNA expression analysis showed 
absence of expression in PC133 and PC324, however, in the other xenografts N-COR was 
expressed (Figure 3c). 
Because the original clinical prostate tumor material of xenograft PC324 was available, 
we also performed array CGH on this DNA sample. We detected the homozygous dele-
tion on 10q (PTEN) and both homozygous deletions on 17p (MKK4 and N-COR) in this 
material (data not shown).
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Structural and functional analysis of N-COR
We sequenced the DNA of all xenografts for exons 2-46 of N-COR, representing the 
coding region, complemented with five human prostate cancer cell lines: PC3, LNCaP, 
DU145, 22Rv1 and MDA Pca 2b. We detected one missense mutation in xenograft PC346 
(GCA->GTA) in exon 13 that encodes the DAD domain of N-COR, and two frame-shift 
mutations, in xenograft PC346 (del A in exon 15) and in cell line MDA Pca 2b (del TC in 
exon 17). Both frame-shift mutations will result in the synthesis of a truncated N-COR 
protein. From sequencing of a cloned fragment of part of the N-COR cDNA (exons 12-16) 
of PC346 we deduced that the two mutations in N-COR were in the same allele, leaving 
expression of one wild type allele. MDA Pca 2b also expresses a wild type allele and a 
mutant allele. 
Next, we investigated the effect of N-COR downregulation by siRNA on growth of the 
prostate cancer cell line LNCaP. Western blot analysis showed that LNCaP cells transfected 
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Figure 3. Characterization of two homozygous deleted regions on chromosome arm 17p. (A) Schematic representation of the 
genomic region where both homozygous deletions map. In black, BACs that are located in the homozygous deletions in DNA 
of PC324. (B) PCR analysis of the 17p region showing two homozygous deletions in PC324, one in PC295 and one in PC133. (C) 
Expression analysis of MKK4 and N-COR as assessed by QPCR. Duplicate experiments relative to PBGD are presented; bars 
indicate standard deviations.
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with N-COR siRNA had downregulated N-COR protein expression (Figure 4a). Growth 
experiments indicated that N-COR downregulation had a small, but significant growth 
advantage on LNCaP cells in presence of the synthetic androgen R1881, compared to 
cells transfected with control siRNA (p=0.025, Figure 4b). In absence of hormone the 
difference in growth rate was not significant (p=0.11).
Discussion
Molecular mechanisms underlying human prostate cancer development and progres-
sive growth are only partially understood. For several of the chromosomal alterations 
detected in primary tumors and in late stage prostate cancer, the genes involved 
remain unknown. In the present study we investigated eleven human prostate cancer 
xenografts for chromosomal alterations. The xenografts represent a variety of clinical 
prostate cancer stages (van Weerden et al., 1996). Xenografts are available in unlimited 
quantities and lack normal cells of human origin, which simplifies the detection and 
further characterization of genomic alterations, particularly homozygous deletions. 
Frequent genomic alterations detected by array CGH in the prostate cancer xenografts 
in this study coincided with alterations described in clinical prostate cancer specimens 
(Sun et al., 2007), confirming that the xenografts are powerful and representative models 
for studying molecular defects in prostate cancer. 
Most of the eleven homozygous deletions described in this study were found on 
chromosomes that are frequently lost in prostate cancer (see Figures 1 and 2), which 
strengthens a possible role in tumorigenesis. Previously, we described the homozygous 
deletions on 10q, where PTEN maps (Hermans et al., 2004; Vlietstra et al., 1998). In the 
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Figure 4. Effect of downregulation of N-COR protein by siRNA on proliferation of the prostate cancer cell line LNCaP. (A) Western 
blot of LNCaP cells transfected with N-COR siRNA or control siRNA showing N-COR expression. Actin is the loading control. (B) 
Proliferation of LNCaP cells transfected with N-COR siRNA or control siRNA as measured by MTT assay at day 0 and at day 4. Cells 
were cultured with or without the synthetic androgen R1881 (10-10M). Bars indicate standard deviation. Statistical analysis was 
done with the Student’s T-test; in the absence of R1881: p=0.11; in the presence of R1881: p=0.025.
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array CGH experiments we missed two previously identified homozygous deletions, one 
on 8p in PC133, containing WRN (Van Alewijk et al., 1999) and, not unexpected, a 30 
kbp homozygous deletion containing exon 5 of PTEN in PC295 (Hermans et al., 2004). 
In addition, we found out that we missed on the arrays two homozygous deletions on 
17p, one containing MKK4 and a second one containing N-COR (this study). Although it 
can be presumed that more, mainly small, homozygous deletions have been missed, it is 
likely that we have identified the majority of the most frequent genomic alterations. 
Obviously, with as exception the unique small interstitial deletion of TMPRSS2-ERG on 
21q (Hermans et al., 2006), array CGH was not able to identify gene fusions or chromo-
somal translocations, genomic duplications or inversions. Identification of these specific 
genomic alterations needs more sophisticated technological approaches. Recently de-
veloped massive parallel sequencing of tumor DNAs compared to normal DNAs seems 
such a promising tool (Campbell et al., 2008; Korbel et al., 2007).
For both the homozygous deletion on 2q in PC329 and the telomeric homozygous 
deletion on 8p in PC295, we lack evidence that they play a role in prostate cancer. The 
positions of the breakpoints suggest that both deletions originated during chromo-
somal translocations. The absence of obvious candidate tumor suppressor genes in the 
deletions supports this hypothesis.
In clinical prostate cancer loss of 13q is frequently detected. Three separate regions 
on 13q14, 13q21-q22 and 13q33 have been suggested to harbor candidate tumor sup-
pressor genes (Dong et al., 2001; Hyytinen et al., 1999; Wolf et al., 2004). We detected two 
different homozygous deletions, on 13q13.1-q13.2 and on 13q14.2, respectively. One of 
these might overlap with the previously described minimal lost fragment on 13q14. The 
13q21-q22 region might contain KLF5, as also identified in the present study (see Results 
section). KLF5 has previously been described as frequently deleted and downregulated 
in intestinal and prostate cancers (Bateman et al., 2004; Chen et al., 2003).
The genomic fragment on 13q13.1-q13.2 contains the BRCA2 tumor suppressor gene, 
which previously has been indicated as a candidate susceptibility gene for hereditary 
prostate cancer (Edwards et al., 2003; Gayther et al., 2000; Latil et al., 1996). Carriers 
of BRCA2 mutations have an elevated risk for developing prostate cancer with a more 
aggressive phenotype (Agalliu et al., 2007; Narod et al., 2008). Remarkably, the homozy-
gous deletion on 13q13.1-q13.2 contains in addition to BCRA2, three more candidate 
tumor suppressor genes: DLC2, APRIN and KL. DLC2 is downregulated in multiple tumors 
(Ullmannova et al., 2006). It encodes a Rho GTPase activating protein presumed to play 
a role in growth suppression (Ching et al., 2003; Leung et al., 2005). APRIN, also known as 
AS3, has a critical role in proliferative arrest in the G0/G1 phase of the cell cycle (Geck et 
al., 2000; Maffini et al., 2002). More recently, it has been reported that APRIN may func-
tion as a regulator of chromatin architectural structure, and as a mediator of hormone-
induced chromatin changes in differentiation and cancer (Maffini et al., 2008). The only 
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gene within this region that is downregulated in part of the other xenografts is KL or 
Klotho. Klotho knockout mice exhibit multiple phenotypes that resemble human aging. 
KL is also able to suppress the action of IGFs, which are associated with cancer, and can 
protect cells from oxidative stress. However, the exact mechanisms underlying these 
activities remain to be elucidated (Tsujikawa et al., 2003; Kurosu et al., 2005, Wang et 
al., 2006). Obviously, this small genomic region with many candidate tumor suppressor 
genes can be very important for further study in clinical prostate cancer.
In the homozygous deletion on 13q14.2 the main candidate tumor suppressor gene is 
RB1 (Konishi et al., 2002; Kubota et al., 1995; Latil et al., 1999). Loss of RB1 has previously 
been associated with prostate cancer and might be an early event (Kubota et al., 1995; 
Phillips et al., 1994). Other candidate tumor suppressor genes that map in the same frag-
ment are ITMB2 (Latil et al., 2003) and CHC1L (Latil et al., 2002). These genes have been 
proposed as candidate tumor suppressor genes based on the finding that they have 
reduced mRNA expression in prostate tumors, but this was not clear from our data. More 
recently, P2RY5 that maps in RB1 intron 17 has been indicated as a novel candidate tumor 
suppressor gene (Kim et al., 2007, Crawford et al., 2008). However, further structural and 
functional analysis of this gene is needed to substantiate this observation.
On 16q we also identified two homozygous deleted regions. In the region on 16q22.2-
q22.3 only ATBF1 is located. The transcription factor ATBF1 has first been indicated as a 
candidate tumor suppressor gene in gastric cancers and Hodgkin’s lymphomas (Kataoka 
et al., 2001; Schwering et al., 2003) and more recently in breast and prostate cancers 
(Sun et al., 2005; Zhang et al., 2005). In the second region on 16q, the homozygous dele-
tion consists of a large part of intron 7 of the putative tumor suppressor gene WWOX 
and spans the fragile site FRA16D (Bednarek et al., 2001; Paige et al., 2001). WWOX is 
frequently affected by translocation and homozygous deletion in multiple tumors. 
However, we observed normal mRNA expression in all the xenografts.
In two xenografts homozygous deletion of MKK4 on 17p were detected. MKK4 is a 
stress activated protein kinase with as targets JNK and p38. MKK4 has been described as 
a metastasis suppressor gene in prostate and ovarian cancer (Taylor et al., 2008, Whit-
marsh et al., 2007). MKK4 expression is inversely correlated with Gleason score in primary 
prostate cancer (Kim et al., 2001; Yoshida et al., 1999). MKK4 was one of the two genes that 
we studied in more detail. However, besides the two homozygous deletions we did not 
detect inactivating MKK4 mutations or MKK4 downregulation. Loss of one copy of MKK4 
was observed in two xenografts (PCEW and PC82). We also carried out a preliminary 
study on MKK4 inactivation in clinical prostate cancer. By array CGH we found in 4 out of 
17 clinical samples loss of the part of 17p where MKK4 maps (data not shown). Robinson 
et al reported absence of correlation between MKK4 mutation or (homozygous) deletion 
and MKK4 protein expression (Robinson et al., 2007). They also showed that translational 
regulation is critical in determining MKK4 protein levels. Combined these data warrant 
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further analysis of MKK4 in prostate cancer, including functional studies and expression 
analysis. 
The other two overlapping homozygous deletions on 17q contained N-COR as candi-
date tumor suppressor gene. Further analysis showed frequent loss or mutation of one 
copy of N-COR in xenografts or cell lines. Preliminary analyses of clinical prostate cancer 
showed loss of one copy of N-COR in 4 out of 17 recurrent prostate tumors (data not 
shown). These findings are indicative for N-COR as the most frequent inactivated tumor 
suppressor gene in this part of 17p.  
N-COR is a well-known co-repressor of nuclear receptors, including the AR (Jepsen 
and Rosenfeld, 2002). However, it has also been shown that N-COR can be recruited by 
many other transcription factors. N-COR is a component of a multiple protein complex 
containing histone deacetylases (HDACs), which inhibits gene expression (Jepsen and 
Rosenfeld, 2002).  
We showed that downregulation of N-COR expression in LNCaP cells by siRNA transfec-
tion resulted in a growth advantage for these cells in presence of the synthetic androgen 
R1881 (Figure 4). So far, a role of N-COR in prostate cancer was unknown. A previous 
study revealed that decreased N-COR protein expression correlated with acquired 
tamoxifen resistance in a breast cancer mouse model (Lavinsky et al., 1998). Moreover, 
in breast cancer a low level of N-COR mRNA expression seems associated with shorter 
disease-free survival (Girault et al., 2003; Zhang et al., 2005). 
In conclusion, in this study we showed that genome-wide analysis of xenograft DNAs 
by array CGH is an effective method to detect genomic alterations, including homozy-
gous deletions, in prostate cancer. Our results support the importance of multiple tumor 
suppressor genes on 13q and of MKK4 on 17p in prostate cancer. Moreover our findings 
indicate that N-COR is a novel candidate tumor suppressor gene in prostate cancer.
materiaLs anD metHoDs
Prostate cancer derived xenografts
The in vivo growing xenografts PCEW, PC82, PC133, PC135, PC295, PC310, PC324, PC329, 
PC339, PC346, and PC374 were propagated on male nude mice (Hoehn et al., 1980; 
Hoehn et al., 1984; van Weerden et al., 1996)
DNA and RNA preparation
Genomic DNA from xenografts and cell lines was isolated using the Puregene system 
from Gentra Systems (Minneapolis, MN) according to the procedure described by the 
manufacturer. Cell line RNA was isolated by the guanidium isothiocyanate procedure; 
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xenograft RNA was isolated according to the LiCl protocol (Sambrook and Russell, 2001). 
The mRNA from normal prostate tissue was purchased from Clontech (Palo Alto, CA) 
Array-based CGH
 Arrays were produced from the human 3600 BAC/PAC genomic clone set of the Wel-
come Trust Sanger Institute, covering the full genome at approximately 1 Mb-spacing. 
Degenerated oligonucleotide PCR-products were prepared for spotting on CodeLink® 
slides (Amersham Biosciences, Piscataway, NJ) according to published protocols (Fiegler 
et al., 2003) with some modifications (Knijnenburg et al., 2004). DNA labeling and 
hybridization were performed essentially as described (Fiegler et al., 2003) with minor 
modifications. After hybridization arrays were scanned in a ScanArray Express HT (Perkin 
Elmer, Freemont, CA). The resulting images were analyzed with GenePix Pro 5.0 software 
(Axon Instruments, Foster City, CA) and subsequently visualized with an excel macro 
(Knijnenburg et al., 2004).
PCR analysis of genomic DNA
Standard polymerase chain reaction (PCR) amplification utilizing Taq polymerase (Pro-
mega, Madison, WI) included 35 cycles of 1 min at 95°C, 1 min 55°C, and 1 min 72°C. PCR 
amplifications were performed in a 50µl reaction volume. The amplified fragments were 
separated on a 2% agarose gel. Primers used for homozygous deletion screening are 
available on request.
mRNA Expression
Analysis of mRNA expression was performed by semiquantitative RT-PCR or QPCR. cDNA 
was synthesized on 2 µg of RNA template using M-MLV RT (Invitrogen Life Technologies, 
Carlsbad, CA) and an oligo(dT)
12
 primer. Specific cDNA fragments were amplified by 
standard PCR for 30 cycles and separated on a 2% agarose gel. QPCR was performed in 
Power Sybr green PCR master mix (Applied Biosystems, Foster City, CA) containing 0.33 
µmol/L forward and reverse primer in an ABI 7700 Sequence Detection System. Ampli-
fied products were quantified relative to porphobilinogen deaminase (PBGD) by the 
standard curve method. Gene-specific RT-PCR/QPCR primers are available on request.
Sequence analysis
PCR products from exon 2-46 of N-COR and of exon 1-11 from MKK4 were purified using 
SAP/ExoI (USB, Amersham Biosciences) according to the manufacturers’ protocol. Frag-
ments were sequenced using the ABI Prism BigDye terminator v3.1 ready reaction cycle 
sequencing kit (Applied Biosystems). Primers for PCR and sequencing are available on 
request. Sequence reactions were run on the ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems).
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siRNA proliferation assay
Equal amounts of LNCaP cells grown on DMEM charcoal stripped FCS were on day 0 
transfected with N-COR siRNA (SmartPool, Thermo Scientific, Lafayette, CO) or control 
siRNA using Dharmafect 3 (Thermo Scientific), according to the manufacturers’ instruc-
tion. Cells were grown with or without 10-10 M R1881. At days 0 and 4 Thiazolyl blue 
tetrazolium bromide dissolved in PBS (MTT reagent; AppliChem, Darmstadt, Germany) 
was added and after 4h cells were harvested. Cells were suspended in DMSO-Sörensen 
buffer and OD 570 nm was measured. Statistical significance is calculated with a Stu-
dent’s T-test (SPSS, Chicago, IL).
Western blot analysis
For Western blot analysis LNCaP cells were transfected with N-COR siRNA or control 
siRNA using Dharmafect 3. Cells were harvested after 48h. Western blot analysis was 
carried out using standard procedures using N-COR (Santa Cruz, Santa Cruz, CA) and 
β-actin loading control (Sigma, Zwijndrecht, The Netherlands) antibodies. Protein bands 
were visualized by chemiluminesence (Pierce, Rockford, IL).
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Table S1. Overview of regions of DNA loss and gain detected in the eleven xenografts by 1Mb spaced genome-wide array CGH
loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
PCEW GS-62-L8 RP3-365I19 1 1 141531879      
 RG-228-K22 RP11-91K8 3 1 134771767 RP11-91K8 RP11-397E9 3 134771767 140451436
 RP11-397E9 RP11-298A18 3 140451436 189918727 RP11-56C4 GS-196-F4 3 193863519 198471847
 RP11-575G10 CTD-2174D2 5 42897645 74970806 RP11-72L22 RP1-244J5 5 86340653 136366234
 RP11-114H21 CTD-2323H12 5 135915628 141198799 RP11-25F13 GS-240-G13 5 144610138 180756037
 RP1-234P15 RP1-84N20 6 75947919 125541230 RP11-104I20 RP5-1110E20 17 25071274 36373682
 RP11-295F4 RP11-448D5 6 132876727 137301607 RP11-220N20 RP11-481C4 17 42087499 46634200
 RP11-345K20 GS-137-E24 10 74954877 135313953 RP11-217N19 RP11-112J9 17 49753469 52172780
 RP11-44F24 GS-221-K18 12 120246686 133387831 RP11-19F16 RP11-342K2 17 52616475 57473353
 RP11-424K7 RP11-533D19 16 49618230 88643456      
 GS-202-L17 RP11-471L13 17 1 12108967      
 RP1-27J12 RP11-403E9 17 14364543 25693265      
 RP11-193B6 GS-2-H14 21 13462479 46900000      
 XX-p8708 RP3-515N1 22 15615802 30027385      
 CTA-397C4 GS-3018-K1 22 43154478 50100000      
PC82 GS-62-L8 RP4-631H13 1 1 53133031 RP11-292A20 RP11-111J6 2 4295218 18724913
 RP11-172I6 RP11-15G16 1 152762033 158660779 RP11-458J18 RP11-299C5 2 19386578 42576881
 RP4-768P8 RP11-440G22 1 181212687 188784525 RP11-519H15 RP11-378A13 2 106939463 219136043
 RP11-492K2 GS-167-K11 1 215864587 245100000 RP11-87G1 RP11-309H15 13 32842471 72777348
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loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
 RP11-262D22 RP11-17L8 2 17064501 20273684      
 RP11-478M12 RP11-19A8 2 41675898 49151272      
 RP11-260K8 RP11-52F10 2 59017517 62800899      
 RP11-434P11 RP11-548D17 2 73728655 83708878      
 RP11-154H23 RP11-220O14 3 71622997 77738883      
 RP11-432A10 CTD-2200O3 5 62010355 75734191      
 RP11-520O10 RP11-451H23 5 177813406 180060082      
 RP11-96B2 RP11-495D4 8 123525975 126798844      
 RP11-509D8 RP11-274B18 9 4911574 68528389      
 RP11-124O11 RP11-292F22 10 42660894 47159666      
 RP11-470J18 RP11-304I5 10 86226512 90615085      
 GS-124-K20 RP11-277E18 12 1 7919008      
 RP11-144O23 RP11-4N23 12 10845028 13642782      
 RP11-37E23 RP11-266E6 13 31703968 34159357      
 RP11-393H6 RP11-388E20 13 71078490 77997374      
 RP11-98N22 RP11-187E13 14 19570817 31601773      
 RP11-58E21 RP11-417P24 14 49608076 105437086      
 RP11-178D12 RP11-169M2 14 53411855 60895362      
 RP11-344L6 GS-191-P24 16 11124 90100000      
 GS-202-L17 RP11-220N20 17 1 42268621      
 RG-129-F16 CTD-3138B18 19 1 63516696      
PC133 RP11-12M5 RP5-936P19 1 176407505 183558585 RP5-916A15 RP4-667F15 1 106670439 109448052
 RP11-157C8 RP11-92H22 4 53206265 72179919 RP11-284N8 RP11-27K13 1 110807864 117317597
 RP11-473A17  8 30946131  RP11-418J17 RP11-46A10 1 119411930 177761286
 RP11-396M20 RP11-80H5 10 88054888 91463649 RP4-768P8 RP11-534L20 1 181212687 203144491
 RP11-359J14 RP11-460N10 12 22465615 33333489 RP11-359A17 GS-167-K11 1 235850850 245100000
 RP11-131F1 RP11-516G5 13 38450249 55883767 GS-8-L3 RP11-141H20 2 330 170070826
 RP11-232K22 GS-1-L16 13 106527433 114100000 RP11-65L3 RP11-556H17 2 179083644 241867426
 RP11-122K22 GS-191-P24 16 50431379 90100000 RG-228-K22 RP11-35C18 3 1 34655794
 RP11-385D13  17 15510169  RP11-474M18 RP11-23M2b 3 84623846 199163913
 GS-839-D20 RP11-418N20 x 1 3106255 GS-24-H17 RP11-192H6 5 1 25333169
 RP11-414C23 RP11-270H4 y 2828841 26727165 RP11-16A6 CTD-2052F19 5 31326937 35043272
      RP11-7M4 RP11-269M20 5 36988555 50093906
      RP11-97A19 RP3-444C7 6 12406236 20759036
      GS-164-D18 RP11-101N13 7 154219 94287000
      RP1-155L11 RP5-1056B24 8 35234984 146167102
      RP11-48L13 GS-135-I17 9 29493271 134300581
      GS-23-B11 RP11-399K21 10 1 76882526
      RP11-388G12 RP11-290I21 12 32552977 62854997
      RP11-76K19 RP11-95G6 13 19136604 27970943
      RP11-98N22 RP11-463C8 14 19570817 76654077
      GS-202-L17 RP11-135N5 17 1 2492162
      RP11-178C3 GS-50-C4 17 55350495 80827381
      GS-52-M11 GS-75-F20 18 1 78100000
      RP11-193B6 RP1-128M19 21 13462479 39702870
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loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
      RP1-265B9 GS-2-H14 21 41559383 46900000
      RP3-411B6 RP11-218L14 x 75792100 154392840
PC135 RP11-465B22 RP11-84A19 1 968368 32025999 RP11-418J17 RP11-206M24 1 11941193 154603342
 RP11-297N6 RP4-621B10 1 75758261 92371893 RP11-163L4 GS-167-K11 1 174439974 245100000
 RP11-206M24 RP5-990P15 1 154602575 175314382 GS-8-L3 RP11-24I5 2 330 44500654
 RP11-372A6 RP11-560C24 2 187527667 213464438 RG-228-K22 RP11-521J5 3 1 125434205
 RP11-9N20 RP11-59J16 3 124853438 128752049 RP11-321A2 RP11-223L18 3 127928382 155113468
 GS-24-H17 RP11-28I9 5 1 45708383 RP11-416A5 RP11-258N2 4 45754361 81811336
 RP11-767J14 GS-57-H24 6 63764613 170561549 RP11-400D2 GS-31-J3 4 135602222 191400000
 RP11-161I2 RP11-231D20 8 18447618 42333644 RP11-241J12 GS-240-G13 5 80045485 180756037
 RP11-172F7 RP11-8B23 9 85287618 89927994 RP11-449G3 GS-3-K23 7 54413839 158261821
 RP11-382A18 RP11-425A6 10 18260400 36004759 GS-77-L23 RP11-369E15 8 1 20890068
 RP11-396M20 RP13-238F13 10 88054888 126190348 RP1-198M21 RP5-1056B24 8 41516869 146167102
 RP11-11N15 CTD-3245B9 11 110352104 118395819 GS-43-N6 RP11-274B18 9 1 68528389
 RP11-76K19 RP11-327P2 13 19136604 51243933 GS-23-B11 RP11-2K17 10 1 15140784
 RP11-570N16 RP11-105D1 15 24960345 49085328 RP13-404M3 RP11-380G5 10 34543824 89798429
 RP11-282M16 GS-124-5 15 65872293 100100000 GS-8-M16 RP11-25J3 12 1 74333757
 RP11-394B2 RP4-597G12 16 69164308 88495411 RP11-410A13 GS-221-K18 12 94459564 133387831
 RP11-526H11 GS-75-F20 18 63881662 78100000 RP11-40A8 GS-1-L16 13 50328528 114100000
 RP5-914B9 RP5-1049G16 20 32566759 45732628 RP11-168D12 RP11-125H8 14 41341385 66870415
 RP11-414C23 RP11-270H4 y 2828841 26727165 RP11-79J20 GS-200-D12 14 88818864 105600000
      RP11-274A17 RP11-296I10 16 33544449 68870687
      GS-202-L17 GS-50-C4 17 1 80827381
      RP11-15A1 GS-325-I23 19 49045897 64100000
      GS-82-O2 RP5-1161H23 20 1 33049748
      RP5-1005L2 GS-81-F12 20 44219240 62892997
      RP11-304D2 GS-63-H24 21 18224008 46958137
      RP11-457M7 RP11-218L14 x 2773172 154392840
PC295 RP4-662P1 RP4-700A9 1 62070695 65399804 RP11-2A4 RP11-23M2b 3 138893138 199163913
 RP11-345J13 RP11-355H10 2 11155158 16164216 RP11-4O3 RP11-263F19 4 58332161 83487099
 RP11-94A14 RP11-305L22 3 10613350 15764879 RP11-515C16 RP11-451H23 5 139904062 180060082
 GS-36-P21 RP11-36B15 4 55628 37499323 GS-164-D18 RP4-612F12 7 154219 41152163
 RP11-140M23 RP11-301L8 4 174274371 186960518 RP4-715F13 GS-3-K23 7 68911602 158261821
 CTC-352M6 CTD-2323H12 5 127603123 141198799 RP11-227F6 RP5-1056B24 8 62411200 146167102
 GS-196-I5 RP11-97A19 6 1 12579760 RP11-384P5 RP11-269P11 9 80182461 125447742
 RP11-707H15 RP11-58A9 6 81474419 94898446 RP11-535A19 RP11-87N22 11 75107934 112764095
 RP5-1112D6 RP3-329H16 6 111684690 119707570 RP11-390F17 RP11-210L7 12 58234674 101460706
 GS-77-L23 RP11-51K12 8 1 40649244 RP11-414J4 GS-124-5 15 72737468 100100000
 RP11-428N21 RP11-373N18 10 68138624 106023281 RP11-383C19 GS-75-F20 18 32335236 78100000
 RP11-87C12 GS-221-K18 12 120771799 133387831 GS-839-D20 RP1-308O1 x 1 42143960
 RP11-550P23 RP11-478H12 13 29914797 88035241      
 RP11-178D12 RP11-64K10 15 53411855 68768604      
 RP11-424K7 GS-191-P24 16 49618230 90100000      
 GS-202-L17 RP11-524F11 17 1 17521462      
 RP3-469A13 RP4-600E6 20 34886009 37666045      
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loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
 RP11-164E1 RP11-113F1 21 38601021 42689289      
PC310 RP4-785P20 RP4-700A9 1 3247831 65399804 GS-8-L3 RP11-540E17 2 330 31641535
 RP5-940F7 GS-167-K11 1 232380898 245100000 RP11-260K8 RP11-21P18 2 59017517 88273126
 RP11-540E17 RP11-24I5 2 31441962 44500654 RP11-299N3 RP11-33E18 3 2181314 5696842
 RP11-519H15 RP11-81E19 2 106939463 189643781 RP11-484D18 RP11-14I2 3 178148602 185002170
 RP11-419H23 RP11-556H17 2 231905223 241867426 GS-164-D18 RP11-95J15 7 154219 46540919
 RP11-119E13 RP11-23M2b 3 188090395 199163913 RP11-200A13 RP11-71N3 8 106002673 133317994
 RP11-324I10 RP11-416A5 4 4242550 45926806 CTB-184C17 RP11-56J3 11 64626437 107646360
 RP11-373J21 RP11-63M2 4 73467553 138314464 GS-8-M16 RP11-333D23 12 1 37369589
 RP1-64M18 CTD-2052F19 5 12216435 35043272 RP11-96P3 RP11-293B1 12 51027859 76638486
 RP11-241J12 RP1-241C15 5 80045485 131577988 RP11-295A20 GS-221-K18 12 87539854 133387831
 RP11-506N21 RP11-538A16 6 62586405 93823810 RP11-463C8 RP11-417P24 14 76653370 105437086
 RP11-95J15 RP11-449G3 7 46360317 54591432 RP11-404G1 RP11-385D13 17 7563870 15510169
 RP11-506M12 RP11-384A20 7 99314269 121279367 GS-839-D20 RP4-639D23 x 1 32127544
 GS-77-L23 RP11-138J2 8 1 27462575      
 RP11-48L13 RP11-417A4 9 29493271 137871989      
 GS-23-B11 RP5-1194E14 10 1 15739245      
 RP11-152H18 RP11-131J4 11 8634965 55007563      
 RP11-125I23 GS-1-L16 13 26843897 114100000      
 RP11-98N22 RP11-61F4 14 19570817 77513223      
 RP11-289D12 RP11-178D12 15 20363717 53412638      
 RP11-2E17 RP11-266O8 15 78200185 91714417      
 RP11-405F3 GS-191-P24 16 56179405 90100000      
 RP11-4F24 RP11-404G1 17 1564767 8574309      
 GS-52-M11 GS-75-F20 18 1 78100000      
 RP11-164E1 GS-2-H14 21 38601021 46900000      
 XX-p8708 GS-3018-K1 22 15615802 50100000      
PC324 RP11-306I4 RP11-326G21 1 77716164 142392028 GS-232-B23 RP11-306I4 1 1 77883950
 RP11-451C2 RP11-12M21 2 102042560 139815008 RP11-418J17 GS-167-K11 1 119411930 245100000
 RP4-613B23 RP11-78O10 3 42599838 50006856 RG-228-K22 RP11-25C10 3 1 12590814
 RP11-122D19 RP11-12A13 3 54007388 96250469 GS-24-H17 RP11-269M20 5 1 50093906
 GS-118-B13 GS-31-J3 4 1 191400000 GS-164-D18 RP5-905H7 7 154219 62271685
 RP11-28I9 GS-240-G13 5 45570659 180756037 RP11-269P11 RP11-417A4 9 125271849 137871989
 RP5-905H7 RP11-5N18 7 62132326 107913946 GS1-756B1 RP11-79I23 10 8219578 60270663
 GS-77-L23 CTD-2115H11 8 1 43438715 RP11-166B18 RP11-165M8 10 61902228 89694968
 GS-43-N6 RP11-205K6 9 1 126460599 RP11-304I5 GS-137-E24 10 90435254 135313953
 GS-23-B11 RP1-249K20 10 1 9198070 RP11-125G9 GS-221-K18 12 20887518 133387831
 RP11-371O16 RP11-809M12 10 59005947 63041017 RP11-489A11 RP11-548B6 16 21304276 23756350
 RP11-396M20 RP11-304I5 10 88054888 90615085 RP11-283C7 RP11-357N13 16 45502891 52626428
 RP11-277E18 RP11-328P13 12 7918143 19281492 RP11-514D23 GS-191-P24 16 84749036 90100000
 RP11-289D12 GS-124-5 15 20363717 100100000 GS-68-F18 RP5-1050D4 17 150 4866267
 RG-191-K2 RP11-489A11 16 1 21473433 RP11-404G1 RP11-471L13 17 7563870 12108967
 RP11-207A10 RP11-523L20 16 22715683 46605357 RP11-121A13 RP11-474K4 17 20112029 27596064
 RP11-467J12 RP11-21B21 16 51466052 87260485 RP11-156E6 RP5-1169K15 17 37192625 40787106
 RP11-104O19 RP11-12H18 17 4001094 8574309 RP11-416K7 RP11-178C3 17 42875381 55498032
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loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
 RP11-401O9 RP11-488L1 17 10055064 13085706 RP11-89H15 GS-362-K4 17 59626448 81600000
 RP11-388F14 RP11-138P22 17 13211602 23308267 GS-52-M11 GS-75-F20 18 1 78100000
 RP11-47L3 RP11-506G7 17 30523581 38327610 RG-129-F16 GS-325-I23 19 1 64100000
 XX-p8708 GS-3018-K1 22 15615802 50100000 RP11-193B6 GS-2-H14 21 13462479 46900000
 RP11-414C23 RP11-270H4 y 2828841 26727165 RP11-457M7 RP11-218L14 x 2773172 154392840
PC329 RP11-45I3 RP4-540O3 1 16532955 19139464 RP11-309N8 RP11-52C8 2 202535825 232659128
 RP11-419H23 RP11-534J17 2 231905223 234218410 GS-196-I5 RP11-349P19 6 1 65280053
 RP11-767J14 GS-57-H24 6 63764613 170561549 GS-164-D18 GS-3-K23 7 154219 158261821
 GS-77-L23 RP11-197P20 8 1 37371241 RP11-98I12 RP5-1056B24 8 36363082 146167102
 RP11-108L12 RP11-164L18 11 42864060 46383009 RP11-166M16 GS-362-K4 17 67169020 81600000
 RP11-125A7 RP11-10M21 13 41262233 66421707      
 RP11-370A2 RP11-332E3 13 68180810 75439997      
 RP11-95C14 RP11-318K19 13 91284445 95498792      
 RP11-279D17 GS-1-L16 13 99118130 114100000      
 RP11-417N10 RP11-285K4 16 70269439 72453658      
 RP11-283E7 RP11-171G2 17 64281884 68366917      
 RP11-164E1 RP11-113F1 21 38601021 42689289      
PC339 RP11-566O4 RP11-141H20 2 109203303 170070826 GS-8-L3 RP11-245N4 2 330 70572498
 RP11-274J22 CTC-329H14 5 41662376 108180023 RP11-65L3 RP11-556H17 2 179083644 241867426
 GS-164-D18 RP11-71F18 7 154219 19394137 RP11-239J2 RP11-165B13 3 114747418 119243578
 RP11-354H2 RP11-437L1 7 115446926 129021533 RP11-71G7 RP11-23M2b 3 177684963 199163913
 RP11-8P6 GS-3-K23 7 136490854 158261821 RP11-434D11 RP11-420L4 5 126045881 169139510
 RP11-279I21 RP11-240L7 9 94473904 96229878 GS-62-L11 RP11-289M23 6 135997 23684090
 RP11-20H14 RP11-107P10 11 104950107 111973902 RP11-89N17 RP11-148A10 7 33525398 103891116
 RP11-37E23 RP11-394J19 13 31703968 74530080 RP11-353D5 RP11-24H3 8 92382762 99366374
 RP11-452G23 GS-191-P24 16 47238951 90100000 RP11-22A24 RP11-17E16 8 120711400 130702085
 RP11-164E1 RP11-113F1 21 38601021 42689289 RP11-160D19 RP11-417A4 9 95433765 137871989
 RP11-414C23 RP11-270H4 y 2828841 26727165 GS-23-B11 RP11-79I23 10 1 60270663
      RP11-765C10 RP11-80H5 10 89705200 91463649
      GS-8-M16 RP11-268A19 12 1 80392099
      RP11-76K19 RP11-141M1 13 19136604 32947408
      RP11-552M6 GS-163-C9 13 73124080 113376104
      RP11-99L13 RP11-78M2 15 22736020 74647142
      RP11-404G1 GS-362-K4 17 7563870 81600000
      RP11-51B9 RP11-178F10 18 7827406 20371175
      RP11-520K18 GS-75-F20 18 56874822 78100000
      RP11-25F24 RP1-128M19 21 23491444 39702870
      RP1-265B9 GS-63-H24 21 41559383 46958137
PC346 RP11-173C1 RP11-204D19 2 39065424 43756723 GS-232-B23 RP11-250D8 1 1 74512062
 RP11-16E8 RP11-2G22 3 21574294 27531253 RP5-963M5 RP11-80B9 1 76580261 237390561
 RP11-396M20 RP11-399O19 10 88054888 90783689 RP11-411G13 GS-167-K11 1 239599404 245100000
 RP11-76K19 GS-1-L16 13 19136604 114100000 RP11-296G16 RP11-211H6 4 1065447 5145322
      GS-164-D18 GS-3-K23 7 154219 158261821
      CTD-2115H11 RP5-1056B24 8 43315811 146167102
      GS-1061-L1 GS-81-F12 20 1 62892997
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loss (min. log2 T/R<-0.3)) gain (min. log2 T/R>0.3)
 Begin (probe) End (probe) chr Begin (bp) End (bp) Begin (probe) End (probe) chr Begin (bp) End (bp)
PC374 RP11-262D22 RP11-106G13 2 17064501 27048324 RP11-418J17 GS-167-K11 1 119411930 245100000
 RP11-540E17 RP11-391D19 2 31441962 51008795 RP11-51K12 RP11-503E24 8 40501073 42674285
 RP11-11G20 RP11-400O18 2 125735232 186543611 RP11-419L20 RP11-2K18 8 110436818 115915271
 RG-228-K22b RP11-488M6 3 1 13656208 RP11-172F7 RP11-78H18 9 85287618 114805811
 GS-118-B13 GS-31-J3 4 1 191400000 RP3-432E18 RP11-173E19 12 46156911 72312988
 CTD-2276O24 RP11-667P13 5 50061472 78198544 RP11-565J15 RP11-559M6 14 45964782 62046831
 RP3-444C7 RP11-176J5 6 20630798 24421543 RP11-68I8 RP11-417P24 14 97835615 105437086
 GS-77-L23 RP1-198M21 8 1 41617043 RP11-500M22 GS-325-I23 19 4806367 64100000
 RP11-404K23 RP11-373J8 9 115288454 127499995      
 RP11-314J18 RP11-115N19 10 70288208 126760588      
 GS-8-M16 RP11-242B24 12 1 37489074      
 RP11-76K19 GS-1-L16 13 19136604 114100000      
 RP11-289D12 GS-124-5 15 20363717 100100000      
 XX-p8708 RP1-76B20 22 15615802 28545603      
 
LL22NC01-
132D12 GS-3018-K1 22 35473472 50100000      
Table S2. RT-PCR analysis of the genes in the eight novel homozygous deleted regions in 11 prostate cancer xenografts.
 PCEW PC82 PC133 PC135 PC295 PC310 PC324 PC329 PC339 PC346 PC374 NP
genes on 2q37.1*
COPS7B ++ ++ ++ ++ ++ ++ ++ – ++ ++ ++ ++
NPPC*1 – – – – – – – – – – – –
ALPP*1 – – – – – – – – – – – –
ALPPL2*1 – – – – – – – – – – – –
ALPI*1 – – – – – – – – – – – –
ECEL1*1 – – – – – – – – – – – –
CHRND*1 – – +/– – – – – – – – – –
CHRNG*1 – – – – – – – – – – – –
TIGD1*2 ND
EIF4EL3 ++ ++ ++ ++ ++ ++ ++ – ++ ++ ++ ++
genes on 8p23.3 *             
ZNF596 + + ++ ++ – + ++ ++ ++ ++ ++ +
FBXO25 ++ ++ ++ ++ +/– ++ ++ ++ ++ ++ ++ ++
INM01 ++ ++ ++ ++ +/–– ++ ++ ++ +/– ++ ++ ++
LOC286161*2 ND
LOC157697 ++ ++ ++ ++ – + ++ ++ + ++ ++ ++
DLGAP2 *1 – – – – – – – – – – – –
genes on 13q13.1 *
BRCA2 ++ ++ ++ ++ ++ – ++ ++ ++ ++ ++ ++
CG018 + + + +/– + – ++ ++ ++ + +/– ++
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Array CGH of DNA from prostate cancer xenografts
 PCEW PC82 PC133 PC135 PC295 PC310 PC324 PC329 PC339 PC346 PC374 NP
LOC88523 ++ ++ ++ ++ ++ – +/– ++ ++ ++ ++ ++
PFAAF5 + + ++ ++ ++ + ++ ++ ++ ++ ++ ++
APRIN ++ ++ ++ ++ ++ – ++ ++ ++ ++ ++ ++
KL ++ ++ +/– +/– +/– – + + ++ – ++ ++
DLC2 ++ ++ ++ ++ ++ – ++ ++ ++ ++ ++ ++
genes on 13q14.2 *
ITM2B ++ ++ ++ – ++ ++ ++ ++ ++ ++ ++ ++
RB1 ++ ++ ++ – ++ + ++ ++ ++ ++ + +/–
P2RY5 ++ ++ ++ – ++ + + +/– + + + +
CHC1L ++ ++ ++ – ++ ++ ++ ++ ++ ++ ++ ++
CYSTRL2  *2 ND
gene 
on16q22.2-q22.3*             
ATBF1 + ++ ++ ++ ++ ++ ++ ++ – ++ ++ ++
gene on16q23.1*             
WWOX + + + + + + + + + + ++ +
genes on 17p12*             
MAP2K4 ++ ++ ++ ++ – ++ – ++ ++ + ++ ++
NCOR-1 ++ ++ – ++ ++ ++ – ++ ++ ++ ++ ++
*: According to the ref seq genes of UCSC Genome Browser, freeze may 2004
*1:  no expression in prostate according to Unigene
*2: 1 exon gene
NP: Normal Prostate. ND: Not determined.
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aBstract
We examined 11 prostate cancer xenografts and 4 cell lines for chromosome 10 altera-
tions. Conventional Comparative Genomic Hybridization (CGH) and array-based CGH 
revealed a pattern of loss of distal 10p, gain of proximal 10p and 10q, and loss of distal 
10q. In addition, array CGH identified 2 high-level amplifications in the cell line PC3, 
homozygous deletions around PTEN in the xenografts PCEW, PC133, PC324 and in PC3 
and small single and double copy deletions around PTEN in PCEW, PC82, PC324, PC346 
and LNCaP. Allelotype analysis confirmed all 10p deletions, 5/6 large 10q deletions, 
the homozygous deletions and the small regions of one copy loss. MXI1, DMBT1 and 
KLF6 were excluded as important tumor suppressor genes. Sizes of homozygous dele-
tions around PTEN ranged from 1.2 Mbp (PC133) to <30 Kbp (PTEN exon 5 in PC295). 
The regions of small single or double copy loss around PTEN were all less than 4.5 Mbp. 
Loss of 1 or 2 copies PTEN was always accompanied by loss of the distal flanking gene 
FLJ11218 and in most cases by loss of the proximal flanking genes MINPP1, PAPSS2 and 
FLJ14600. Furthermore, differential expression was detected for FLJ11218 and PAPSS2. 
Complete deletion or inactivating mutation of PAPSS2 was found in at least 3 samples. 
Additional to 4 homozygous deletions, 1 missense mutation was detected in FLJ11218. 
In conclusion, our data provide evidence for a small region around PTEN as the major 
chromosome 10 alteration in prostate cancer xenografts and cell lines. PTEN inactivation 
is in part of the samples accompanied by loss of one MINPP1 allele, loss of one copy, 
mutation or low expression of PAPSS2, and most frequently with loss of 1 or 2 copies or 
low expression of FLJ11218.
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introDuction
Prostate cancer is the most frequently diagnosed cancer and the second leading cause 
of male cancer death in Western and Northern Europe, Northern America and Australia 
(Greenlee et al., 2001). At present, an adequate therapy of metastatic prostate cancer 
is not available. In order to identify novel therapeutic targets, knowledge of the major 
molecular alterations is urgently needed. 
In prostate cancer, most frequent deletions were found for 6q, 8p, 13q and 16q, indicat-
ing the localization of tumor suppressor genes on these chromosomal arms (Visakorpi 
et al., 1995; Cher et al., 1996; Nupponen et al., 1998b; Alers et al., 2000). Less frequent 
chromosomal losses were found for 5q, 10q and 17p. The most frequently gained chro-
mosome arm was 8q, followed by 7p, 7q and 20q.
Loss of 10q is generally considered as a late step in prostate cancer progression. Al-
lelic imbalance studies indicated several separate regions at 10q22-q26 to be affected, 
suggesting the inactivation of more than one tumor suppressor gene  (Gray et al., 1995; 
Ittmann, 1996; Komiya et al., 1996; Trybus et al., 1996; Cairns et al., 1997; Feilotter et al., 
1998; Leube et al., 2002). Loss of 10q is not unique for prostate cancer. Frequent loss 
of distal 10q has also been described in renal cell carcinoma (Morita et al., 1991), non-
Hodgkin’s lymphoma (Speaks et al., 1992), glioblastoma (James et al., 1988; Fujimoto et 
al., 1989), meningioma (Rempel et al.,1993), malignant melanoma (Reifenberger et al., 
1999), small lung cell cancer (Kim  et al., 1998), bladder cancer (Cappellen et al., 1997), 
and endometrial carcinoma (Peiffer et al., 1995; Nagase et al., 1997). 
The PTEN tumor suppressor gene at 10q23.3, which encodes a lipid and protein phos-
phatase, is frequently altered in prostate cancer (Cairns et al., 1997; Teng et al., 1997; 
Gray et al., 1998; Feilotter et al., 1998; Vlietstra et al., 1998; Whang et al., 1998; Wang et 
al., 1998; McMenamin et al., 1999). Complete PTEN inactivation was detected at varying 
frequency in primary tumors and in up to 60% of metastases, cell lines and xenografts. 
PTEN is even more frequently implicated in glioblastoma (Li et al., 1997; Steck et al, 1997; 
Wang et al., 1997; Rasheed et al., 1997; Teng et al., 1997) and endometrial carcinoma 
(Tashiro et al., 1997), and to a lesser extent in many other tumors. Additional to PTEN, 10q 
harbors the candidate tumor suppressor genes MXI1 at 10q25.2 and DMBT1 at 10q26.2. 
(Eagle et al., 1995; Mollenhauer et al., 1997).
Less is known about 10p alterations in prostate cancer. Variable frequencies of loss 
of distal 10p in prostate cancer have been found (Ittmann, 1996; Trybus et al., 1996, 
Fukuhara et al., 2001; Narla et al., 2001). Recently, mutation of KLF6 on 10p15 in prostate 
cancer has been described (Narla et al., 2001; Chen et al., 2003). 
Xenografts and cell lines are powerful tools in the search for genetic alterations in 
human cancer. They are available in unlimited quantities and, importantly, they lack 
normal cells of human origin, which simplifies the analysis of chromosomal alterations, 
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and the study of structural alterations and expression of individual genes. Previously, we 
described frequent PTEN inactivation in prostate cancer xenografts and cell lines (Vliet-
stra et al., 1998). In the present study we analyze the role of chromosome 10 in prostate 
cancer by conventional CGH, array-based CGH and allelotype analysis. Further, we pres-
ent data on the expression and structure of the candidate tumor suppressor genes MXI1, 
DMBT1 and KLF6. In addition, we describe the structure, deletion and expression of PTEN 
flanking genes, and we address the issue of PTEN haplo-insufficiency in prostate cancer.
materiaLs anD metHoDs
Prostate Cancer derived Cell Lines and Xenografts 
The in vitro growing cell lines LNCaP, PC-3, DU-145 and TSU were cultured under stan-
dard conditions. The in vivo xenografts PC82, PCEW, PC133, PC135, PC295, PC310, PC324, 
PC329, PC339, PC346 and PC374 were propagated on male nude mice (Hoehn et al., 
1980, 1984; van Weerden et al., 1996). 
DNA and RNA preparation 
Genomic DNA from cell lines and xenografts was isolated utilizing the Puregene system 
from Gentra Systems (Minneapolis, MN) according to the procedure described by the 
manufacturer. 
Cell line RNA was isolated by the guanidium isothiocyanate procedure; xenograft RNA 
was isolated by the LiCl protocol (Sambrook and Russell 2001). mRNAs from fetal brain 
and normal prostate tissue were purchased from BD Biosciences Clontech (Palo Alto, 
CA).
Conventional Comparative Genomic Hybridization
Conventional CGH was performed essentially as described (Kallioniemi et al., 1992). In 
brief, tumor DNA and normal male reference DNA samples were labeled by nick transla-
tion (Nick translation system, Invitrogen Life Technologies, Carlsbad, CA) with bio-dUTP 
(Roche Diagnostics, Almere, The Netherlands) and digoxigenin (Roche Diagnostics), 
respectively. Labeled DNA samples (200 ng each) and 15µg COT-1 DNA was ethanol-pre-
cipitated and dissolved in 10 µl hybridization mix (50% formamid, 0.1% Tween-20, and 
10% dextran sulfate in 2xSSC at pH7.0). The probe mixture was denatured (10 min, 72°C), 
pre-hybridized (30 min, 37°C) and hybridized to normal male chromosome spreads (72 h, 
37°C). Next, slides were washed, and fluorescent detection of the biotin- and dioxigenin-
labeled DNA probes was by fluorescein isothiocyanate (FITC)-conjugated avidin (Vector 
Labs, Burlingame, CA) and anti-digoxigenin-rhodamine (Roche Diagnostics) staining, 
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respectively. Chromosomes were DAPI counterstained (4’6’-diamidino-2-phenylindole) 
(Sigma, St. Louis, MO) in Vectashield anti-fade solution (Vector Labs). 
Images were acquired with an epifluorescent microscope equipped with a cooled 
CCD camera (Photometrics Inc., Tuscon, AZ), a triple-band pass beamsplitter emission 
filters (P-1 filter set, Chroma Technology, Brattleboro, VT), and a Quips XL image analysis 
system (version 3.1 Vysis Inc., Downers Grove, IL). Chromosomal regions were scored as 
lost if the mean green to red ratio was below 0.85 and gained if this ratio was above 1.15. 
Eight or more metaphases were analyzed per sample.
Array CGH
Array CGH was performed essentially as described previously (Veltman et al., 2002 and 
2003) with minor modifications, including the use of an automated hybridization station 
and advanced normalization procedures (Vissers et al., submitted). The chromosome 10 
data presented here are part of a genome-wide array CGH study. Chromosome 10 is 
covered by 219 BAC clones, resulting in an average coverage of one clone per 620 Kbp. 
Mapping of BAC clones was derived from the April 2003 release of the UCSC human Ge-
nome database (http://genome. ucsc.edu). Clones were robotically spotted in triplicate 
onto CMT-GAPS coated glass slides (Ultragaps, Corning, Schiphol-Rijk, The Netherlands) 
using a Cartesian Prosys 5510TL arrayer (Genomic Solutions, Cambridgeshire, UK). The 
array CGH profiles were established through hybridization of 500 ng Cy3-dUTP labeled 
genomic DNA combined with 500 ng Cy5-dUTP labeled control genomic DNA using a 
GeneTac Hybridization Station (Genomic Solutions). After scanning, fluorescence test 
over reference ratios (T/R values) were determined for each clone, subsequently log2 
transformed and normalized per array subgrid by applying Lowess curve fitting with a 
smoothing factor of 0.2. Thresholds for copy number gain and loss were set at log2 T/R 
values of +0.3 and –0.3, respectively, based on previous work (Vissers et al., submitted). 
Log2 T/R values below –1 were indications of homozygous deletions; ratios above +1 
were interpreted as high-level amplification. 
PCR and PCR-SSCP
Standard PCR amplifications utilizing Taq polymerase (Promega, Madison, WI) included 
35 cycles of 1 min at 95°C, 1 min at 50°C or 55°C, and 1 min at 72°C. For allelotyping 
and PCR-SSCP, 1 µCi [alpha-32P]dATP (Amersham Biosciences, Bucks, UK) was added to 
a 15 µl reaction mix. Amplified, radio-labeled polymorphic microsatellite markers were 
separated on a sequence gel. SSCP of radio-labeled gene specific PCR products were 
analyzed on a 6% non-denaturing polyacrylamide gel containing 10% glycerol. Gels 
were run at 7W, overnight at room temperature. For detection of homozygous deletions, 
PCR amplifications were performed in a 50 µl reaction volume. Amplified fragments were 
separated on a 2% agarose gel.
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Allelotype analysis and screening for homozygous deletions
Polymorphic microsatellite markers applied for allelotype analysis and screening for ho-
mozygous deletions at 10p were: D10S602, D10S1745, CA237H5A, CA237H5B, D10S591, 
D10S1729, D10S189, D10S547, D10S191, D10S595, D10S197, D10S193, and at 10q: D10S220, 
D10S581, D10S537, D10S1688, D10S1730, D10S1686, D10S1687, CA163M19, D10S579, 
D10S215, D10S1765, AFMa086WG9, D10S541, CA13J3, CA80H5, D10S1753, D10S583, 
D10S1680, D10S1726, D10S192, D10S187, D10S209, D10S217. Most PCR primer sequences 
can be found in Genome Database (http://gdbwww.gdb.org). Additional primer sets 
are: CA237H5A: gcagagcagccttcagtaat and cacttggcaaactacagtgc; CA237H5B: caagag-
catgagtcccattg and gaaccaatcagtcaccaagc; CA163M19: gttttgcccagttgaagtca and tcct-
tccccaactattctatc; CA13J3: gattagcacaacactgggtag and accctctggggaagtactat; CA80H5: 
accagattggatgtgcatgc and caaccagcagtatctgtcac. Positions of markers on chromosome 
10 were derived from the April 2003 release of the UCSC human Genome database. 
 Primer sets utilized in screening for homozygous deletions of KLF6, MINPP1, PAPSS2, 
FLJ14600, FLJ11218, LIPF, DKFZp761K1824, ACTA2, TNFRSF6, CH25H, LIPA, IFIT2, IFIT4, IFIT1, 
RI58, PANK, MPHOSPH1 and MXI1 are available upon request. 
The 74K, 36K, G14Ext, G14 and 60K primer sets for detection of homozygous deletions 
in DMBT1 by PCR on genomic DNA have been published previously (Mollenhauer et 
al., 1997). For more detailed analysis of the homozygous deletion in DMBT1 by PCR-
SSCP the primers DMBTME39-F (5’-ACTTCAGAGGTAGGAGGGT-3’) and DMBTME39-R 
(5’-AGGTAGAGAGTGAGCCCTAG-3’) were utilized.
mRNA expression 
Analysis of mRNA expression was performed by semi-quantitative RT-PCR. cDNA was 
synthesized on 1 µg RNA template utilizing 200 U M-MLV RT (Invitrogen Life Technolo-
gies) and a T
12
-site primer (5’-GCATGCGAATTCGGATCCT
12
-3’) in a buffer, containing 10 
mM DTT, 1 mM dNTPs, and 40 U RNAsin (Promega) for 1 h at 37°C. RNA polymerase II 
was utilized as a control. Specific cDNA fragments were amplified by standard PCR. Gene 
specific RT-PCR primers are available upon request.
Structures of candidate tumor suppressor genes and PTEN flanking genes 
For PCR-SSCP analysis, appropriate fragments of all exons of MINPP1, PAPSS2, TNFRSF6, 
FLJ11218, MXI1 and KLF6 were amplified. Primer sequences are available upon request. 
Selected amplified fragments were purified over QIAquick spin columns (Qiagen, Hilden, 
Germany), cloned into pGEM-T Easy (Promega), and sequenced according to the dideoxy 
chain termination method (Sambrook and Russell, 2001). 
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resuLts
Alterations of chromosome 10 are among the most frequent chromosomal changes 
in prostate cancer as determined by allelotype analysis (Gray et al., 1995; Trybus et al., 
1996; Ittmann, 1996; Komiya et al., 1998; Leube et al., 2002). However, conventional CGH 
studies show less frequent alterations (Nupponen et al., 1998; Alers et al., 2000). To in-
crease our insight into the role of chromosome 10 in prostate cancer, we studied overall 
chromosome 10 alterations in prostate cancer xenografts and cell lines by conventional 
CGH, array CGH and allelotype analysis. In addition we investigated deletion, mutation 
and expression of individual candidate tumor suppressor genes. 
Conventional Comparative Genomic Hybridization 
In conventional CGH 8 out of 15 xenografts and cell lines showed gain or loss of specific 
parts of chromosome 10 (Figure 1). Loss of the distal region of 10p was found in PC310 
(p13-pter), PC324 (p14-pter) and PC3 (p13-pter) (3/15). Small changes at the telomeres 
were not taken into account, because of limited reliability. The majority of gains were 
found around the centromere (5/15): PC135 (q11.2-q22), PC324 (p11.2-p12 and q21-
CELL LINES
XENOGRAFTS
PCEW PC82 PC133 PC135 PC295 PC310
PC324 PC329 PC339 PC346 PC374
PC3 LNCaP FGC TSU DU145
Figuur 1
Hoofdstuk 3
Figure 1. Chromosome 10 alterations identified by conventional CGH in prostate cancer xenografts and cell lines. CGH mean is 
0.85-1.15; number of chromosomes analyzed was 12-16. A bar to the right of a chromosome ideogram indicates gain, a bar to 
the left indicates loss of the chromosomal region. 
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q24), PC339 (p11.2-p14), PC374 (p12-q21) and PC3 (p11.2-q22). Losses of 10q were 
most frequent (6/15). They were present in PC133 (q22-qter), PC135 (q23-qter), PC295 
(q21-q23), PC339 (q23-qter), PC374 (q22-q25) and PC3 (q23-qter). In PCEW, PC82, PC329, 
PC346, LNCaP, TSU and DU145 clear chromosome 10 alterations were not detected. 
Summarizing, chromosome 10 alteration in prostate cancer xenografts and cell lines 
shows a characteristic pattern of loss of distal 10p, gain of proximal 10p and proximal 
10q, and loss of distal 10q.
Array CGH
Array CGH has the advantage over conventional CGH that it detects smaller regions 
of chromosomal gains and losses, and most importantly high-level amplifications and 
homozygous deletions (Veltman et al., 2003). The chromosome 10 array that we utilized 
was composed of 219 BAC clones, covering the chromosome with an average spacing of 
one clone per 620 Kbp.  Figure 2 shows representative examples of the profiles obtained. 
The positions of BAC clones are in Mbp form the top of 10p. Loss of telomeric 10p was 
clearly present in PC310 and in PC324; loss of a more proximal part of 10p was detected 
in PC135 (see Figure 2). Gain of large regions of both chromosome 10 arms was seen in 
PC135, PC324 and PC3 (Figure 2). Two small regions of high-level amplifications were 
identified in PC3, at 10p11.2 and 10q22.2, respectively. Losses of large 10q regions were 
detected in PC133, PC135, PC295 and PC374 (see PC135 as an example, Figure 2). Array 
CGH did not detect chromosome 10 alterations in xenograft PC329 and the cell lines TSU 
and DU145 (data not shown).
The BAC array contained 3 clones, RP11-57C13, RP11-79A15 and RP11-129G17, which 
directly flanked PTEN at 10q23.3 (89.8 Mbp) (see Figure 6A). The adjacent clones in the 
BAC array, RP11-9M11 and RP-11-67L13, map further away from PTEN. In the PCEW, 
PC133 and PC324 array, RP11-129G17 had a log2 T/R value of less than –1. In PC3 this 
value was -0.75 (see Figure 2 for PCEW, PC324 and PC3). All 4 DNA samples are known 
to contain a homozygous deletion of PTEN  (Vlietstra et al., 1998). In PCEW, the log2 
T/R value of RP11-57C13 and RP11-79A15 was also below –1, indicative of complete 
deletion of this region in PCEW and not in other samples (see also Figure 6A). Interest-
ingly, the regions of loss around PTEN seem very small (<4.5 Mbp) in PC82, PC346 and 
LNCaP, which all contain a PTEN point mutation, and in PCEW and PC324 that carry a 
homozygous deletion (see Figure 2).  PC82 also showed a small region of loss on 10q11.2 
next to the centromere, a region difficult to study by conventional CGH.
Allelotype analysis of chromosome 10
To obtain more detailed information of chromosome 10 alterations, the 15 genomic 
DNA samples were also screened for 35 polymorphic microsatellite markers along both 
chromosomal arms. A high marker density was chosen in a small region around the PTEN 
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locus, at 89.8 Mbp, and around KLF6 at 3.9 Mbp. The results are summarized in Figure 3. 
Previously published PTEN alterations (Vlietstra et al., 1998) are indicated at the bottom 
of Figure 3.  
A B
C D
E F
G H
Figuur 2
Figure 2. Chromosome 10 alterations as detected by array CGH of prostate cancer xenografts and cell lines. Panels  A-H 
represent individual chromosome 10 profiles of 8 cases, with clones ordered within chromosome 10 from pter to qter on the 
basis of the physical mapping positions in the April 2003 release of the UCSC Genome database. Each small square represents 
the mean log2 transformed and Lowess normalized test over reference intensity ratio of an individual BAC. The standard 
deviation of each measurement is shown as a vertical bar. PC324 (A), PCEW (B), and PC3 (F) show a homozygous deletion of 
the PTEN region. A small single copy deletion of this region is shown for PC346 (C), LNCaP (D) and PC82 (F). Other regions 
with copy number alterations include loss of telomeric 10p in PC324 (A) and PC310 (G), high-level amplification at 10p11.2 and 
10q22.2 in PC3 (F), and a complex pattern of copy number changes in PC135 (H).
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Because matching normal DNA samples were not available for comparison, 5 con-
secutive mono-allelic bands of highly polymorphic markers was taken as indicative for 
loss of one copy of the corresponding chromosomal region. According to this definition, 
complete loss of one copy of chromosome 10 was found for TSU. Loss of distal 10p, 
including KLF6, was detected in PC310, PC324 and PC3. Large regions of apparent loss 
at 10q were present in PC133, PC295, PC339, PC374 and PC3. As also indicated by array 
CGH, a remarkable large number of small regions of loss of 10q23.3 were detected in 
samples with (PCEW, PC82, PC324, PC346 and LNCaP) or without (PC135 and DU145) 
complete PTEN inactivation. Homozygous deletions and mutation of PTEN were found 
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CA237H5A - 10p15.1 3.9 1 2 1 1 2 1 1 1 2 2 1 1 2 1 2
CA237H5B - 10p15.1 4.0 2 2 1 2 2 1 1 2 2 1 MSI 1 MSI 1 MSI
D10S591 71 10p15.1 4.5 1 1 2 1 2 1 1 2 2 1 2 1 MSI 1 1
D10S1729 72 10p15.1 4.9 2 2 1 1 2 1 1 2 1 2 MSI 1 2 1 MSI
D10S189 73 10p14 6.9 2 1 1 2 1 1 1 2 1 2 2 1 2 1 1
D10S547 74 10p14 10.7 1 1 2 2 1 1 2 2 2 2 2 1 2 1 1
D10S191 81 10p13 14.7 1 1 1 2 2 1 2 2 2 2 MSI 1 MSI 1 MSI
D10S595 85 10p12.31 20.8 2 2 2 2 2 2 2 2 2 2 2 1 MSI 1 MSI
D10S197 75 10p12.1 26.7 1 2 2 2 2 2 2 1 2 MSI MSI 1 2 1 MSI
D10S193 81 10p11.23 30.7 2 1 2 2 2 2 2 2 1 2 2 1 2 1 MSI
D10S220 84 10q11.23 52.2 1 2 1 1 2 2 1 2 1 2 2 2 1 1 MSI
D10S581 80 10q21.3 65.7 2 1 1 1 2 1 1 1 1 1 2 1 2 1 MSI
D10S537 83 10q22.1 72.3 2 2 1 1 1 2 2 2 1 MSI 1 1 MSI 1 MSI
D10S1688 86 10q22.1 72.5 1 1 2 1 1 1 2 2 1 2 1 1 MSI 1 1
D10S1730 83 10q22.3 78.8 1 2 2 1 1 2 1 1 1 MSI MSI 1 2 1 MSI
D10S1686 86 10q23.1 85.7 2 2 1 2 1 2 2 2 1 2 MSI 1 2 1 MSI
D10S1687 81 10q23.2 88.8 2 2 1 2 1 2 2 2 2 2 1 1 1 1 2
CA163M19 - 10q23.2 89.1 1 2 1 2 1 2 2 2 2 1 1 1 1 1 MSI
D10S579 59 10q23.31 89.5 0 1 1 1 1 1 1 1 2 1 1 1 1 1 1
D10S215 81 10q23.31 89.6 0 1 1 1 1 2 1 2 2 1 1 1 1 1 1
D10S1765 83 10q23.31 89.7 0 1 0 1 1 2 1 2 2 1 1 1 1 1 1
AFMa086WG9 - 10q23.31 89.8 0 1 0 1 1 1 0 1 1 1 1 0 1 1 1
D10S541 78 10q23.31 90.1 0 1 0 1 1 2 0 2 1 1 1 0 1 1 1
CA13J3 - 10q23.31 90.5 2 2 0 1 1 1 1 2 1 2 1 1 MSI 1 1
CA80H5 - 10q23.31 91.5 2 1 1 2 1 2 2 1 1 2 2 1 2 1 2
D10S1753 74 10q23.31 92.5 1 2 1 1 1 2 2 1 1 2 1 1 1 1 1
D10S583 84 10q23.33 94.5 1 2 1 2 1 2 1 1 1 2 1 1 1 1 1
D10S1680 82 10q23.33 95.7 2 2 1 1 2 2 1 2 1 MSI 1 1 1 1 MSI
D10S1726 76 10q24.2 100.8 2 1 1 2 2 2 1 1 1 MSI MSI 1 MSI 1 MSI
D10S192 78 10q24.31102.6 2 2 1 2 1 2 2 2 1 MSI 1 1 1 1 MSI
D10S187 84 10q25.3 118.8 2 2 1 1 2 2 2 2 1 2 MSI 1 MSI 1 MSI
D10S209 74 10q26.12122.4 2 2 1 1 2 2 1 2 1 2 1 1 2 1 MSI
D10S217 81 10q26.2 129.5 1 2 1 1 2 2 2 2 1 MSI MSI 1 2 1 MSI
* April 2003 freeze Genome Browser UCSC
PTEN
PTEN 10q23.31 89.8 - - - + - + - + + - - - - + +
Figuur 3
Figure 3. Chromosome 10 alterations identified by allelotype analysis in prostate cancer xenografts and cell lines. If two bands 
of different lengths were detected, two allelic forms were retained in the DNA. One band indicates the presence of one allele or 
two alleles of identical length. The homozygous deletions in PCEW, PC133, PC295, PC324, and PC-3 are represented by “0”. The 
status of the PTEN gene is shown at the bottom of the figure. (+) indicates wild-type PTEN; (-) indicates inactivated PTEN.
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both in small and large regions of allelic loss (PCEW, PC82, PC324, PC346 and LNCaP, 
and PC133, PC295, PC374 and PC3, respectively; see Figure 2). In PC346, PC374, LNCaP 
and DU145, several polymorphic markers showed microsatellite instability (MSI), which 
limited the accuracy of allelotype analysis. Gains, which might be scored by allelic imbal-
ance, were not taken into account.
Analysis of candidate tumor suppressor genes 
Previous allelotype analyses indicated that PTEN might not be the only tumor suppres-
sor gene on chromosome 10q (Trybus et al., 1996; Ittmann, 1996; Komiya et al., 1998; 
Leube et al., 2002). Distal to PTEN the candidate tumor suppressor genes MXI1 (10q25.2) 
and DMBT1 (10q26.2) have been mapped (Edelhoff et al., 1994; Shapiro et al., 1994; 
Mollenhauer et al. 1997). MXI1 antagonizes MYC in modulation of gene expression and 
tumorigenesis (Lahoz et al., 1994). DMBT1 is unstable in cancer cells and might play a role 
in immune defense and epithelial cell differentiation (Mollenhauer et al., 1997, 2000). We 
examined the expression and structure of both genes in the 15 prostate cancer cell lines 
and xenografts. No homozygous deletions or somatic mutations of MXI1 were detected, 
and MXI1 mRNA was present in all RNA samples (data not shown). In the DMBT1 gene, 
an intragenic homozygous deletion of the markers G14EXT and G14 was found in PC135 
(Figure 4A). This homozygous deletion was further examined by PCR-SSCP, utilizing a 
primer set, which amplified the repeat units in DMBT1 (Figure 4B; Mollenhauer et al., 
1999). Only in PC135 an aberrant PCR-SSCP pattern was visible. Sequencing of the am-
plified fragments combined with the presence of marker 36K (Figure 4A) indicated that 
the maximum size of the homozygous deletion in DMBT1 was between exons 6 and 27 
(Figure 4C). Semi-quantitative RT-PCR showed low DMBT1 expression in PC82 and PCEW 
(data not shown).
Recently, a variable frequency of inactivating mutations in KLF6 on 10p15 has been 
described in prostate cancer (Narla et al., 2001; Chen et al., 2003). However, examination 
of KLF6 in the 15 xenografts and cell lines revealed normal expression and absence of 
homozygous deletions or inactivating mutations (data not shown). 
Loss of the PTEN flanking region at 10q23.3
In mouse prostate cancer models not only complete PTEN inactivation, but also PTEN 
haplo-insufficiency has been implicated in tumorigenisis (Di Cristofano et al., 2001; 
Kwabi-Addo et al., 2001; You et al., 2002; Kim et al., 2002). The role of PTEN haplo-
insufficiency in human prostate cancer is not well defined. Investigation of the PTEN 
locus (Figure 3), compared with PTEN inactivation data (Figure 3, bottom; Vlietstra et al., 
1998) learned that the xenografts PC310 and PC329 contain 2 wild-type  PTEN alleles. 
In 9 DNA samples both PTEN alleles were inactivated by homozygous deletion (PCEW, 
PC133, PC295, PC324 and PC3) or deletion of one allele combined with a point mutation 
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(PC82, PC346, PC374 and LNCaP). Loss of 1 copy of PTEN  might have occurred in PC135, 
PC339 and DU145 (Figure 3). TSU was not taken into account, because all chromosome 
10 markers showed one allelic form. Array CGH did not confirm loss of PTEN in DU145 
(data not shown). More detailed studies also excluded PC339 (see below). So, PTEN 
haplo-insufficiency seems only present in PC135.
PTEN flanking genes might be complementary or independent candidate genes 
involved in prostate cancer. We searched 16 genes flanking PTEN for homozygous de-
letions, and the borders of small regions of allelic loss or homozygous deletion were 
accurately mapped. The order of genes and candidate genes was taken from the UCSC 
Genome database (see also Figure 6A). Figure 5 illustrates the genes at 10q23.3, which 
were deleted in the xenografts and cell lines, as determined by PCR. The first distal PTEN 
flanking gene, FLJ11218, was completely or partially deleted in all samples containing 
PTEN deletion, except for PC295. MINPP1, PAPSS2, FLJ14600 and LIPF were deleted in part 
of the samples. None of the DNA samples without complete deletion of PTEN contained 
a homozygous deletion of the 16 flanking genes (data not shown; see for genes investi-
gated Materials and Methods and Figure 6A). 
A P
CE
W
PC
82
PC
13
3
PC
13
5
PC
29
5
PC
31
0
PC
32
4
PC
32
9
PC
33
9
PC
34
6
PC
37
4
PC
3
LN
Ca
P
TS
U
DU
14
5
60
k
74
k
36
k
G1
4e
xt/
G1
4
1 557 26Exon
10 Kb
DMBT1
B
C
Figuur 4
Figure 4. Characterization of the homozygous deletion in DMBT1 in PC135. (A) Agarose gel analysis of the indicated 
amplified DMBT1 gene fragments in PC135. (B) PCR-SSCP of the repeat units of DMBT1 in prostate cancer xenografts and 
cell lines. (C) Schematic representation of the deleted segment in DMBTI in PC135.
71
Chromosome 10 alterations in prostate cancer
Figure 6 summarizes the calculations of the lengths of homozygous deletions and 
mono-allelic regions in the PTEN region. These calculations not only took into account 
the outcome of microsatellite repeat analyses, but also single nucleotide polymor-
phisms in MINPP1, PAPSS2, FLJ11218 and TNFRSF6 genes (see Materials and Methods). 
The homozygous deletions in PCEW, PC133, PC295, PC324 and PC3 ranged in size from 
1.2 Mbp (PC133) to <30 Kbp (PC295) (Figure 6B, see also Figures 3 and 5). In both PC324 
and PCEW, the telomeric border of the deletion was in intron 5 of FLJ11218. In PCEW, the 
deletions in both 10q copies were small and almost identical in lengths. In PC324, the 
mono-allelic region around PTEN was less than 2 Mbp. The mono-allelic regions in PC82 
and PC346, which both contain a PTEN point mutation, and in DU145 and PC135, which 
do not contain inactivated PTEN were less than 3 Mbp (Figures 3 and 6C,D). So, in many 
samples small mono-allelic regions around the PTEN locus could accurately be mapped. 
Most DNA samples did not only loose one or two copies of PTEN, but also one or two 
copies of FLJ11218 and one copy of MINPP1, PAPSS2 and FLJ14600. PC339 is an exception, 
because the mono-allelic region starts in FLJ11218, distal from PTEN to 10qtel. 
Mbp
MINPP1 Exon 1
MINPP1 Exon 6
PAPSS2 Exon11
89.39
89.44
89.63
PTEN Exon 1
PTEN Exon 5
PTEN Exon 9
FLJ14600 Exon 4 89.66
89.75
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89.85
FLJ11218 Exon 7
LIPF Exon 6
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FLJ11218 Exon 4
90.16
90.25
90.56
90 79.
Figuur 5 
Figure 5. Genes at 10q23.3 inactivated by homozygous deletion in the prostate cancer xenografts PCEW, PC133, PC295 
and PC324 and the cell line PC3. The figure shows agarose gel electrophoresis of amplified exons of the indicated genes. The 
positions of the genes on chromosome 10 in Mbp from the top of the p arm are indicated at the right.
Chapter 3
72
Expression and structure of genes flanking the PTEN locus
To investigate further a possible contribution of PTEN flanking genes in prostate cancer, 
the expression patterns of 14 genes in 3 Mbp flanking the PTEN  locus, bordered by 
the polymorphic markers D10S1687 and D10S1753 (see Figure 6A) were analyzed by 
semi-quantitative RT-PCR The results are summarized in Table I. The 1 exon genes DK-
FZp761K184 and CH25H were not included. MINPP1, PAPSS2 and FLJ11218 expressions 
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Figure 6. Schematic representation of the homozygous deletions and mono-allelic regions flanking the PTEN locus in prostate 
cancer xenografts and cell lines. (A) Genes mapping distal and proximal of PTEN. Data are from the April 2003 release of the 
UCSC gene map. (B) Homozygous deletions (open bars) and mono-allelic regions (gray bar) in PC295, PC324, PCEW, PC133 and 
PC3. Grey blocks indicate unknown border of loss (C) Mono-allelic regions (gray bars) in PC82, PC346, PC374 and LNCaP. A cross 
indicates PTEN inactivation by point mutation (see Vleitstra et al., 1998). (D) Mono-allelic regions in PC135, DU145, PC339 and 
TSU, which lack complete PTEN inactivation.
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are shown as examples in Figure 7. A mixed pattern of expression profiles was found. 
Obviously, except for PTEN in PC295, homozygous deletion of a gene correlated with 
absence of expression. In the semi-quantitative RT-PCR no clear-cut correlation was 
found between the copy number and expression level of a gene, indicating gene-copy 
independent regulatory mechanisms to be more important. The stomach-specific gene 
LIPF was hardly expressed in the prostate tumor cells. Most other genes showed a rather 
stable expression level. Potentially interesting variable expression patterns were seen 
for PAPSS2, FLJ11218, and the interferon-regulated gene family IFIT1,2,4, RI58. High 
expression of the latter gene family almost perfectly correlated with androgen indepen-
dence of a xenograft or cell line, PC82 is an exception (Table 1). PAPSS2 not only showed 
absence of expression due to homozygous deletion of the gene (PCEW), but expression 
was also undetectable or very low in PC133, PC324, PC329 and LNCaP. FLJ11218 expres-
sion was not only absent in the 4 samples, where the gene was completely deleted, but 
also absent or very low in PC135, PC346, LNCaP and TSU.
Four flanking genes, which were selected on the basis of frequent deletion and low 
expression (FLJ11218) or function, the phospholipid phosphatase MINPP1, the sulfatase 
PAPSS2 and the tumor necrosis factor receptor TNFRSF6, were searched for point muta-
tions. In MINPP1 and TNFRSF6 polymorphisms, but no somatic mutations were detected. 
In PAPSS2 a polymorphism, which is presumed to decrease its function  (Met295 in 
PC133; see Xu et al., 2002), one frame-shift (deletion C in codon 355 in LNCaP) and a 
missense mutation [GTG to ATG (V45M) in PC346] were found. In FLJ11218 we frequently 
observed the polymorphism GAG/GAC (E37D) in exon 1, and polymorphisms in introns 
4 and 6. In addition, we detected in PC374 the missense mutation ATT to AGT (N232S) 
in exon 5 in PC374.
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Figure 7. Expression of MINPP1, PAPSS2 and FLJ11218 mRNA in prostate cancer xenografts and cell lines. Expression was 
monitored by agarose gel electrophoresis of semi-quantitative RT-PCR products. RNA polymerase II was used as a control.
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Summarizing, low expression or inactivation of 1 or 2 copies of the telomeric flanking 
gene FLJ11218 always paralleled PTEN inactivation. Less frequent alterations in PAPSS2 
copy number, structure or expression were detected. In approximately half of the DNA 
samples one copy of MINPP1 was lost.
Discussion
In this study, we characterized chromosome 10 alterations in xenografts and cell lines 
derived from human prostate cancer. Although it can be argued that xenografts and cell 
lines acquire extra genetic alterations during in vivo and in vitro culturing, as we were 
able to study for some xenografts, most genetic alterations are already present in the 
tumor tissue from which the xenografts derive. We choose for xenogafts and cell lines 
because they lack normal human cells, which enabled accurate study of homozygous 
deletions, regions of chromosomal loss and gene expression patterns. 
The conventional CGH and array CGH data indicated a pattern of loss of distal 10p, gain 
of proximal 10p and 10q and loss of distal 10q. Previous conventional CGH studies of DNA 
from prostate cancer patients showed a similar pattern, although at a lower frequency 
(Cher et al., 1996; Nupponen et al., 1998b; Alers et al., 2000). Absence of chromosome 10 
alterations in LNCaP and TSU, and the loss-gain-loss pattern in PC3 were in accordance 
with previous CGH data of these cell lines (Nupponen et al., 1998a). A recent CGH study 
on a different panel of xenografts also provided the overall picture of loss of distal 10p 
and distal 10q and gain of the middle part of chromosome 10 (Laitinen et al., 2002). In all 
studies loss of part of the q arm is the most frequent chromosome 10 alteration.
Array CGH data of chromosome 10 in prostate cancer xenografts and patient tissues 
are not yet available. In general, our conventional CGH and array CGH data showed the 
same large regions of loss and gain, although the 10p and 10q losses in the array CGH of 
PC3 are not very clear (compare Figures 1 and 2). Obviously, array CGH had the advan-
tage to detect small homozygous deletions and high-level amplifications, not visible in 
conventional CGH. Except for the exon 5 deletion in PC295, all previously described PTEN 
homozygous deletions (Vlietstra et al., 1998) were detected by array CGH. Importantly, 
many regions of single copy loss around PTEN were also small. No doubt, a tilted BAC 
array, covering chromosome 10 completely should further increase the sensitivity of ar-
ray CGH. It should also be instrumental in detection of homozygous deletions and PTEN 
haplo-insufficiency in DNA tissues from all stages of prostate cancer. From our findings 
it can be assumed that until now conventional CGH of prostate cancer tissues frequently 
missed loss of PTEN, underestimating its role in tumorigenesis.
Recently, cDNA arrays have been applied for the analysis of genomic DNA from LNCaP, 
PC3 and DU145 cell lines (Clark et al., 2003). The results indicated absence of alterations 
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in LNCaP and DU145, and amplification of the middle part of chromosome 10 in PC3. We 
confirmed by allelotype analysis the homozygous deletion of SFTPA2 at 10q22 in PC3 
described by Clark et al. (data not shown). However, we did not find the homozygous de-
letion by array CGH, due to the absence of a BAC that covers SFTPA2. Interestingly, three 
BACs (RP11-78F9, RP11-342M3 and RP11-31L4), which map directly proximal to SFTPA2 
at 10q22.3, showed high-level amplification in PC3 (see Figure 2). In PC3, chromosome 
10 seems to be involved in several translocations (Pan et al., 1999). A frequently detected 
breakpoint in PC3 and other prostate cancer cell lines maps at band 10q22 (Pan et al., 
2001). This knowledge combined with the abrupt transition from amplification to dele-
tion at 10q22 in PC3, suggests that SFTPA2 is at the border of a translocation. SFTPA2 
might be lost due to an unbalanced translocation. A breakpoint at 10q22, followed by 
amplification of proximal 10q and loss of distal 10q, might also be present in PC135 
(Figure 2). The homozygous deletion of PTEN in PC3 was not detected in the cDNA array 
(Clark et al., 2003), which might be caused by cross-hybridization with the PTEN pseudo-
gene, a drawback of the application of cDNA arrays for genomic analyses. 
The two high-level amplifications in PC3, at 10p11.2 and 10q22.3 respectively, might 
provide a first clue to the most important amplified genes on proximal 10p and 10q in 
prostate cancer. However, many genes are located in the amplified region at 10p11.2, 
and an obvious candidate cannot be pinpointed as yet. PPIF (cyclophilin F) and the can-
didate gene FLJ90798 map precisely in the high-level amplification at 10q22.3. Whether 
these genes or proximal flanking genes are most important for tumor growth remains to 
be established. The previously in PC3 observed amplified and over-expressed uPA gene 
(Helenius et al., 2001) maps approximately 5.5 Mbp centromeric of PPIF and FLJ90798. 
Further gene hunting should benefit from the identification of overlapping high-level 
amplifications in prostate cancer DNA samples.
Although in some DNA samples hampered by microsatellite instability, allelotype 
analysis was very informative. Many small regions of apparent chromosomal loss at the 
PTEN locus could easily be detected. In general, large regions of a mono-allelic band in 
allelotype analyses matched with 10q deletions as detected by CGH. However, allelotype 
analysis did not detect deletion of a large region of 10q in PC135. Further, chromosome 
10 allelotype analysis did not match CGH in TSU. No chromosome copy changes were 
seen by CGH, but allelotype analysis showed one allelic form of all markers. This is strong 
evidence for isodisomy chromosome 10 in this cell line. A similar observation was made 
for chromosomes 6 and 8 (Verhagen et al., 2002, and Van Alewijk, unpublished data), 
suggesting defective chromosome segregation in TSU.
Allelotype analysis confirmed loss of distal 10p in PC310, PC324 and PC3. However, 
we did not find alterations in KLF6 at 10p15, as previously reported in prostate cancer 
tissues (Narla et al., 2001; Chen et al., 2003). Although it can be argued that the number 
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of samples studied is small, our data indicate that the most frequently affected tumor 
suppressor gene on 10p remains to be identified.  
Allelotype analysis of 10q23.3 in tumors from patients frequently showed a higher 
percentage of allelic loss at the PTEN locus than PTEN alterations (Feilotter et al., 1998; 
Pesche et al., 1998). There might be several explanations for this observation. First of 
all, complete inactivation of PTEN by point mutation or homozygous deletion might 
have been missed. Secondly, it has been proposed that in these samples not PTEN, 
but a more distal gene was inactivated. We could not find evidence for this argument. 
No alterations in MXI1, at 10q25.2, previously implicated at low frequency in prostate 
cancer were observed (Eagle et al., 1995; Prochownik et al., 1998). Neither did we detect 
at high-frequency deletions in the unstable DMBT1 gene, which has been described as 
a candidate tumor suppressor gene in several other tumor types (Mollenhauer et al., 
1999). We also could not find complete inactivation of one of the PTEN flanking genes 
in the absence of PTEN alteration. Therefore, an attractive alternative is PTEN haplo-
insufficiency as the underlying molecular background of 10q loss in early stage prostate 
cancer. In general xenografts and cell lines should be considered as late stage prostate 
cancer, accordingly the high percentage of complete inactivation of PTEN is not surpris-
ing. PTEN haplo-insufficiency seems to be present in PC135 and possibly DU145 (Figure 
3). Careful examination of DNA from micro-dissected prostate cancer samples with a 
variety of experimental approaches should be carried out to address the important issue 
of PTEN haplo-insufficiency in human prostate cancer. In favor of a role of PTEN haplo-
insufficiency in human prostate cancer are mouse model studies. In four prostate cancer 
models, based on prostate specific SV40-Tag expression (TRAMP model), inactivation 
of Ink4a/Arf, Cdkn1b or Nkx3.1, Pten haplo-insufficiency stimulated tumor growth (Di 
Cristofano et al., 2001; Kwabi-Addo et al., 2001; You et al., 2002; Kim et al., 2002).
Although we could not find evidence for a PTEN independent role of flanking genes 
in prostate cancer, a complementary role cannot be excluded. Two observations are im-
portant in this regard: the high frequency of PTEN inactivation by homozygous deletion, 
and the remarkable small size of 10q losses that accompany many PTEN inactivations. 
The latter observation limits the candidate genes to those directly flanking PTEN. We did 
not study in detail FLJ14600, because it is clearly expressed in almost all xenografts and 
cell lines. MINPP1 would have been an interesting candidate, because like PTEN it is able 
to affect phospholipid metabolism. However, the specificity of MINPP1 seems different 
from PTEN, and MINPP1 is in only part of the samples affected by loss of one gene copy. 
The sulfatase gene PAPSS2 shows more frequently loss of one copy. In addition, PAPPS2 
is not expressed or expressed at a low level in several xenografts and cell lines. Inter-
estingly, also 2 presumed inactivating mutations were detected, although both are in 
samples, which already show a low level of PAPSS2 expression (PC133 and LNCaP). Argu-
ing against a role of PAPSS2 deficiency in prostate cancer is the expression of the related 
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gene PAPSS1 in all cell lines and xenografts (data not shown). The strongest candidate to 
complement PTEN in tumorigenesis is the candidate gene FLJ11218. It is inactivated by 
homozygous deletion in 4 DNA samples, and loss of one copy or low expression is found 
in many other samples (Figures 6 and 7). Unfortunately, so far the function of FLJ11218 
is unknown. However, our data warrant further study of this candidate gene in prostate 
cancer.
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aBstract
Recently, a unique fusion between the prostate-specific, androgen-regulated TMPRSS2 
gene and the ETS genes ERG, ETV1 or ETV4 has been described in clinical prostate cancer. 
We investigated mechanisms of expression of four ETS genes, ERG, ETV1, ETV4 and FLI1, 
in eleven xenografts representing different stages of prostate cancer. All five androgen-
dependent xenografts showed as major transcripts over-expression of two splice 
variants of TMPRSS2:ERG, linking TMPRSS2 exon 1 or 2 sequences to ERG exon 4. In one 
of two androgen-sensitive xenografts fusion transcripts of TMPRSS2 and ETV1 were de-
tected. Array-based comparative genomic hybridization and interphase fluorescence in 
situ hybridization indicated both interstitial deletions and translocations as mechanisms 
of TMPRSS2:ERG gene fusion. Importantly, TMPRSS2 to ERG fusions were also observed 
in three of four androgen-independent, androgen receptor negative xenografts and in 
two androgen receptor negative clinical prostate cancer specimens, however, the fusion 
gene was not expressed.  In almost all androgen receptor negative tumor samples over-
expression of wild type ETV4 or FLI1 was detected. Combined our observations indicate 
a key role of fusion of TMPRSS2 and ETS genes in most androgen-regulated prostate 
cancers, which might be bypassed by androgen-independent expression of wild-type 
ETS factors in late stage disease.
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introDuction
Prostate cancer is the most frequent cancer in men in countries with a western lifestyle 
and the second cause of male cancer death (1). Surgery and radiation are standard 
therapy of localized prostate cancer. Palliative therapy of metastatic prostate cancer aims 
at blocking androgen receptor (AR) function. A better understanding of the molecular 
mechanisms of tumorigenesis is essential for the development of novel therapies. Ad-
ditionally, knowledge of the mechanism of prostate cancer development will improve 
prediction of the clinical course of the disease.
Recently, overexpression of the ETS gene ERG has been described in clinical prostate 
cancer (2). Subsequently, it was shown that overexpression of ERG and related ETV1 was 
due to fusion of the TMPRSS2 gene to either ERG or ETV1 (3). This important finding 
adds gene fusion to the mechanisms of gene overexpression in epithelial tumors. At 
low frequency, TMPRSS2 might also be fused to ETV4 in prostate cancer (4). Expression 
of TMPRSS2 that maps to 21q22 is androgen-regulated and prostate-specific (5). ERG is 
also located on 21q22, approximately 3 Mbp proximal to TMPRSS2. ETV1 maps to 7p21 
and ETV4 to 17q21. Together with FLI1, modified ERG, ETV1 and ETV4 are well-known 
oncogenes involved in translocations in Ewing sarcoma and acute myeloid leukemia 
(6).
We investigated the ETS genes ERG, ETV1, ETV4 and FLI1 in human prostate cancers 
transplanted on nude mice. Xenografts are powerful models for dedicated genetic and 
molecular studies because they lack normal cells of human origin. The xenografts utilized 
represent a variety of clinical stages of prostate cancer, ranging from primary tumors 
and local metastases to recurrent disease and distant metastases, and from androgen-
dependent to androgen-independent cancers (7-9). Our data reveal both interstitial 
deletion and gene translocation as mechanisms of fusion between TMPRSS2 and ERG. 
Further our results show high overexpression of two splice variants of the TMPRSS2:ERG 
fusion gene in all androgen-dependent xenografts and absence of ERG overexpression 
in late stage, AR negative xenografts, even if they contain a TMPRSS2:ERG fusion gene. 
The latter observation was also made in AR negative clinical prostate cancer. In almost 
all late-stage, AR negative prostate cancer samples apparently androgen-independent 
expression of wild type ETV4 and FLI1 is detected. These findings show a key role of 
TMPRSS2:ERG in androgen-dependent prostate cancer, which might be bypassed by 
other ETS factors in late stage, AR negative disease. 
Chapter 4
86
materiaLs anD metHoDs
Prostate cancer samples.
The in vivo growing xenografts PCEW, PC82, PC133, PC135, PC295, PC310, PC324, PC329, 
PC339, PC346, and PC374 were propagated by serial transplantation on male nude mice 
as described (7-9). PCEW, PC82, PC295, PC310 and PC329, derived from primary tumors 
or local metastases, are androgen-dependent. PC133, PC324, PC339, PC346 and PC376 
are derived from distant metastases or local progressive disease and are androgen-
independent (PC133, PC324, PC339) or androgen-sensitive (PC346, PC374). PC135 is 
androgen-independent and derived from a lymph node metastasis (see Supplementary 
Table S1).
Clinical prostate tumor samples were obtained from recurrent disease by transurethral 
resection (TUR-P) after informed consent, following approval of the institutional ethical 
committee.
DNA and RNA preparation.
Genomic DNA was isolated utilizing the Puregene system from Gentra Systems (Min-
neapolis, MN) according to the procedure described by the manufacturer. Xenograft 
RNA was isolated according to the LiCl protocol (10). For isolation of RNA from clinical 
samples the Illustra mini RNA kit (General Electric Healthcare, Fairfield, CT) was utilized. 
Array-based CGH.
Arrays were produced from the human 3600 BAC/PAC genomic clone set of the Wel-
come Trust Sanger Institute, covering the full genome at approximately 1 Mb-spacing. 
Degenerated oligonucleotide PCR-products were prepared for spotting on CodeLink® 
slides (General Electric Healthcare) according to published protocols (11) with some 
modifications (12). DNA labeling and hybridization were performed essentially as de-
scribed (11) with minor modifications (13). After hybridization arrays were scanned in a 
ScanArray Express HT (Perkin Elmer, Freemont, CA). The resulting images were analyzed 
with GenePix Pro 5.0 software (Axon Instruments, Foster City, CA) and subsequently 
visualized with an excel macro (12).
Quantitative PCR.
Analysis of mRNA expression was performed by QPCR. Two μg RNA was reverse tran-
scribed utilizing 400 U M-MLV RT (Invitrogen Life Technologies, Carlsbad, CA) and an 
oligo-dT12 primer. QPCR was performed in an ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). QPCR reactions were performed in Power 
SYBR Green PCR Master Mix (Applied Biosystems) containing 330 nM forward and re-
verse primer in a total volume of 25 μl. Thermocycling conditions were according to 
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the recommendations of the manufacturer. Amounts of specific RNAs for each sample 
were determined relative to posphobilinogen deaminase (PBDG) by the Standard curve 
method (Applied Biosystems). Primer combinations used: PBGD-F: (5’-CATGTCT-
GGTAACGGCAATG-3’) and PBGD-R: (5’-GTACGAGGCTTTCAATGTTG-3’). PSA-4A: 5’-
ACGTGTGTGCAAGTTCACC-3’ and PSA-5B: 5’- TGTACAGGGAAGGCCTTTCG-3’. TMPRSS2-F: 
5’- CCTCTGGTCACTTCGAAGAAC-3’ and TMPRSS2-R: 5’-GTAAAACGACGTCAAGGACG-3’. 
AR-7/8A: 5’- TGACTCCGTGCAGCCTATTG-3’ and AR-8B: 5’- ATGGGAAGCAAAGTCTGAAG-3’. 
TMPRSS2-E1:ERG-E4F: 5’-AGCGCGGCAGGAAGCCTTA-3’ and ERG-E4/5R: 5’-CATCAG-
GAGAGTTCCTTGAG-3’. TMPRSS2-E2:ERG-E4F: 5’- GATGGCTTTGAACTCAGAAGC-3’ and 
ERG-E4/5R. TMPRSS2-E3F: 5’-CCACCAGCTATTGGACCTTA-3’ and ERG-E4/5R: 5’-CATCAG-
GAGAGTTCCTTGAG-3’. TMPRSS2–E1F: 5’-GAGCTAAGCAGGAGGCGGA-3’ and ETV1-E5R: 
5’-TGACTGCAGGCAGAGCTGAT-3’. TMPRSS2-E2F: 5’-CCTATCACTCGATGCTGT-3’ and ETV1-
E5R. ERG-F: 5’-TGCTCAACCATCTCCTTCCA-3’ and ERG-R: 5’-TGGGTTTGCTCTTCCGCTCT-3’. 
ETV1-F: 5’-CATACCAACGGCGAGGATCA-3’ and ETV1-R: 5’-TGGAGAAAAGGGCTTCTGGA-3’. 
ETV4-F: 5’-ACCGGCCAGCCATGAATTAC-3’ and ETV4-R: 5’-GAGAGCTGGACGCTGATTG-3’. 
FLI1-F: 5’-GAGGAGCTTGGGGCAATAAC-3’ and FLI1-R: 5’-AGAGCAGCTCCAGGAGGAAT-3’. 
Interphase fluorescent in situ hybridization (FISH).
Nuclear suspensions of the prostate cancer xenografts were prepared essentially as 
described by Vindelov et al (14). Interphase FISH was performed as described (15). 
BAC clones RP11-164E1, RP5-1031F17 (both flanking ERG, see Figure 2A), RP11-113F1 
(TMPRSS2, see Figure 2A), RP11-79G16 (ETV1), RP11-268E15 (ETV4) and RP11-44O2 (FLI1) 
were purchased from BacPac resources (Oakland, CA). Specificity of BACs is shown in 
Supplementary Figures S1 and S2. BAC DNA clones were biotin-16-dUTP or digoxigenin-
11-dUTP labeled using a nick translation reagent kit (Vysis, Downers Grove, IL) according 
to the manufacturer’s directions. Biotin-labeled probes were visualized with FITC-
conjugated avidin (Vector Laboratory, Burlingame, CA) and digoxigenin labeled probes 
with rhodamine conjugated anti-digoxigenin antibody (Roche, Mannheim, Germany). 
Cells were DAPI counterstained. Images of the three fluorochromes were collected on 
an epifluorescence microscope (Leica DM, Rijswijk, The Netherlands) equipped with ap-
propriate filter sets (Leica) and a CCD cooled camera (Photometrics, Tucson, AZ). 
Sequence analysis.
PCR products were purified utilizing SAP/Exonuclease I (USB Corporation, Cleveland, 
OH) according to manufacturer’s instruction. Purified PCR fragments were labeled utiliz-
ing the ABI BigDye Terminator Ready Reaction kit v3.1 (Applied Biosystems) according 
to manufacturer’s instructions. In the sequence reactions the same primers were used 
as for fragment amplification. Sequence samples were run on the ABI 3100 genetic 
Analyzer (Applied Biosystems).
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resuLts anD Discussion
Eleven xenografts derived from various stages of clinical prostate cancer (Supplemen-
tary Table S1; 7-9) were utilized to decipher the role of ETS genes. PCEW, PC82, PC295, 
PC310, PC329, PC346 and PC374 are AR positive. PCEW, PC82, PC295, PC310 and PC329 
grow androgen-dependent on male nude mice; PC346 and PC374 are to a varying extent 
androgen-sensitive. PC133, PC135, PC324 and PC339 are androgen independent. 
First, expression of AR, PSA and TMPRSS2 in xenografts was assessed by QPCR. There is a 
good correlation between the expression of AR and the well-known androgen-regulated 
PSA and TMPRSS2 genes in androgen-dependent and androgen-sensitive xenografts 
(Figure 1A) (5, 9, 16). An exception is PC310, which shows AR and PSA expression, but 
clearly is TMPRSS2 negative (see below). All androgen-independent xenografts are AR 
negative or express an inactive AR, as deduced from lack of PSA and TMPRSS2 expression 
(see also (17)).
Next, we investigated expression of ERG and TMPRSS2:ERG fusion transcripts utiliz-
ing an ERG specific primer set and primer sets spanning TMPRSS2 exons 1, 2 or 3 and 
ERG exon 4, respectively, combined with an ERG exon 4/5 primer (Figure 1B).  In all five 
androgen-dependent xenografts ERG overexpression corresponded with AR and PSA 
expression, linking ERG to a functional AR and to strict androgen-dependent tumor 
growth. Overexpression of ERG correlated with the presence of TMPRSS2:ERG fusion 
transcripts. As confirmed by sequencing, due to alternative splicing in all five xenografts 
two transcripts were present, one containing TMPRSS2 exon 1 linked to ERG exon 4 and 
a second, linking TMPRSS2 exons 1 and 2 to ERG exon 4, respectively (Figure 1D). PCEW 
contained a third transcript linking part of TMPRSS2 exon 3 to ERG exon 4 due to use of a 
cryptic splice donor site in TMPRSS2 exon 3. The open reading frame (ORF) of transcript 
1 is predicted to start at an internal ATG in ERG exon 4. In transcripts 2 and 3 the ORF will 
begin at the start codon of TMPRSS2 and continues in-frame with the indicated part of 
ERG (Figure 1D). The reason of the high frequency of alternative splicing is at present un-
clear. Possibly expression of a truncated ERG protein from the TMPRSS2(exon 1):ERG(exon 
4) fusion transcript favors tumor growth. 
Androgen-sensitive PC374 showed high ETV1 overexpression (Figure 1C). High ETV1 
expression correlated with TMPRSS2:ETV1 gene fusion, as shown by interphase fluo-
rescent in situ hybridization (FISH) on nuclear suspensions utilizing ETV1 and TMPRSS2 
specific BACs (Figure 1C), and the presence of two splice variants of TMPRSS2:ETV1 (Fig-
ure 1C,D). ERG and ETV1 were not overexpressed in PC346 or in late stage, AR negative 
prostate cancer xenografts.  Interphase FISH indicated that low level ETV1 expression in 
PC135 could not be correlated with TMPRSS2 gene fusion (Figure 1C). 5’-RACE confirmed 
that ETV1 expressed in PC135 was wild type (data not shown).
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TMPRSS2 and ERG map in the same orientation at short distance on chromosome band 
21q22.2-q22.3 (Figure 2A). To determine the mechanism of TMPRSS2:ERG  gene fusion, 
genomic DNA from the five xenografts overexpressing the fusion gene was investigated 
by 1 Mbp spaced array-based comparative genomic hybridization (array-CGH). Two dif-
ferent representative array-CGH profiles of chromosome 21 are depicted in Figure 2B,C. 
In PC295 the region between ERG and TMPRSS2 was lost, as indicated by the low T/R ratio 
of the four BACs mapping in this chromosomal region (Figure 2B). A similar profile was 
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Figure 1. Expression of AR, PSA, TMPRSS2 and ERG and ETV1 fusion transcripts in prostate cancer xenografts. A, 
QPCR of AR, PSA and TMPRSS2 mRNAs. B, QPCR of ERG and TMPRSS2:ERG fusion transcripts. C, QPCR of ETV1 and 
TMPRSS2:ETV1 fusion transcripts and interphase FISH with TMPRSS2(green spots) and ETV1 (red spots) specific BACs 
of nuclei from PC135 and PC374. D, Composition of TMPRSS2:ERG and TMPRSS2:ETV1 fusion transcripts. Details of 
methods, FISH BACs and QPCR primers are described in the Materials and Methods section. PBGD expression was utilized as a 
QPCR reference. 
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present in PC329 (data not shown). Although PC82 contains the fusion transcript, the 
region between ERG and TMPRSS2 was largely present (Figure 2C). A comparable profile 
was found in PCEW and PC310 (data not shown). In PC310 the profile was accompanied 
by a small homozygous deletion of the last exons of TMPRSS2 (data not shown), explain-
ing total absence of TMPRSS2 transcripts in this xenograft. We extended the array-CGH 
data by interphase FISH of PC82, PC295 and PC310 nuclei. We utilized as hybridization 
probes BACs RP11-164E1 and RP5-1031P17, which map at a distance of approximately 
1 Mbp, flanking ERG at positions indicated in Figure 2A. Both BACs exclusively stained 
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Figure 2. Array-based CGH analysis of chromosome 21 and interphase FISH of nuclei of prostate cancer xenografts PC295 
and PC82. A, Chromosome 21 region indicating the position of ERG, TMPRSS2 and flanking genes in Mbp from the top of 
the p arm. Positions of BAC clones in this region are indicated above the map. Genes mapping in this chromosomal region are 
indicated below the map. BACs utilized in interphase FISH are in red or green. B, PC295: Array CGH of 21q and representative 
interphase FISH (two green and one red spot) of a nucleus, utilizing BACs RP11-164E1 (green) and RP5-1031P17 (red). C, PC82: 
Array CGH of 21q and representative interphase FISH of a nucleus, utilizing the same BACs as above. Ratio’s of green to red spots 
in interphase FISH, as calculated from over 30 nuclei, are indicated below the pictures. Separate spots in the PC82 nucleus are 
indicated by white arrows. Positions of ERG and TMPRSS2 in the array CGH figures are indicated by black arrows. Vertical 
axis: Log2 ratio of normalized hybridization signal of tumor DNA versus reference DNA (T/R).
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chromosome band 21q22.2 and showed two spots on interphase nuclei from normal 
cells (Supplementary Figure S1A,B). Representative nuclei of PC295 and PC82 are pre-
sented in Figure 2B,C, respectively. In nuclei from PC295 cells we found a higher number 
of green than red spots (average ratio 1.6), indicative of loss of the region between ERG 
and TMPRSS2 in one copy of chromosome 21. In PC82 and PC310 we observed an identi-
cal number of green and red spots (average ratio’s 1.0 and 1.1, respectively). In PC82 that 
contains four copies of chromosome 21, three pairs of red and green spots were always 
closely linked and one pair was clearly separated, as illustrated in Figure 2C. Both array-
CGH and FISH data strongly suggest two different mechanisms of TMPRSS2:ERG fusion: 
one by an approximately 3 Mbp interstitial deletion of one copy of chromosome 21, and 
a second more complex mechanism by chromosomal translocation. 
Array-CGH of genomic DNA from two of the six xenografts that did not over-express 
TMPRSS2:ERG showed a remarkable pattern. In the androgen-independent, AR negative 
xenografts PC133 and PC339 we detected a similar interstitial deletion as in PC295 and 
PC329. The chromosome 21 profile of PC339 is depicted in Figure 3A. Long range PCR 
followed by sequencing confirmed the fusion between TMPRSS2 and ERG in PC133, map-
ping the chromosomal breakpoints in ERG intron 3 and in TMPRSS2 intron 1, respectively 
(Figure 3B). Similarly, PCR plus sequencing identified TMPRSS2:ERG fusion in PC324 that 
does not show a 21q22 interstitial  deletion. This adds a third AR negative xenograft 
to those with TMPRSS2:ERG gene fusion without expression of the fusion gene. Like in 
PC133 the breakpoint in PC324 is in TMPRSS2 intron 1. We also mapped the breakpoints 
in AR positive PC82, PC295, PC310 and PC329 (Figure 3B). As expected from expression 
data (Figure 1B), these breakpoints were in intron 2 of TMPRSS2 and in intron 3 of ERG. 
All six breakpoints in ERG were in the last part of intron 3, suggesting a preferred region 
of recombination in this part of the gene. It remains to be investigated whether the dif-
ference in TMPRSS2 introns involved in ERG fusion between AR positive and AR negative 
xenografts, intron 2 and 1 respectively, is coincidental or of functional importance. The 
absence of TMPRSS2:ERG expression in PC133, PC324 and PC339 (Figure 1B) indicates 
that it is not involved in the androgen-independent growth of these xenografts. Im-
portantly, however, the presence of TMPRSS2:ERG in genomic DNA strongly suggests 
that the fusion gene has been instrumental in an earlier androgen-dependent stage of 
tumor growth.
We postulated that in PC133, PC324 and PC339 androgen-regulated ERG expression is 
bypassed and subsequently downregulated by other mechanisms of progressive tumor 
growth. One mechanism to become independent of androgen-regulated ERG overex-
pression might be by androgen-independent increased expression of a member of the 
ETS transcription factor gene family. As shown in Figure 1, we had no evidence that this 
was the case for ERG or ETV1. Therefore we investigated in the xenografts expression of 
two other ETS transcription factors known to be involved in oncogenesis, ETV4 and FLI1. 
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ETV4 was highly expressed in PC133 and FLI1 in PC324 and PC135 (Figure 3C,D).  Also 
in PC339 we observed expression of FLI1. ETV4 and FLI1 were not or hardly expressed 
in androgen-dependent or androgen-sensitive xenografts. Overexpression was not the 
result of fusion to TMPRSS2 as illustrated by interphase FISH (Figure 3C,D). Additional 
5’-RACE experiments confirmed that ETV4 and FLI1 mRNA in AR negative xenografts was 
wild type and not the result of fusion to other genes (data not shown). 
In clinical prostate cancer many recurrent tumors still express a functional AR. How-
ever, a substantial proportion of recurrent tumors is heterogeneous for AR expression 
or is AR negative (18, 19). We investigated whether like in xenografts TMPRSS2:ERG 
gene fusion without expression of the fusion gene was present in clinical samples. Ar-
ray CGH showed in four of eleven recurrent tumors the interstitial deletion at 21q22 
indicative of TMPRSS2:ERG fusion (see Figure 4A,B for examples). From three of these 
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Figure 3. Genetic and expression analysis of AR negative prostate cancer xenografts. A, Array CGH of chromosome 21q of 
androgen-independent, AR negative xenograft PC339 (see for details Figure 2 and Materials and Methods). B, Positions of 
breakpoints in ERG and TMPRSS2 in xenograft DNAs. Breakpoints were mapped by standard long range PCR utilizing a 
mixture of Taq and Proofstart DNA polymerase, as indicated by the manufacturer (Qiagen, Valencia, CA). Above the genes the 
positions of breakpoints in AR positive, androgen-dependent xenografts are shown, below the genes the breakpoints in AR 
negative xenografts are indicated. C, QPCR of ETV4 expression in prostate cancer xenografts. D, QPCR of FLI1 expression in 
prostate cancer xenografts. Details are described in the legend to Figure 1 and in Materials and Methods. Standard 5’-RACE, 
utilizing the Generacer kit from Invitrogen, indicated that ETV4 and FLI1 transcripts in AR negative PC133, PC135, PC324 
or PC399 were wild type. Inserts in C and D show representative interphase FISH pictures of nuclei from indicated xenografts, 
showing the absence of fusion of TMPRSS2 to ETV4 or FLI1. In all pictures the green spots indicate TMPRSS2; in C, the 
red dots represent ETV4; in D, the red spots represent FLI1. 
93
The TMPRSS2:ERG fusion gene in prostate cancer
tumors (T1-1, T1-8 and T3-7) RNA was available. Importantly, we also had available DNA 
and RNA from recurrent tumor T1-7 of which AR negative xenograft PC324 was derived. 
These four tumors and a control recurrent tumor without TMPRSS2:ERG fusion (T6-9) 
were investigated by QPCR for specific gene expression patterns (Figure 4C,D). T1-1, 
T3-7 and T6-9 expressed AR and its target genes PSA and TMPRSS2, although expres-
sion in T1-1 was low. In contrast, T1-8 and, as expected, T1-7 showed hardly any AR, PSA 
and TMPRSS2 expression. All tumor samples had a basal level of ERG expression. ERG 
overexpression combined with TMPRSS2:ERG fusion transcripts was clearly detected in 
T3-7, and absent in T1-8 and T1-7. T1-1 showed a low level of TMPRSS2:ERG expression, 
which might indicate tumor heterogeneity. The data confirm and extend the findings 
in xenografts showing that AR negative tumors can carry a TMPRSS2:ERG fusion gene 
without expression of the gene. Background expression levels and presumed heteroge-
neity of tumors hampered accurate investigation of ETV4 and FLI1 in the clinical samples 
(Supplementary Figure S3). ETV4 expression was highest in AR negative T1-8 and T1-7, 
but differences with other tumor samples were small. Like in PC324, expression of FLI1 
was high in T1-7, but also T1-1 showed high expression of FLI1. The latter might be ex-
plained by tumor heterogeneity, as proposed previously (Figure 4C,D). Obviously, more 
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Figure 4. Array-based CGH of chromosome 21 and specific gene expression patterns of clinical recurrent prostate cancer 
specimens. A,B, Array CGH of chromosome 21 of recurrent tumors T1-8 and T3-7. Positions of ERG and TMPRSS2 are 
indicated by black arrows. Vertical axis: Log2 ratio of normalized hybridization signal of tumor DNA versus reference DNA (T/R). 
C, QPCR of AR, PSA and TMPRSS2 mRNAs. D, QPCR of ERG and TMPRSS2:ERG fusion transcripts. Details of methods and 
QPCR primers are described in the Materials and Methods section. PBGD expression was utilized as a QPCR reference. 
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detailed immunohistochemical studies, including AR and ETV4 or FLI1 double staining 
are needed to substantiate the latter observation.
In conclusion, our xenograft data extend previous observations in clinical prostate 
cancer (3, 4) and shed new light on the role of ETS transcription factors in prostate 
cancer. First, we detected two mechanisms of gene fusion between ERG and TMPRSS2. 
Secondly, we observed that TMPRSS2:ERG overexpression is functionally correlated with 
AR expression. Both in xenografts and clinical samples we showed that the TMPRSS2:ERG 
fusion gene can be present in absence expression of the gene in AR negative tumors. 
Furthermore, our data suggest that other members of the ETS family, possibly wild type 
ETV4 or FLI1, might take over the role of androgen-regulated TMPRSS2:ERG in late stage 
AR negative prostate cancer.
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suPPLementary information
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aBstract
TMPRSS2-ERG gene fusion is the most frequent genetic alteration in prostate cancer. 
TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate. 
TMPRSS2 transcripts can start at either exon 1 or at a more upstream and less well 
characterized exon 0. To gain insight in the mechanism of TMPRSS2-ERG expression 
we determined the specific characteristics of transcripts starting at exon 1 and exon 
0. TMPRSS2(exon 0) and TMPRSS2(exon 1) transcripts were similarly androgen-regulated 
in prostate cancer cell lines, but the expression levels of TMPRSS2(exon 1) were much 
higher. Comparison of expression in different tissues showed TMPRSS2(exon 0) expres-
sion to be much more prostate-specific. In seven androgen-receptor-positive prostate 
cancer xenografts, TMPRSS2(exon 1) transcripts were expressed at similar levels, but 
TMPRSS2(exon 0) transcripts were expressed at very variable levels. The same phenom-
enon was observed for TMPRSS2-ERG fusion transcripts. In clinical prostate cancers, the 
expression of TMPRSS2(exon 0)-ERG was even more variable. Expression of TMPRSS2(exon 
0)-ERG transcripts was detected in 55% (24 of 44) of gene-fusion-positive primary tu-
mors, but only in 15% (4 of 27) of gene-fusion-positive recurrences and at much lower 
levels. Furthermore, in primary tumors, expression of TMPRSS2(exon 0)-ERG transcripts 
was an independent predictor of longer biochemical progression-free survival.
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introDuction
Recently, recurrent fusions of prostate-specific and androgen-regulated TMPRSS2 to the 
ETS genes ERG, ETV1, ETV4 and ETV5 have been reported as the most frequent genetic 
alterations in clinical prostate cancer (1-9). TMPRSS2-ERG fusion is detected in 40-70% 
of clinical prostate cancers. Fusion of ETV1, ETV4 and ETV5 to TMPRSS2 are much less 
frequent, but ETV1, ETV4 and ETV5 have multiple fusion partners. Expression of most 
of these partner genes is prostate-specific and androgen-regulated (1-3, 5-9). Some 
clinical studies have shown an association between TMPRSS2-ERG and a more aggressive 
prostate cancer phenotype (10-14). However, other studies did not find a statistically 
significant association with recurrence-free survival (15), or even described TMPRSS2-
ERG to be correlated with a more favorable outcome (16, 17).
TMPRSS2 has more than one first exon (UCSC Genome Browser, genome.ucsc.edu). Not 
only fusion transcripts starting at the well known TMPRSS2 exon 1, but also transcripts 
that start from a more upstream and less well characterized alternative first exon, here 
denoted exon 0, have been identified (15, and Hermans, unpublished). 
In the present study we determined the specific characteristics of TMPRSS2 transcripts 
starting at exon 1 and exon 0 in benign prostatic tissue and in prostate cancer. Moreover, 
we investigated clinical prostate cancer samples (primary tumors and recurrences) for 
expression of TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG fusion transcripts. In 
the primary tumors we correlated fusion gene expression with time to biochemical 
progression after radical prostatectomy. Our data show different expression patterns of 
TMPRSS2(exon 0) and TMPRSS2(exon 1) transcripts. Further, our findings indicate a more 
favorable prognosis of tumors with TMPRSS2(exon 0)-ERG expression.
materiaLs anD metHoDs
Prostate cancer cell lines and xenografts.
Prostate cancer cell lines LNCaP and DuCaP were grown in RPMI-1640 supplemented 
with 5% fetal calf serum and antibiotics. Androgen receptor (AR) positive prostate can-
cer xenografts PCEW, PC82, PC295, PC310, PC329, PC346 and PC374, and AR-negative 
xenografts, PC133, PC135, PC324 and PC339, were propagated by serial transplantation 
on male nude mice as described (18). 
Clinical samples.
Primary prostate tumors were obtained by radical prostatectomy and recurrent tumors 
by transuretheral resection of the prostate (TURP). Hematoxilin/eosin stained tissue sec-
tions were histologically evaluated by two pathologists (Van der Kwast, Van Leenders). 
Chapter 5
102
Only samples that contained at least 70% tumor cells were selected. The clinical and 
pathological demographics of the patients with primary prostate tumors included in the 
statistical analysis (N=67) are given in supplementary Table S1. Tissues were snap-frozen 
and stored in liquid nitrogen. Use of the samples for research purposes was approved by 
the Erasmus MC Medical Ethics Committee according to the Medical Research Involving 
Human Subjects Act (MEC-2004-261).
RNA isolation.
RNAs from the prostate cancer cell lines LNCaP and DuCaP cultured in the absence or 
the presence of 10-9M R1881 were isolated using the RNeasy RNA extraction kit (Qiagen, 
Valencia, CA). RNA from clinical prostate cancer samples was isolated from frozen tis-
sue sections using RNA-Bee (Campro Scientific, Berlin, Germany). Xenograft RNA was 
isolated according to the LiCl protocol.
Quantitative PCR (QPCR). 
Total RNA was reverse transcribed using M-MLV reverse transcriptase (Invitrogen, Carls-
bad, CA) and an oligo dT12 primer. cDNAs of 16 different tissues were purchased from 
Clontech (Mountain View, CA). QPCR reactions were performed in Power SYBR Green PCR 
Master Mix (25 μl), containing 0.33 µM forward and reverse primer in an ABI Prism 7700 
Sequence Detection System (Applied Biosystems). Amplified products were quantified 
relative to Porphobilinogen Deaminase (PBGD). Primers are listed in supplementary 
Table S2.
Statistical analysis. 
Associations between clinical and histopathological variables and expression of 
TMPRSS2-ERG transcripts were evaluated by the Pearson’s Chi-square (X²) test, the 
Mann-Whitney U test, or Kruskal-Wallis test, where appropriate. Expression of TMPRSS2-
ERG transcripts was correlated with the primary end point: biochemical progression-free 
survival, defined as time from radical prostatectomy to date of biochemical recurrence. 
Biochemical recurrence was defined as: 1) a PSA-level higher than 0.2 ng/ml at two 
consecutive measurements with a three-month-interval if the PSA-nadir was < 0.1 ng/
ml, or 2) a PSA-nadir of ≥ 0.2 ng/ml. Patients that died from other causes than prostate 
cancer, or that were lost to follow-up, were censored at the date of last PSA-test. Patients 
were routinely followed three-monthly the first year after radical prostatectomy, the 
second year semi-annually and subsequently at 12-month intervals. In case of progres-
sion, patients were again followed every three months. Kaplan-Meier curves were 
constructed to assess the probability of remaining free of biochemical recurrence as a 
function of time after surgery. The differences between the survival curves of the groups 
were tested using the log-rank test, or Breslow method if appropriate. A Cox propor-
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tional regression analysis with forward stepwise elimination was performed to assess 
the impact of various parameters on time to recurrence. In the multivariate analysis the 
model included pathological T-stage, surgical margin status, the Gleason score of the 
primary tumor and expression of indicated TMPRSS2-ERG fusion transcripts. Patients 
with unknown parameters were excluded from the analysis. Statistical analyses were 
performed using the Statistical Package for Social Sciences, version 15.0 (SPSS, Chicago, 
IL), with a significance level of 0.05 (two-tailed probability).
resuLts
TMPRSS2-ERG gene fusion is present in 40-70% of primary prostate tumors. ERG and 
TMPRSS2 are located ~3 Mbp apart on chromosome 21q22.3 in the same orientation 
(Fig 1A). The most common TMPRSS2-ERG fusion transcripts are composed of TMPRRS2 
exon 1, or exons 1 and 2, linked to exon 4 of ERG. Less frequently, fusion of TMPRSS2 exon 
1 or 2 to other ERG exons have been detected (19). Genomic databases describe that 
TMPRSS2 transcripts might also contain an alternative first exon, here denoted exon 0, 
that maps ~4 kbp upstream of exon 1 (Fig. 1A). TMPRSS-ERG fusion transcripts might also 
contain TMPRSS2 exon 0 (15, and Hermans unpublished).
We determined the specific characteristics of transcripts starting at either exon 0 or 
exon 1 of TMPRSS2. First, we investigated the tissue-specificity of both transcripts on 
RNA from 16 different normal tissues. Although expression of TMPRSS2(exon 1) mRNA 
was highest in prostate, these transcripts were also detected in lung, kidney, pancreas 
and colon. In contrast, TMPRSS2(exon 0) mRNA had a prostate-specific expression pat-
tern (Fig 1B). Subsequently, we performed QPCR analysis on RNA from prostate cancer 
cell lines DuCaP and LNCaP, cultured in absence or presence of the synthetic androgen 
R1881. Both TMPRSS2 transcripts were induced by androgens (Fig. 1C). Notably, in the 
cell lines expression of TMPRSS2(exon 0) transcripts was very low compared with expres-
sion of TMPRSS2(exon 1).
Testing of RNAs from eleven human prostate cancer xenografts for expression of TM-
PRSS2 starting at either exon 0 or exon 1 showed that six AR-positive xenografts, PCEW, 
PC82, PC295, PC329, PC346 and PC374, expressed TMPRSS2(exon 1) at similar levels (Fig. 
1D). Xenograft PC310 showed no expression of TMPRSS2, because of a homozygous de-
letion (8). Four xenografts expressed TMPRSS2(exon 0) with a much more variable level 
of expression. None of the AR-negative xenografts expressed TMPRSS2.
Previously we have shown that five androgen-dependent xenografts, PCEW, PC82, 
PC295, PC310 and PC329, contained TMPRSS2(exon 1)-ERG mRNA (8). Comparison of 
TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG expression  by QPCR showed that three 
xenografts, PC82, PC295 and PC329, expressed TMPRSS2(exon 0)-ERG at different expres-
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sion levels (Fig. 1D). However, the other two xenografts with TMPRSS2-ERG transcripts, 
PCEW and PC310, did not express TMPRSS2(exon 0)-ERG at all. No large variation in ex-
pression levels was seen for TMPRSS2(exon 1)-ERG transcripts in the five xenografts (Fig. 
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Figure 1. Characterization of TMPRSS2 and TMPRSS2-ERG transcripts starting at exon 0 or exon 1. (A) Schematic 
representation of the TMPRSS2-ERG locus on chromosome band 21q22.3. The most frequent gene fusion events are 
indicated. The enlarged genomic region containing TMPRSS2 shows exon 0 and exon 1 repeat sequences. (B) Tissue-
specific expression of TMPRSS2(exon 0) and TMPRSS2(exon 1) mRNA assessed by QPCR analysis on a cDNA panel 
from 16 different normal tissues. Mean of duplicate experiment relative to PBGD with standard deviation (SD) is shown. 
(C) Androgen-regulated expression of TMPRSS2(exon 0) (left panel) and TMPRSS2(exon 1) (right panel) mRNA in 
AR-positive prostate cancer cell lines LNCaP and DuCaP. LNCaP and DuCaP cells were grown in absence and presence of synthetic 
androgen R1881 (10-9 M) for 24h. Mean of duplicate experiments relative to PBGD with SD are depicted. Note that the level of 
TMPRSS2(exon 0) expression is much lower in the cell lines than in the normal prostatic tissue (panel B). (D) QPCR analysis 
of TMPRSS2(exon 0) and TMPRSS2(exon 1) (left panel) and TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-
ERG (right panel) transcripts in eleven human prostate cancer xenografts. Mean of duplicate experiments relative to PBGD 
with SD are shown.
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1D). This difference in expression level between TMPRSS2(exon 0)-ERG and TMPRSS2(exon 
1)-ERG transcripts was similar as observed for wild type TMPRSS2(exon 0) and (exon 1) 
transcripts. 
Next, we determined the expression of TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG 
transcripts in a cohort of 126 fresh-frozen clinical prostate cancer samples (81 primary 
tumors and 45 recurrent tumors) (Fig. 2A). TMPRSS2-ERG transcripts were detected in 
54% (44/81) of the primary tumors and in 60% (27/45) of the recurrences. In the primary 
tumors, 20/81 (25%) of the cases exclusively expressed TMPRSS2(exon 1)-ERG transcripts, 
three samples (4%) exclusively expressed TMPRSS2(exon 0)-ERG and 21 (51%) expressed 
both transcript subtypes. In the recurrent tumors exclusive expression of TMPRSS2(exon 
1)-ERG was detected in 23/45 (51%) of the cases, whereas none expressed exclusively 
TMPRRS2(exon 0)-ERG and only 4 cases (9%) expressed both subtypes. Expression levels 
of TMPRSS2(exon 0)-ERG transcripts were significantly higher in primary tumors than in 
recurrent tumors (p=0.015), and variation in expression was much larger in the primary 
tumors than in the recurrences (Fig. 2B). In contrast, the percentage of tumors express-
ing TMPRSS2(exon 1)-ERG transcripts was in the same range for primary and recurrent 
tumors and also the expression levels of these transcripts did not differ between both 
tumor types  (p=0.74).  
We correlated expression of TMPRSS2(exon 0)-ERG with clinical outcome in the primary 
prostate cancer cohort (N=81) to see whether it was of prognostic value. We excluded 
from the analysis 10 patients that were known to harbor fusion or overexpression of 
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Figure 2. Expression of TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG transcripts in clinical prostate cancer 
samples. (A) Distribution of TMPRSS2-ERG transcript subtypes in primary tumors and in recurrences. Primary tumors: N=81; 
Recurrent tumors: N=45. (B) Box plot of TMPRSS2(exon 0)-ERG and TMPRSS2(exon 1)-ERG mRNA expression levels 
in primary tumors and recurrences. Outliers are depicted by an ° and extremes are depicted by an *.
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other ETS genes, and 4 patients whose primary treatment was not a radical prostatec-
tomy. Despite the very long follow-up available (median more than 10 years) only 11 out 
of the remaining 67 patients died from prostate cancer, precluding statistical analysis. 
Instead, we used time to PSA recurrence after radical prostatectomy as an end point. 
The patients’ demographics are summarized in supplementary Table S1. No differences 
were seen in clinical and histopathological characteristics between patients expressing 
TMPRSS2-ERG and gene-fusion-negative patients, although TMPRSS2-ERG-negative pa-
tients had higher Gleason scores with borderline significance (p=0.053) (supplementary 
Table S3). The median time to PSA progression was not significantly different between 
the two groups: 73.2 versus 122.1 months (95% CI: 32.7-113.7 versus 70.6-173.6, p=0.45) 
(Fig. 3A). 
Within the TMPRSS2-ERG positive population the only difference between patients 
that exclusively expressed TMPRSS2(exon 1)-ERG transcripts and patients that expressed 
the TMPRSS2(exon 0)-ERG subtype was that the former had higher pathological stages 
than the latter (p=0.009) (supplementary Table S4). The median time to PSA progression 
for patients expressing TMPRSS2(exon 0)-ERG transcripts was significantly longer than for 
patients that exclusively expressed TMPRSS2(exon 1)-ERG transcripts:158.2 versus 50.5 
months (95% confidence interval (CI): 98.9-217.5 versus 32.6-68.4, p=0.012) (Fig. 3B). 
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Figure 3. Kaplan-Meier curves showing biochemical progression-free survival of prostate cancer patients defined by 
TMPRSS2-ERG fusion transcript status and time to PSA progression after radical prostatectomy. (A) Biochemical progression-
free survival curves for prostate cancer patients with or without expression of TMPRSS2-ERG transcripts. (B) Biochemical 
progression-free survival curves for the TMPRSS2-ERG-positive group, which was stratified in patients with and without 
expression of TMPRSS2(exon 0)-ERG transcripts.
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Using a Cox proportional hazards model, positive surgical margins, Gleason score ≥ 
7, pathological stage ≥ pT3a, and absence of TMPRSS2(exon 0)-ERG transcripts were all 
associated with a worse biochemical progression-free survival. Importantly, multivariate 
analysis with forward stepwise selection showed expression of TMPRSS2(exon 0)-ERG 
fusion transcripts to be an independent predictor of progression-free survival (HR = 0.34 
(95% CI: 0.14-0.84, p=0.019)) (Table I). 
Discussion
This study addresses two important aspects of TMPRSS2-ERG expression in prostate 
cancer. First of all, a remarkable difference in expression characteristics was detected 
between TMPRSS2(exon 1) and TMPRSS2(exon 1)-ERG transcripts on the one hand, and 
TMPRSS2(exon 0) and TMPRSS2(exon 0)-ERG transcripts on the other hand. Secondly, the 
clinical data indicated a more favorable prognosis for prostate cancer patients express-
ing TMPRSS2(exon 0)-ERG transcripts. 
Table 1. Results of univariate and multivariate analyses
Univariate Multivariate
Variable N Median time to 
PSA recurrence 
(months)
95% CI p-value HR
(95% CI)
p-value HR
(95% CI)
p-value
Surgical margins
positive
negative 30
31
43.9
122.1
31.0-56.8
49.5-194.7
< 0.001 7.5 (3.0-18.5)
1.0
< 0.001 7.7 (3.0-19.4) 0.001
Gleason Score
≥ 7
< 7
26
35
68.2
155.4
41.5-94.9
117.7-192.2
0.037 2.1 (1.0-4.5)
1.0
0.041
pT-stage
extraprostatic 
organconfined
43
18
65.0
158.2
37.4-92.5
146.7-169.7
< 0.001 5.7 (1.9-16.8)
1.0
0.002
TMPRSS2(exon 0)-
ERG expression
Yes
No 2140 158.2
68.2
98.9-217.5
36.8-99.6
0.015 0.36 (0.15-0.85)
1.0
0.02 0.34 (0.14-0.84) 0.019
Abbreviations:
CI = confidence interval
HR = hazard ratio
pT-stage = pathological stage
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It is estimated that almost half of all genes in the human genome contain more than 
one first exon, as an important mechanism to regulate gene expression (20, 21). Here, we 
showed that TMPRSS2 transcripts starting at exon 0 were much more prostate-specific 
than those starting at exon 1, and that the expression level of transcripts containing 
exon 0 was much more variable. Further, our xenograft data indicated that the fusion 
to ERG did not preferentially influence the use of TMPRSS2 exon 0 or exon 1. TMPRSS2 
exon 0 is located in a retroviral repeat element, ERVL-B4 (Fig. 1A). This repeat does not 
contain a standard LTR promoter element, however, other retroviral repeat sequences 
might function as cryptic promoters (20). Within the same retroviral repeat the TMPRSS2 
sequence present in a TMPRSS2-ETV4 fusion transcript is located (4). Although a different 
5’-UTR might affect translation efficacy, the major protein translated from the fusion 
transcripts seems an identical N-truncated ERG protein, which is translated from an ATG 
in the ERG exon 4 part of the fusion transcripts. 
It could be speculated that the prostate-specific TMPRSS2(exon 0) transcripts are 
expressed in tumors with a more differentiated phenotype. Recurrent tumors represent 
late stage prostate cancer that normally have a less differentiated phenotype. In our 
study, 55% of the recurrences had a Gleason score ≥ 8, compared with 15% of the pri-
mary tumors. An alternative explanation is that expression from exon 0 is stimulated by 
the stromal compartment, which will be different in primary tumors and recurrences. 
Obviously, there are no stromal cells present during in vitro culture of prostate cells, 
which had very low expression levels of TMPRSS2(exon 0) (Fig. 1).
The prognostic significance of TMPRSS2-ERG gene fusion remains subject of debate, al-
though a growing number of studies has been published on this matter (10-17). Because 
technology used to investigate TMPRSS2-ERG varies (FISH or QPCR) and compositions of 
patient cohorts differ considerably, it is difficult to draw general conclusions from avail-
able data. In the present study on a well-defined patient cohort with a very long median 
follow-up, there was no difference in time to PSA recurrence after radical prostatectomy 
between patients that expressed TMPRSS2-ERG and patients without expression of the 
fusion gene. 
In two studies on watchful waiting cohorts, it was shown that patients having 
TMPRSS2-ERG fusion had a higher incidence of metastases or cancer-specific death than 
gene-fusion-negative patients (10, 11). FISH analysis showed that patients with an inter-
stitial deletion of genomic sequences between TMPRSS2 and ERG (so called ‘class Edel’) 
had poorer cancer-specific and overall survival than gene-fusion-negative patients, or 
than patients with TMPRSS2-ERG fusion without loss of the genomic region between the 
two genes (10). Other studies have correlated TMPRSS2-ERG with biochemical progres-
sion after radical prostatectomy, like in the present study. Prior to the identification of 
the TMPRSS2-ERG, Petrovics et al. found that patients with high expression levels of ERG 
had longer PSA recurrence-free survival than patients without ERG overexpression (16). 
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Recently, similar results were reported by Saramaki et al. (17), using FISH-analysis of 
TMPRSS2-ERG. However, other studies claimed a negative correlation between TMPRSS2-
ERG and PSA recurrence (12-14). Perner et al. indicated that patients with TMPRSS2-ERG 
rearrangement through deletion showed a trend for higher PSA recurrence rate than 
patients without fusion (13). Wang et al. provided evidence that specific TMPRSS2-ERG 
splice variants were associated with early PSA recurrence (14).
Information on TMPRSS2(exon 0)-ERG transcripts in prostate cancer is still scarce. So far, 
this transcript was only identified by Lapointe et al. (15). However, the clinical implications 
of this specific fusion transcript subtype were not investigated. The low expression fre-
quency of TMPRSS2(exon 0)-ERG transcripts in late stage prostate cancer, and the favorable 
prognosis for patients expressing this fusion transcript in primary tumors, as shown in our 
study, urges further investigation of the heterogeneity of TMPRSS2-ERG in prostate cancer. 
More systematic identification of specific fusion transcripts like TMPRSS2(exon 0)-ERG 
or alternatively spliced mRNAs (14) might assist in a molecular classification of prostate 
cancers which can be integrated in therapeutic decision making in the future.
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suPPLementary information
Table S1. Clinical and pathological characteristics of 67 patients with primary prostate cancer
Characteristic
Mean age (± SD) 62.5 ± 5.4 years
Median follow-up (± SD) 127.0 ± 48.3 months
Mean PSA (± SD) 15.6 ± 22.8 ng/ml
cT-stage
organconfined
extraprostatic
unknown
45
13
9
67.2%
19.4%
13.4%
pT-stage
pT2a
pT2b
pT2c
pT2x
pT3a
pT3b
pT4
unknown
2
3
13
1
24
16
5
3
3.0%
4.5%
19.4%
1.5%
35.8%
23.9%
7.5%
4.5%
Surgical margins
positive
negative
unknown
31
32
4
46.3%
47.8%
6.0%
Gleason score
< 7
= 7
> 7
38
19
10
56.7%
28.3%
15.0%
Occult metastases at RP
Yes
No
unknown
7
56
4
10.4%
83.6%
6.0%
PSA recurrence
Yes
No
Unknown
33
33
1
49.3%
49.3%
1.5%
Local recurrence
Yes 
No
Unknown
9
55
3
13.4%
82.1%
4.5%
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Distant metastases during follow-up
Yes
No
Unknown
11
55
1
16.4%
82.1%
1.5%
Death
Yes
No
27
40
40.3%
59.7%
Prostate cancer death
Yes
No
Unknown
11
54
2
16.4%
80.6%
3.0%
Abbreviations:
SD = standard deviation
cT-stage = clinical stage
pT-stage = pathological stage
RP = radical prostatectomy
Table S2. Primer sequences of primers used for QPCR analysis
Target Forward 5’->3’ Reverse 5’->3’
PBGD catgtctggtaacggcaatg gtacgaggctttcaatgttg
TMPRSS2 E1-E3 gagctaagcaggaggcgga aggggttttccggttggtatc
TMPRSS2 E0-E3 gactacttctactccaccag aggggttttccggttggtatc
TMPRSS2(exon 0)-ERG gactacttctactccaccag catcaggagagttccttgag
TMPRSS2(exon 1)-ERG gagctaagcaggaggcgga catcaggagagttccttgag
Table S3. Clinical and pathological characteristics of patients expressing TMPRSS2-ERG versus patients not expressing TMPRSS2-ERG 
TMPRSS2-ERG positive 
(n=44)
TMPRSS2-ERG negative 
(n=23)
p-value Test
mean age (± sD) 62.2 (± 5.6) 63.0 (± 5.1) 0.57 MWU
mean Psa (± sD) 16.1 (± 26.7) 14.8 (± 12.5) 0.30 MWU
Gleason score
< 7
≥ 7
29 (65.9%)
15 (34.1%)
9 (40.9%)
13 (59.1%)
0.053 Chi²
pt-stage
extraprostatic 
organconfined
13 (31.0%)
29 (69.0%)
6 (27.3%)
16 (72.7%)
0.76 Chi²
surgical margins
Positive
Negative
21 (50.0%)
21 (50%0
10 (47.6%)
11 (52.4%)
0.86 Chi²
Abbreviations:
SD = standard deviation
MWU = Mann-Whitney U test
pT-stage = pathological stage
*Patients with unknown parameters were not included in the analysis
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Table S4. Clinical and pathological characteristics of patients expressing TMPRSS2(exon 0)-ERG fusion transcripts versus 
patients exclusively expressing TMPRSS2(exon 1)-ERG fusion transcripts
TMPRSS2(exon 0)-ERG 
expression (n=24)
exclusive TMPRSS2(exon 1)-ERG 
expression (n=20)
p-value test
mean age (± sD) 61.5 (± 4.8) 63.1 (± 6.4) 0.40 MWU
mean Psa (± sD) 19.7 (± 35.2) 11.9 (± 10.3) 0.63 MWU
Gleason Score
< 7
≥ 7
15 (62.5%)
9 (37.5%)
14 (70.0%)
6 (30.0%)
0.60 Chi²
pt-stage
extraprostatic 
organconfined
11 (47.8%)
12 (52.2%)
2 (10.5%)
17 (89.5%)
0.009 Chi²
surgical margins
Positive
Negative
9 (39.1%)
14 (60.9%)
12 (63.2%)
7 (36.8%)
0.12 Chi²
Abbreviations:
SD = standard deviation
MWU = Mann-Whitney U test
SD = standard deviation
pT-stage = pathological stage
*Patients with unknown parameters were not included in the analysis
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aBstract
Recently, fusion of ERG to the androgen-regulated, prostate-specific TMPRSS2 gene 
has been identified as the most frequent genetic alteration in prostate cancer. At low 
frequency TMPRSS2-ETV1 and TMPRSS2-ETV4 fusion genes have been described. In this 
study we report two novel ETV4 fusion genes in prostate cancer: KLK2-ETV4 and CANT1-
ETV4. Both gene fusions have important unique aspects. KLK2 is a well-established 
androgen-induced and prostate-specific gene. Fusion of KLK2 to ETV4 results in the 
generation of an additional ETV4 exon, denoted exon 4a. This novel exon delivers an ATG 
for the longest open reading frame, in this way avoiding translation start in KLK2 exon 1. 
Although wild-type CANT1 has two alternative first exons (exons 1 and 1a), only exon 1a 
was detected in CANT1-ETV4 fusion transcripts. We show that CANT1 transcripts starting 
at exon 1a have an androgen-induced and prostate-specific expression pattern, whereas 
CANT1 transcripts starting at exon 1 are not prostate-specific. So, the two novel ETV4 
fusion partners possess as predominant common characteristics: androgen-induction 
and prostate-specific expression.
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introDuction
Prostate cancer is the most common malignancy in men in Western countries (1). 
Growth of prostate tumors depends on androgen signalling, mediated by the androgen 
receptor (AR). Metastatic disease is treated by endocrine therapy, however, all tumors 
eventually become resistant to this therapy. The majority of resistant tumors still contain 
a functional active AR (2). In part of these tumors AR is overexpressed due to amplifica-
tion of a small region of the X chromosome, where AR maps (3).
Most frequent genomic alterations in primary prostate cancers are losses of large 
fragments of chromosome arms 6q, 8p, 13q and 16q and gain of 8q (4, 5). In a subset of 
tumors a small region of loss of chromosome 21q22 has been detected. This genomic al-
teration is associated with recurrent fusion of prostate-specific and androgen-regulated 
TMPRSS2 (6) to the ETS transcription factor gene ERG, which maps at a distance of 3 Mbp 
from TMPRSS2 on 21q (7).
TMPRSS2-ERG fusion is present in 40-70% of clinical prostate cancers (7, 8, and Hermans 
unpublished). The gene fusion is an early event that has also been detected in a propor-
tion of precursor lesions (9). Although in many tumors TMPRSS2-ERG overexpression is 
accompanied by loss of the region between TMPRSS2 and ERG, in others this region has 
been retained, indicative of different mechanisms of gene fusion (10). At low frequency, 
fusion of TMPRSS2 to a second ETS gene, ETV1, that maps to chromosome band 7p21, has 
been reported (7, 10). TMPRSS2 seems the only fusion partner of ERG, but it has recently 
been shown that ETV1 has more fusion partners (11, and Hermans unpublished).
For a third ETS gene, ETV4, only fusion to TMPRSS2 has been described (12). In the 
present study we identified in clinical prostate cancer samples two unique novel ETV4 
fusion partners: Kallikrein 2 (KLK2) and Calcium Activated Nucleotidase 1 (CANT1). KLK2, 
or hGK1, is a well-known prostate marker highly homologous to KLK3 or prostate-
specific antigen (PSA) (13). Like KLK3, KLK2 is prostate-specific and androgen-regulated 
expressed (13, 14). We show that CANT1 expression is also androgen-regulated. CANT1 
possesses two alternative first exons, but only one of these is present in the CANT1-ETV4 
fusion transcript. In contrast to the majority of CANT1 transcripts, this mRNA is preferen-
tially expressed in the prostate. The novel fusion genes indicate prostate-specificity and 
androgen-regulation as important characteristics of ETV4 fusion partners in prostate 
cancer. 
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materiaLs anD metHoDs
Samples.
Two series of clinical prostate cancer samples were obtained from the tissue bank of 
the Erasmus University Medical Center (Rotterdam, The Netherlands). Samples were 
snap-frozen and stored in liquid nitrogen. All samples contained at least 70% tumor 
cells. Collection of patient samples has been performed according to national legisla-
tion concerning ethical requirements. Use of these samples has been approved by the 
Erasmus MC Medical Ethics Committee according to the Medical Research Involving 
Human Subjects Act (MEC-2004-261). Prostate cancer xenografts were propagated by 
serial transplantation on male nude mice as described (10, 15).
DNA and RNA isolation.
RNA from clinical prostate cancer specimens was isolated using the RNA-Bee kit (Cam-
pro Scientific, Berlin, Germany). DNA was isolated using the DNeasy DNA extraction kit 
(Qiagen, Valencia, CA). Xenograft RNA was isolated according to the LiCl protocol. RNA 
from the prostate cancer cell line LNCaP cultured in the presence of 10-9M R1881, or in 
the absence of hormone was isolated using the RNeasy RNA extraction kit (Qiagen).
mRNA expression analysis.
Analysis of mRNA expression was performed by RT-PCR or by QPCR. Two μg RNA was 
reverse transcribed using 400 U M-MLV RT (Invitrogen, Carlsbad, CA) and an oligo-dT12 
primer. cDNA’s of 16 different tissues were purchased from Clontech (Mountain View, 
CA). RT-PCR products were analyzed on a 1.5% agarose gel. QPCR was performed in an 
ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA), using 
Power SYBR Green PCR Master Mix (Applied Biosystems), containing 330 nM forward 
and reverse primer, in a total volume of 25 μl. Thermocycling conditions were accord-
ing to the recommendations of the manufacturer. mRNA expression was determined 
relative to Porphobilinogen deaminase (PBDG) by the Standard curve method (Applied 
Biosystems). Primers are listed in supplementary Table S1.
RNA Ligase-Mediated Rapid Amplification of cDNA Ends (RLM-RACE).
5’ RLM-RACE was performed using the GeneRacer kit from Invitrogen according to 
instructions of the manufacturer. To obtain the 5’-sequence, cDNA was amplified with 
Qiagen Taq (Qiagen) using the Generacer 5’-primer and an ETV4 exon 6 primer. PCR 
products were separated over a 1.5% agarose gel, bands were excised, purified and 
sequenced on an ABI 3100 genetic analyser (Applied Biosystems). 
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Array Comparative Genomic Hybridization (array CGH).
Arrays were produced from the human 3600 BAC/PAC genomic clone set of the Welcome 
Trust Sanger Institute, covering the full genome at approx. 1 Mb-spacing. DNA labeling 
and hybridization were performed as previously described (10). After hybridization ar-
rays were scanned in a ScanArray Express HT (Perkin Elmer, Freemont, CA). The resulting 
images were analyzed with GenePix Pro 5.0 software (Axon Instruments, Foster City, CA) 
and subsequently visualized with an excel macro.
Interphase fluorescent in situ hybridization (FISH).
Interphase FISH was done on 5 µm frozen tissue sections as described previously (10). 
BAC clones RP11-100E5 and RP11-209M4 (both flanking ETV4) were purchased from 
BacPac Resources (Oakland, CA). Specificity of BACs was confirmed on metaphase chro-
mosome spreads. BAC DNA’s were either Spectrum Orange or Spectrum Green labeled 
using a Nick Translation Reagent Kit (Vysis, Downers Grove, IL). Tissue sections were 
counterstained with DAPI in anti-fade solution (Vector Laboratories, Burlingame, CA). 
Images of the three fluorochromes were collected on an epifluorescence microscope 
(Leica DM, Rijswijk, The Netherlands) equipped with appropriate filter sets (Leica) and a 
CCD cooled camera (Photometrics, Tucson, AZ).
Breakpoint mapping.
Fusion points were mapped by standard long-range PCR on 200 ng genomic DNA in 
the presence of 0.5 µM of each forward (fusion partner) and reverse (ETV4) primer with 
Taq polymerase and Proofstart DNA polymerase (Qiagen). Primers are given in Supple-
mentary Table 1. PCR products were separated on a 1% agarose gel. Specific amplified 
fragments were isolated and sequenced. 
resuLts anD Discussion
ETV4 expression was studied by QPCR on two sets of clinical prostate cancer samples. 
Set 1 was composed of 84 clinical prostate cancer samples (49 primary prostate tumors, 
11 lymph node metastases and 24 recurrent tumors) and set 2 of 36 primary prostate 
tumors and 29 recurrent tumors. In primary tumor 98, and in recurrent tumor 206, both 
from set 1, ETV4 overexpression was detected (Fig 1A). In the second set we did not 
detect ETV4 overexpression (data not shown), indicating that overexpression is a rare 
event, occurring in <2% clinical prostate cancers. Follow up experiments showed that 
ETV4 overexpression was caused by fusions to two different genes with unique proper-
ties. 
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First, RT-PCR experiments with TMPRSS2 and ETV4 specific primers excluded TMPRSS2 
as fusion partner (data not shown). Next, we performed 5’ RNA ligase-mediated rapid 
amplification of cDNA ends (RLM-RACE), using a reverse primer in ETV4 exon 6. Sequenc-
ing of the amplified fragments showed KLK2 (sample 98) and CANT1 (sample 206) as novel 
ETV4 fusion partners. The presence of KLK2-ETV4 and CANT1-ETV4 fusion transcripts in 
the individual samples was confirmed by RT-PCR (Fig 1B). 
The KLK2-ETV4 mRNA fragment detected by RLM-RACE, was composed of KLK2 exon 
1 linked to a new ETV4 exon (here denoted exon 4a), followed by ETV4 exon 5 and 6 
sequences (Fig 1C). The novel ETV4 exon 4a has a length of 133 bp and delivers the ATG 
start codon of the longest predicted open reading frame in the KLK2-ETV4 fusion tran-
script (Fig 1D). KLK2 maps to chromosome band 19q13 and ETV4 on chromosome band 
17q21. Because of the orientations of KLK2 and ETV4, KLK2-ETV4 gene fusion cannot be 
explained by a single chromosomal translocation. 
The CANT1-ETV4 fragment detected by RLM-RACE contained one of the two described 
exons 1 of CANT1 (here denoted exon 1a). This exon maps approx. 4 Kbp downstream 
of the other first exon (here denoted exon 1) (Fig 1C). CANT1 exon 1a delivers the ATG 
start codon of the predicted ETV4 open reading frame. Remarkably, CANT1-ETV4 fusion 
transcripts starting at CANT1 exon 1 were not detected, although wild-type CANT1 tran-
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Figure 1 Expression of ETV4 and characterization of ETV4 fusion transcripts in clinical prostate cancer samples. (A) QPCR 
analysis of ETV4 expression in clinical prostate cancer samples compared to PBGD expression. Overexpression of ETV4 was 
detected in samples 98 and 206. Met: regional lymph node metastasis. (B) Confirmation of KLK2-ETV4 (sample 98) and 
CANT1-ETV4 (sample 206) fusion transcripts by RT-PCR, using ETV4 and fusion partner specific primers. RNA from prostate 
cancer cell line PC3 was used as a negative control. An RNA Pol II amplified fragment is shown as a loading control. (C) Schematic 
representation of KLK2-ETV4 and CANT1-ETV4 fusion transcripts. Exons are indicated by colored boxes. In both transcripts 
ATG start codons and TAG stop codons of longest predicted open reading frames are indicated.  (D) Sequence of ETV4 exon 4a 
and flanking sequences. The ETV4 exon 4a sequence is underlined. KLK2 intron 1 sequence present in the fusion gene is in 
red. Splice sites are bold. The ATG start codon in ETV4 exon 4a is depicted in bold and italic.
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scripts starting either at exon 1 or 1a of the non-rearranged second allele were present 
in the tumor sample and in normal prostate (data not shown). CANT1 and ETV4 map in 
the same orientation on 17q, at a distance of approx. 35 Mbp. However, array-based 
CGH showed that the genomic region between ETV4 and CANT1 was not lost (data not 
shown), indicating that either an internal rearrangement of 17q had occurred or that 
this region was reintegrated in another part of the genome.
ETV4 rearrangements in samples 98 and 206 were confirmed by split signal FISH 
with probes flanking ETV4 at both sites (Fig 2A). Next, the genomic fusion points were 
mapped by long-range PCR and sequencing (Fig 2B,C). As expected, the breakpoints 
of CANT1-ETV4 were located in CANT1 intron 1, downstream from exon 1a, and in ETV4 
intron 5, respectively. This latter breakpoint was located in a MER20 repeat, a low copy 
repetitive element known to be involved in unstable genomic regions prone to chro-
mosomal rearrangement (16). Breakpoints in KLK2 and ETV4 in sample 98 were not in 
repetitive sequences. The breakpoint in ETV4 intron 4 of the KLK2-ETV4 rearrangement 
was 2 bp upstream of ETV4 exon 4a (Fig 1D, 2C). Due to the gene fusion the purine-rich 
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38.8 39.2ETV4
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Figure 2 Characterization of ETV4 fusion genes in clinical prostate cancer samples. (A) Schematic representation of the 
ETV4 genomic region on chromosome 17. Distance from the top of chromosome is indicated in Mbp. Orientation of ETV4 is 
indicated by blue arrowhead. BAC probes used in split signal FISH are indicated in colors corresponding to FISH staining. Split 
signal FISH on frozen tissue sections confirms ETV4 rearrangements in samples 98 and 206 as indicated by arrows. Schematic 
representation of genomic breakpoints in ETV4, KLK2, and CANT1 as found by long-range PCR and sequencing. Numbered 
exons are depicted as open boxes. Positions of genomic breakpoints are shown by red arrows. Distances in kbp between exons 
are indicated. (C) Sequences of CANT1-ETV4 and KLK2-ETV4 fusion points. Fusion point is indicated by red arrow. 
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ETV4 intron sequence was replaced by a more pyrimidine-rich sequence of KLK2 intron 
1, generating a novel splice acceptor sequence. To confirm that the rearrangement 
induced ETV4 exon 4a, a splicing assay was performed (Fig S1). ETV4 exon 4a was indeed 
retained if the KLK2-ETV4 fusion sequence was used, but not if intron 4 sequence of 
wild-type ETV4 was used in the assay (Fig S1).
KLK2 is a well-known androgen-regulated and prostate-specific gene (13, 14). To 
establish the specific characteristics of CANT1 expression, QPCR analysis on cDNAs from 
eleven human prostate cancer xenografts derived from various stages of the disease and 
with different AR status was performed (10, 15). We compared expression of transcripts 
starting at CANT1 exon 1 and transcripts starting at exon 1a to KLK2 expression. KLK2 
mRNA expression was completely restricted to xenografts with highest AR expression 
(Fig 3A). CANT1 transcripts starting at exon 1a showed highest expression in the more 
differentiated, androgen-dependent xenografts (Fig 3B). In contrast, transcripts starting 
at exon 1 were expressed at variable levels in all xenografts. Further analysis of RNA from 
LNCaP prostate cancer cells, which were in vitro cultured in the presence of the synthetic 
androgen R1881 or in the absence of hormone, showed that both transcripts starting at 
CANT1 exon 1 and exon 1a are induced by androgens (Fig 3C). As expected KLK2 expres-
sion was strongly induced by androgens. Next we tested the tissue-specificity of the 
CANT1 and KLK2 transcripts in a cDNA panel from 16 different normal tissue samples. 
KLK2 showed an expected strictly prostate-specific expression pattern (Fig 3D). Remark-
ably, transcripts starting at CANT1 exon 1 were ubiquitously expressed, but transcripts 
starting at exon 1a had a much more restricted expression pattern, with highest expres-
sion in the prostate (Fig 3E). 
Both KLK2-ETV4 and CANT1-ETV4 have specific, unique characteristics. KLK2-ETV4 
because a novel ETV4 exon is generated (exon 4a) and CANT1-ETV4 because CANT1 exon 
1a is exclusively used in CANT1-ETV4 fusion transcripts. A KLK2-ETV4 fusion protein con-
taining the N-terminal KLK2 signal peptide would be secreted and could not function 
as a transcription factor. However, the start codon in the novel ETV4 exon 4a, which is 
preceded by an in frame stop codon, prevents the generation of such a fusion protein. 
Instead, synthesis of a truncated ETV4 protein, starting in ETV4 exon 4a can now be 
predicted (Fig 1D). Exclusive usage of CANT1 exon 1a as first exon in CANT1-ETV4 fusion 
transcripts might have various explanations, including the positions of breakpoints of 
the specific genomic rearrangement and the prostate-specific expression of transcripts 
starting at exon 1a. 
In prostate cancer, TMPRSS2 is the common fusion partner of the ETS family members 
ERG, ETV1 and ETV4. Recently, several novel ETV1 fusion partners have been identified: 
SLC45A3, HERV-K_22q11.23, C15orf21, HNRPA2B1 (11), with different expression character-
istics. Based on expression profiles the fusion partners were divided into distinct classes 
of ETV1 rearrangements, separating prostate-specific, androgen upregulated genes and 
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downregulated genes, and ubiquitously regulated genes.  Recently, we identified three 
novel ETV1 fusion partners: FOXP1, HERVK17 and EST14 (Hermans unpublished). Both 
HERVK17 and EST14 have a prostate-specific and androgen-induced expression pattern; 
FOXP1 seems expressed in many tissues. The three ETV4 partners identified, TMPRSS2, 
KLK2 and CANT1, show identical expression profiles: upregulation by androgens and 
prostate-specificity.
The common expression pattern of ETV4 fusion partners indicates a similar mechanism 
of gene fusion. It is tempting to speculate that the genomic region of prostate-specific 
genes is unstable in a specific cell type. Based on the stem cell/progenitor cell concept 
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Figuur 3Figure 3 Characteristics of KLK2 and CANT1 mRNA expression. Expression of (A) KLK2 and AR mRNA, and (B) of transcripts 
starting in CANT1 exon 1 and CANT1 exon 1a, respectively, in eleven human prostate cancer xenografts. PBGD expression 
is used as control. (C) Androgen-regulated expression of KLK2 and CANT1 transcripts assessed by QPCR analysis in LNCaP cells 
grown in the absence or in the presence of the synthetic androgen R1881 (1 nM). Expression relative to PBGD is presented. 
Tissue-specific expression of (D) KLK2 and (E) CANT1 transcripts. Tissue-specific expression was tested on a cDNA panel from 
16 different normal tissues by QPCR analysis and is shown relative to PBGD expression. In all experiments, standard deviations, 
as indicated by vertical bars, are calculated from two independent experiments.
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of tumor development (17), progenitor cells of the luminal epithelial prostate cells, in 
which expression of the prostate-specific fusion partners is expected to be activated, 
are interesting candidates. In this regard, we could confirm TMPRSS2 induction during 
development of the mouse prostate (Hermans, unpublished). Unfortunately, there are 
no appropriate mouse counterparts of KLK2 and CANT1(exon 1a). 
A second process that might play a role in a common mechanism of gene fusion in-
cludes the nuclear compartmentalization of gene expression. It might be proposed that 
prostate-specific genes are all expressed in a limited number of nuclear compartments, 
or so-called transcription factories (18, 19). Possibly, ETV4 is expressed in the same com-
partments. In accordance with the latter hypothesis, it has recently been shown that 
IGH and cMYC, which are fusion partners in Burkitt lymphoma and plasmacytoma, are 
preferentially expressed in the same nuclear regions at in vitro B cell stimulation (20). 
Taken together, the results from this study show that ETV4 has multiple fusion partners 
and highlight the importance of meticulous examination of gene fusions. Importantly, 
key determinants of ETV4 fusion partners are not chromosomal location or expression 
level, but their androgen-regulated and prostate-specific expression pattern.
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suPPLementary information
supplementary table s1 Primer sequences
Primer name Forward (5’->3’) Reverse (5’->3’)
QPcr and race  
ETV4 E12-13 accggccagccatgaattac gagagctggacgctgattc
PBGD catgtctggtaacggcaatg gtacgaggctttcaatgttg
ETV4 E6 tccttcttgatcctggtggt
KLK2 E1 ttctctccatcgccttctct
CANT1 E1a gctggagaaacaaaccctct
KLK2 E4-5 tccaatgacatgtgtgctag caccattacagacaagtgga
CANT1 E1-2 ttagcccagccaagcccagc agaacgtcaggatcaccttc
CANT1 E1a-2 gctggagaaacaaaccctct agaacgtcaggatcaccttc
AR tgactccgtgcagcctattg atgggaagcaaagtctgaag
splicing assay
KLK2-ETV4 atactcgagctaaatccgcacccttttca ataggatcccttcaaattggggctttgga
ETV4 atactcgagtacatgctgctgccctgtac ataggatcccttcaaattggggctttgga
SD-SA tctgagtcacctggacaacc atctcagtggtatttgtgagc
Breakpoint mapping
KLK2 E1 ttctctccatcgccttctct
KLK2 I1 cagtcctaccacagtctact
ETV4 I4 gagaaagtgagaaggagcga
CANT1 E1a gctggagaaacaaaccctct
CANT1 I1 tctgggagatagctggtttg
ETV4 E6 tccttcttgatcctggtggt
ETV4 I5A cggatcacaaggtcaggaat
ETV4 I5B agcagcaaagagttggttcc
ETV4 I5C tggtgaaaccctgtctctac
ETV4 I5D  gttggtctcaaactcctgac
127
Novel ETV4 fusion genes in prostate cancer
RNA POL II
Splicing
ET
V4
KL
K2
-E
TV
4
pS
PL
3
pSPL3
E1 E2
KLK2-ETV4
ETV4
4a
4a …tggtgatggatggccaggtctgaggg…
…cacttatccttggtttcaggtctgaggg…
SV40 polyadenylation siteSV40 origin 
and promoter
SD SA
A B
Figuur S1
Figure S1. Detection of ETV4 exon 4a in a splicing assay. (A) Schematic representation of the constructs used in the splicing 
assay. Appropriate KLK2-ETV4 and ETV4 genomic fragments, containing the ETV4 exon 4a sequence were amplified 
and subsequently integrated in the multiple cloning site of splicing vector pSPL3 (Invitrogen). Primer sequences are given in 
Table S1. KLK2 derived sequences are in green, ETV4 sequences are in light or dark blue. LNCaP prostate cancer cells were 
transiently transfected with KLK2-ETV4, ETV4 and control splicing constructs using the calcium phosphate precipitation 
method. Cells were harvested after 48 h and RNAs were isolated as described in Materials and Methods. Next, cDNAs were 
prepared and amplified with primers SD and SA in exons 1 and 2 of pSPL3, respectively. (B) Amplified fragments were analyzed 
over a 1.5% agarose gel, isolated and sequenced. An amplified  RNA pol II fragment was used as a control. Control empty pSPL3 
gave the expected E1/E2 fragment. pSPL3(KLK2-ETV4) cDNA contained E1 and E2 sequence and ETV4 exon 4a. pSPL3(ETV4) 
cDNA contained the expected E1/E2 fragment and a larger fragment composed of E1 and E2 sequences, and the sequence of 
the last part of ETV4 exon 4a, due to the usage of a cryptic splice acceptor site in exon 4a (double underlined in Fig 1D). This 
shortened exon is probably an artifact, because it was not observed if wild-type ETV4 mRNA was analyzed by RT-PCR with 
ETV4 exon 4 and exon 5 specific primers (data not shown). 
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aBstract
In this study we describe the properties of novel ETV1 fusion genes, encoding N-trun-
cated ETV1 (dETV1), and of full length ETV1, overexpressed in clinical prostate cancer. 
We detected overexpression of novel ETV1 fusion genes or of full length ETV1 in 10% 
of prostate cancers. Novel ETV1 fusion partners included FOXP1, an EST (EST14) and an 
endogenous retroviral repeat sequence (HERVK17). Like TMPRSS2, EST14 and HERVK17 
were prostate-specific and androgen-regulated expressed. This unique expression pat-
tern of most ETV1 fusion partners seems an important determinant in prostate cancer 
development. In transient reporter assays full length ETV1 was a strong transactivator, 
whereas dETV1 was not. However, several of the biological properties of dETV1 and full 
length ETV1 were identical. Upon stable-overexpression, both induced migration and 
invasion of immortalized non-tumorigenic PNT2C2 prostate epithelial cells. In contrast 
to dETV1, full length ETV1 also induced anchorage-independent growth of these cells. 
PNT2C2 cells stable-transfected with dETV1 or full length ETV1 expression constructs 
showed small differences in induced expression of target genes. Many genes involved 
in tumor invasion/metastasis, including uPA/uPAR and MMPs, were upregulated in both 
cell types. Integrinβ3 (ITGB3) was clearly upregulated by full length ETV1, but much less 
by dETV1. Based on the present data and on previous findings a novel concept of the 
role of dETV1 and of full length ETV1 overexpression in prostate cancer is proposed.
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introDuction
The ETS transcription factor family is composed of 27 members (1-3). Depending on the 
cellular context they can function as transactivators or transrepressors. ETS transcription 
factors modulate many cellular functions, including proliferation, apoptosis, differentia-
tion, tissue remodeling, migration, invasion and angiogenesis (1-3). Altered expression 
or properties of ETS transcription regulators affects the control of these processes. 
Recurrent chromosomal rearrangements are well-defined in leukemias, lymphomas 
and sarcomas (4). These rearrangements result in fusion genes that express oncogenic 
proteins with altered properties or in overexpression of wild type oncogenes. In Ewing 
sarcoma and in acute myeloid leukemia, gene fusions of members of the ETS gene fam-
ily have been found. At low frequency, gene fusions have also been described in solid 
tumors (4). However, recent analyses showed common gene fusions in prostate cancer, 
all involving members of the ETS transcription factor family (5-9). 
In 40-70% of clinical prostate cancers, ERG (21q22.1) is directly linked to androgen-
regulated, prostate-specific TMPRSS2, which is located 3 Mbp upstream of ERG. At low 
frequency, fusions of TMPRSS2 to ETV1, ETV4 and ETV5, which map on different chromo-
somes, have been described (5, 7, 8, 10). 
Considering the complexity of fusion genes in haematological and mesenchymal 
malignancies, we questioned whether this would also be true for gene fusions in pros-
tate cancer. Here we describe overexpression of ETV1 in 8 out of 84 clinical prostate 
cancer samples. In four samples full length ETV1 is overexpressed, but in the other four 
samples we detected novel ETV1 fusion genes, which result in predicted N-truncated 
ETV1 proteins. Novel fusion partners include FOXP1, an EST (EST14) and an endogenous 
retroviral sequence (HERVK17, identified in two samples). Like TMPRSS2 (11), both EST14 
and HERVK17 are androgen-regulated and prostate-specific. 
Transient reporter assays with full length ETV1 and N-truncated ETV1 (dETV1) showed 
that these proteins possess different transcription regulation functions. However, QPCR 
analysis of prostate epithelial cells with stable overexpression of full length ETV1 or 
dETV1 indicated less pronounced differences in expression of candidate target genes. 
Biological assays showed no significant difference in migration and invasion properties 
between full length ETV1 and dETV1 expressing cells. However, full length ETV1 is ca-
pable of inducing anchorage-independent growth, whereas dETV1 is not. We propose a 
different role of dETV1 and full length ETV1 in prostate cancer.
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materiaLs anD metHoDs
Tissue samples.
Primary prostate cancer samples were obtained by radical prostatectomy, regional 
lymph node metastases were collected during surgery, recurrences were obtained by 
trans-urethral resection (TURP). Samples were snap-frozen and stored in liquid nitrogen. 
Use of the samples for research purposes was approved by the Erasmus MC Medical 
Ethics Committee according to the Medical Research Involving Human Subjects Act 
(MEC-2004-261). 
Hematoxilin/eosin (HE) stained tissue sections were histologically evaluated by two 
pathologists (Van der Kwast, Van Leenders). All samples contained at least 70% tumor 
cells. 
Balb/c mouse prostate tissues were collected at different developmental stages (16.5 
and 18.5 embryonal day and postnatal days 3, 9, 15 and 50). 
RNA and DNA preparations.
RNA from clinical prostate cancer specimens was isolated from frozen tissue sections 
using RNA-Bee (Campro Scientific, Berlin, Germany). DNA was isolated from frozen sec-
tions using the DNeasy DNA extraction kit (Qiagen, Valencia, CA). RNAs from the prostate 
cancer cell lines LNCaP and DuCaP cultured in the presence of 10-9M of the synthetic 
androgen R1881, or in the absence of hormone, from PNT2C2 cells overexpressing full 
length ETV1 or dETV1, and from mouse prostates of different developmental stages were 
isolated using the RNeasy RNA extraction kit (Qiagen). 
Breakpoint mapping.
Positions of fusion points were mapped by standard long-range PCR on 200 ng ge-
nomic DNA in the presence of 0.5 µM of each forward (fusion partner) and reverse (ETV1) 
primer with Taq polymerase and Proofstart DNA polymerase (Qiagen). For primers see 
Supplementary Table 1. PCR products were separated on a 1% agarose gel. Specific am-
plified fragments were isolated and sequenced in an ABI 3100 genetic analyzer (Applied 
Biosystems, Foster City, CA). 
mRNA expression.
mRNA expression was analyzed by RT-PCR or by QPCR. cDNA was prepared with M-MLV 
reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA) and an oligo-dT12 
primer. cDNA’s of 16 different tissues were purchased from Clontech (Mountain View, 
CA).
RT-PCR products were analyzed over a 1.5% agarose gel. QPCR was done in Power 
SYBR Green PCR Master Mix (25 μl), containing 0.33 µM forward and reverse primer in an 
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ABI Prism 7700 Sequence Detection System (Applied Biosystems). Amplified products 
were quantified relative to Porphobilinogen Deaminase (PBGD; human RNAs), or Hy-
poxanthine guanine phosphoribosyl transferase 1 (Hprt; mouse RNAs) by the Standard 
curve method (Applied Biosystems). For primers see Supplementary Table 1.
RNA Ligase-Mediated Rapid Amplification of cDNA Ends (RLM-RACE).
5’- RLM-RACE was performed using the GeneRacer kit (Invitrogen).  cDNA was amplified 
with Taq polymerase (Qiagen) using the Generacer 5’-primer and a gene-specific primer 
(ETV1 exon 6 Reverse). RACE PCR products were analyzed on a 1.5% agarose gel, bands 
were excised, purified and sequenced.
Interphase fluorescent in situ hybridization (FISH).
Interphase FISH was done on 5 µm frozen tissue sections as described previously (5). BAC 
clones RP11-79G16 (ETV1), RP11-154H23 (FOXP1), RP11-460G19 (EST14), RP11-1099M24 
and RP11-1B5 (both flanking HERVK17) (see Fig. 2A) were purchased from BacPac Re-
sources (Oakland, CA). Specificity of BACs was confirmed on metaphase chromosome 
spreads. BAC DNA clones were either Spectrum Orange or Spectrum Green labeled 
using a Nick Translation Reagent Kit (Vysis, Downers Grove, IL). Tissue sections were 
counterstained with DAPI in anti-fade solution (Vector Laboratories, Burlingame, CA). 
Images of the three fluorochromes were collected on an epifluorescence microscope 
(Leica DM, Rijswijk, The Netherlands) equipped with appropriate filter sets (Leica) and a 
CCD cooled camera (Photometrics, Tucson, AZ). 
Construction of expression plasmids.
cDNAs of full length ETV1 and the different ETV1 fusion transcripts were PCR amplified 
and cloned into pGEMT-easy (Promega, Madison, WI). For primers see Supplementary 
Table 1. Inserts were sequence verified and subsequently cloned into the Not1 site in 
the pcDNA3 expression vector (Invitrogen). Similarly, full length ETV1 cDNA and dETV1 
cDNA were integrated in the expression vector pWPXLd (provided by Didier Trono). 
Reporter assays. 
LNCaP prostate tumor cells and immortalized non-tumorigenic PNT2C2 prostate epithe-
lial cells (12) (provided by Norman Maitland) were grown in DMEM supplemented with 
5% FCS and antibiotics. Cells were cotransfected with full length ETV1 or truncated ETV1 
expression constructs and the ETS reporter PALx8-TK-Luc (provided by Boh Wasylyk) 
essentially as described (13). Cells were harvested after 24h and luciferase activity was 
measured in a LUMAC 2500 Biocounter (Lumac, Landgraaf, The Netherlands). 
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Western blot analysis.
For Western blot analysis, LNCaP cells were transfected with pcDNA3-ETV1 or pcDNA3-
dETV1 expression construct or empty vector. PNT2C2 cells were transfected with 
pWPXLd-ETV1, pWPXLd-dETV1 expression vectors or control pWPXLd-GFP. Cells were 
harvested after 48h. Western blot analysis was carried out using standard procedure 
with ER81 (C-terminal, Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin loading 
control (Sigma, St Louis, MO) antibodies. Bands were visualized by chemiluminescence 
(Pierce, Rockford, IL).
Infection with ETV1 lentivirus.
To obtain lentiviruses, 293T cells were cotransfected with pWPXLd-ETV1, pWPXLd-
dETV1 or pWPXLd-GFP (control) and pPAX2 and pMD2.G (Didier Trono) using the 
calcium-phosphate precipitation method. PNT2C2 cells were infected with lentiviruses 
expressing either full length ETV1 or dETV1, or with control virus. Pools of infected cells 
were propagated and used in the biological assays as described below.
Migration and Invasion Assays.
Migration and invasion assays of PNT2C2-ETV1, PNT2C2-dETV1 and control PNT2C2-GFP 
cells (1x105 cells/well) were performed according to the instructions of the manufacturer 
of the trans-wells (Chemicon, Bellerica, MA). The migration assay was stopped after 24 h 
incubation; the invasion assay was terminated after 48 h.
Proliferation Assay.
Equal amounts of PNT2C2-ETV1, PNT2C2-dETV1 and control PNT2C2-GFP cells were 
seeded in T25 culture flasks. At day 0, 2, 4, 6 and 8, Thiazolyl blue tetrazolium bromide 
dissolved in PBS (MTT reagent; AppliChem, Chesire, CT) was added and after 4 h cells 
were harvested. Cells were suspended in DMSO-Sörensen buffer and OD 570nm was 
measured.
Soft-Agar Assay. 
A bottom layer of 0.6% low melting agarose in normal culture medium was prepared in 
six-well culture plates. On top, a layer of 0.3% agarose containing 1x104 cells (PNT2C2-
ETV1, PNT2C2-dETV1 or control PNT2C2-GFP) was plated. At day 14 cells were stained 
with crystal violet and numbers of colonies in representative microscope fields were 
counted. 
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resuLts 
We investigated 84 clinical prostate cancer samples (49 primary tumors, 11 lymph node 
metastases and 24 recurrent tumors) for ETV1 overexpression. In eight samples, divided 
over each clinical subgroup, ETV1 overexpression was found (Fig. 1A), however, QPCR 
failed to detect TMPRSS2-ETV1 fusion transcripts (Fig. 1B). QPCR with two ETV1 primer 
sets, one amplifying an exon 1-2 fragment and a second set amplifying an exon 11-12 
fragment showed in four samples (37, 89, 308, 247) an ~1:1 signal ratio, indicative for 
full length ETV1 expression (Fig. 1C). However, in four other samples (32, 104, 116, 342) 
a high exon 11-12 to exon 1-2 ratio, indicative for gene fusion was detected. 5’-Rapid 
Amplification of cDNA Ends (5’-RACE), followed by sequencing revealed that the four 
tumor samples with equal signal intensities for the two amplified ETV1 fragments, 
indeed overexpressed full length ETV1. Novel fusion genes were present in samples 
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Figure 1 Expression of ETV1 and characterization of ETV1 fusion transcripts in clinical prostate cancer specimens. (A) 
Expression of ETV1 compared to PBGD in clinical prostate cancer samples as assessed by QPCR. Overexpression of ETV1 
was detected in eight samples. MET: Regional Lymph Node Metastasis. (B) QPCR analysis for TMPRSS2-ETV1 fusion gene 
expression in clinical samples with ETV1 overexpression. Prostate cancer xenograft PC374 is the TMPRSS2-ETV1 positive 
control, and xenograft PC135, overexpressing wild type ETV1 is a negative control (5). Expression relative to PBGD plus 
Standard Deviations (SD) of a duplicate experiment is depicted. (C) Signal intensities of ETV1 exon 1-2 QPCR compared to 
ETV1 exon 11-12 QPCR. A reduced ETV1 exon 1-2 to ETV1 exon 11-12 ratio is indicative for ETV1 gene fusion. Xenografts 
PC374 (TMPRSS2-ETV1 fusion) and PC135 (wild type ETV1) are controls. Mean values plus SD of a duplicate experiment 
are presented. Samples 32, 104, 116, 342 and PC374 had a statistically significant higher exon 11-12 to exon 1-2 ratio (p<0.05, 
paired samples T-test). (D) Confirmation by RT-PCR with ETV1 and fusion gene specific primers of the fusion transcripts found 
by 5’-RACE. HERVK17-ETV1 specific fragments of different sizes are present in samples 104 and 116. Due to alternative 
splicing of ETV1 exon 5, sample 342 shows two EST14-ETV1 fragments, and sample 32 contains two FOXP1-ETV1 
fragments. RNA pol II amplification is shown as a loading control. 
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with high ETV1 exon 11-12 to 1-2 ratio’s. These novel ETV1 fusion partners were FOXP1, a 
gene encoding a spliced EST (here denoted EST14), and an endogenous retroviral repeat 
sequence (denoted HERVK17; two samples). All fusion transcripts were confirmed by 
RT-PCR (Fig. 1D). 
In contrast to ERG and TMPRSS2, ETV1 and its three novel fusion partners all map to 
different chromosomes; ETV1 is located on 7p, FOXP1, EST14 and HERVK17 on 3p, 14q 
and 17p, respectively (Fig. 2A). Chromosomal rearrangements in the four samples with 
fusion transcripts were confirmed by interphase fluorescent in situ hybridization (FISH) 
with specific BAC probes (Fig. 2A,B). HERVK17 did not function as a retrotransposon (14), 
because in both sample 104 and 116 split signal FISH with flanking BACs showed separa-
tion of genomic fragments proximal and distal to one HERVK17 copy (Fig. 2C).  Their 
appropriate orientations (Fig. 2A) allow fusion of ETV1 to FOXP1 and EST14 by standard 
recurrent chromosomal translocations. The HERVK17-ETV1 fusion can most likely be 
explained by the integration of an ETV1 genomic segment into the fusion chromosome 
(17p). 
For fusions of HERVK17 and EST14 to ETV1 we precisely mapped the fusion point by 
long range PCR followed by sequencing (Fig. 2D and Supplementary Fig.1).  The break-
points in ETV1 are in intron 4 (104 and 342) and in intron 5 (116); the latter breakpoint 
is in an Alu repeat (Fig. 2D and Supplementary Fig. 1). The breakpoint in EST14 is in its 
only intron, however, the genomic alteration turned out to be more complex (Fig. 2D). 
Additionally to the fusion to ETV1, a 117 kbp deletion from EST14 to C14orf25 (intron 4), 
removing FOXA1, was found. Both the interstitial deletion and the fusion to ETV1 involve 
a LINE retroviral repeat, pointing to a role of this sequence in genomic instability (14, 15). 
HERVK17 is a defective retroviral sequence (Fig. 2A, D). The two breakpoints in HERVK17 
mapped within 1 kbp from each other, both in a HERVK sequence flanking the 3’-LTR. 
To increase our knowledge on properties and expression of fusion genes, we studied 
in detail the composition of fusion transcripts and the regulation of expression of the 
various ETV1 fusion partners, including TMPRSS2. Figure 3A schematically summarizes 
the major ETV1 fusion transcripts found by RT-PCR and sequencing. Note that part of 
the fusion transcripts lack ETV1 exon 5, due to alternative splicing. Depending on the 
transcript, the ATG start codon is provided by ETV1 exon 6 or by the fusion partner. In all 
cases the stop codon is in ETV1 exon 12.
In the FOXP1-ETV1 fusion transcript, part (154 bp) of FOXP1 exon 11 is coupled to the 
ETV1 sequence (Fig. 3A and Supplementary Fig. 2). The same part of this exon is present 
at the 5’-end of mRNA encoding the FOXP1C isoform (16). Unfortunately, the complex 
structure of the FOXP1 locus, including several different first exons and extensive alter-
native splicing, prevented accurate detailed analyses of its expression.
EST14 maps between MIPOL1 and FOXA1 on 14q21.1. The EST14-ETV1 fusion transcript 
contains part of the known exon 1 of this two exon EST (Unigene Hs.229997), linked to 
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ETV1 (Fig 3A and Supplementary Fig. 3). EST14 is weakly androgen-regulated in LNCaP 
and DuCaP prostate cancer cells (Fig. 3B). EST14 expression is highest in the prostate (Fig. 
3C). Similarly, the flanking gene FOXA1, but not MIPOL1, is preferentially expressed in the 
prostate, indicating a common control region (Supplementary Fig. 4).  Expression of the 
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Figure 2 Characterization of ETV1 fusion genes in clinical prostate cancer specimens. (A) Schematic representations of 
genomic regions of ETV1, FOXP1, HERVK17 and EST14 flanking genes on chromosomes 7, 3, 17 and 14, respectively. 
Distance from the top of chromosomes are indicated in Mbp. Directions of transcription are shown by blue arrowheads. BAC 
clones used in interphase FISH analysis are depicted in colors corresponding to FISH staining in b and c. (B) Interphase FISH 
on frozen tissue sections confirms FOXP1-ETV1, EST14-ETV1 and HERVK17-ETV1 gene fusions.  FOXP1-ETV1 
fusion is indicated by a white arrow (upper left panel, sample 32); duplicated EST14-ETV1 fusions are shown in the upper 
right panel (sample 342); HERVK17-ETV1 fusions are depicted in the lower left and right panels. (C) Break apart FISH of 
HERVK17 in samples 104 and 116. Both cases show separation of the yellow signal into red and green spots (white arrows). 
(D) Schematic representation of the breakpoints in ETV1, EST14 and HERVK17. Exons in ETV1, EST14 and C14orf25, 
and HERVK17 are indicated by open boxes. Positions of breakpoints detected in fusion genes are indicated by red arrows. 
Speckled box indicates genomic HERVK17 sequence. LTRs in HERVK17 are shown in filled boxes. Breakpoints of the 117 
Kbp deletion in EST14/C140rf25 are in blue arrows. The LINE repeat in C14orf25 containing two breakpoints is shown 
as a green bar. Breakpoints in ETV1 are in large intron 4 (samples 104 and 342) or in small intron 5 (sample 116).  Both 
breakpoints in defective HERVK17 are in a HERVK17 sequence flanking the 3’-LTR. Indicated below HERVK17 are: 
Transcript 1 (present in databases as FLJ35294), and a novel spliced transcript detected in prostate cells, starting in the 
5’-LTR (transcript 2). 
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mouse Est14 ortholog (mEst14; Mm.387080) is also prostate-specific (data not shown). 
Like expression of mTmprss2, expression of mEst14 increased during mouse prostate 
development, and is highest in the adult prostate (Fig. 3D). 
HERVK17 maps between ALOX15B and ALOX12B on 17p13.1 (Fig. 2A). The 5’-LTR of this 
HERV has promoter activity, and several unspliced transcripts from this promoter are 
known (Hs.336697; transcript 1 in Fig. 2D). HERVK17-ETV1 fusion transcripts are com-
posed of 264 bp of the retroviral transcript linked to either ETV1 exon 5 or 6 (Fig. 3A, 
A
C D
0
3
6
9
16,5 ed 18,5 ed 3 d 9 d 15 d 50 d 
mTmprss2
mEst14
Ta
rg
et
/H
pr
t
B1 5 6 12
ATG
21 5 6 12
TGA
TMPRSS2 ETV1
TAA
TAA
1 5 6 12
ATG
HERVK17
1 6 12
ATG
TAA
TAA
1 5 6 12
ATG
EST14
1 6 12
ATG
TAA
TAA
11 6 12
ATG
FOXP1
11 5 6 12
ATG TAA
TAA
0
2
4
6
8
10
TMPRSS2 HERVK17 EST14
LNCaP dcc
LNCaP R1881
DuCaP dcc
DuCaP R1881
Ta
rg
et
/P
BG
D
0
2
4
6
8
he
artbra
in
pla
ce
ntalun
g
liv
er
sk
ele
tal
 m
us
cle
kid
ne
y
pa
nc
rea
s
sp
lee
n
thy
mu
s
pro
sta
te
tes
tis
ov
ary
sm
all
 in
tes
tin
e
co
lon
pe
rip
he
ral
 le
uc
oc
yte
TMPRSS2
HERVK17
EST14
Ta
rg
et
/P
BG
D
Figuur 3Figure 3 Properties of ETV1 fusion transcripts and regulation of expression of ETV1 fusion partners HERVK17 and EST14. 
(A) Schematic representation of the different transcripts as detected by RT-PCR and sequencing. Exons are shown in colored 
boxes. ATG start codons and TAA stop codons of predicted long open reading frames are indicated in all transcripts.  Almost all 
fusion transcripts are present in two forms, with or without ETV1 exon 5. The TMPRSS2-ETV1 fusion transcripts contain 
either exon 1 or exon 1 and 2 of TMPRSS2 fused to ETV1 exon 5 (5). Open reading frames start at an ATG in ETV1 exon 
6, or at an in frame ATG in the segment derived from the fusion partner. (B) Androgen-regulated TMPRSS2, EST14 and 
HERVK17 mRNA expression in androgen receptor positive LNCaP and DuCaP prostate cancer cells. LNCaP and DuCaP cells were 
grown in absence and presence of the synthetic androgen R1881 (10-9 M) for 24 h. mRNA expression was measured by QPCR 
and is presented relative to PBGD expression. Mean values and SD of a duplicate experiment are presented (p<0.05, paired 
samples T-test; except for EST14 in LNCaP, p 0.07). (C) Tissue-specific expression of EST14, HERVK17 and TMPRSS2 
mRNA. Transcript levels were assayed by QPCR on a cDNA panel from 16 different normal tissues and are presented relative to 
PBGD expression. Mean values plus SD of a duplicate experiment are depicted. EST14, HERVK17 and TMPRSS2 are 
higher expressed in prostate compared to all other tissues (p<0.05, paired samples T-test).  (D) mEst14 and mTmprss2 
mRNA expression during mouse prostate development. Time points of RNA isolation are indicated. QPCR data plus SD are 
presented relative to Hprt expression. Obviously, a mouse ortholog of HERVK17 does not exist.
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Supplementary Fig. 5). In wild type retroviruses the same splice donor site, as used here 
for HERVK17-ETV1 transcripts, is used to remove the gag sequence, and produces mRNAs 
encoding pol and env. We detected by RT-PCR in prostate cells a novel HERVK17 tran-
script, starting in the 5’-LTR (exon 1), followed by a second exon in the HERV sequence 
downstream of the 3’-LTR (transcript 2, Fig. 2D). The breakpoints are in the intron of this 
novel transcript. Expression of HERVK17 is strongly androgen-regulated, and even more 
prostate-specific than TMPRSS2 and EST14 (Fig. 3B, C). HERVK17 flanking ALOX15B, but 
not ALOX12B, is also preferentially expressed in the prostate (Supplementary Fig. 4).
Figures 3A and 4A summarize the different open reading frames and predicted trans-
lated proteins of the ETV1 fusion transcripts.  Wild type ETV1 is composed of 12 exons, 
with the start codon in exon 1 and the stop in exon 12 (17). The DNA binding domain 
of ETV1, ETS domain, is located in the C-terminal half of the protein. In the N-terminal 
region, aa 42-73 is an acidic transactivation domain (TAD). In fusion transcripts, transla-
tion is predicted to start at an internal ATG in ETV1 exon 6 (aa 132) or at an in frame 
ATG from the fusion partner followed by ETV1 fragments of different sizes (aa 80-477 or 
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Figure 4 N-truncated ETV1 present in prostate cancer can inhibit transcription activation by full length ETV1. (A) Schematic 
representation of full length ETV1 and the predicted ETV1 truncated proteins and fusion proteins present in prostate cancer  
(compare Fig. 3a). TAD: Transactivation domain, ETS: ETS domain (DNA binding domain). (B) Transcription activation by ETV1 
and dETV1. PNT2C2 cells were cotransfected with pWPXLd-ETV1, pWPXLd-dETV1 or pWPXLd-GFP and the PALx8-TKluc reporter 
construct. Luciferase activity relative to full length ETV1 is depicted. Expression of full length ETV1 and truncated ETV1 was 
visualized on Western blots. Actin is the loading control (C) LNCaP cells were cotransfected with pcDNA3-ETV1, pcDNA3-dETV1 
or empty vector and the PALx8-TK-Luc reporter construct. The figure shows Luciferase activity relative to full length ETV1 
activity. The insert shows a Western blot of full length ETV1 and N-truncated ETV1, expressed in transfected LNCaP cells. (D) 
dETV1 can decrease ETV1 activity. LNCaP cells were transfected with pcDNA3-ETV1 and pcDNA3-dETV1 in a 1:3 ratio, and the 
PALx8-TK-Luc reporter construct. Experiments were performed in quadruplicate. The figure shows the mean value plus Standard 
Error relative to ETV1 activity. 
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shorter) (Figs 3A and 4A). So, all fusion transcripts predict production of ETV1 lacking 
the N-terminal TAD. 
To test the functional properties of ETV1 in prostate cells, expression constructs of 
full length ETV1 and truncated ETV1 (dETV1) were generated. The correct size of the 
proteins was verified by Western blotting in transiently transfected immortalized non-
tumorigenic PNT2C2 prostate epithelial cells with low endogenous ETV1 expression 
and in an LNCaP prostate cancer subline without ETV1 expression (Fig. 4B,C). Transient 
transfection of PNT2C2 cells with ETV1 expression constructs and an ETS reporter gene 
clearly showed that full length ETV1 functioned as a transactivator, whereas dETV1 
was not or hardly active (Fig. 4B) (see also (18)). Similar results were obtained in LNCaP 
cells (Fig. 4C) and in 3T3 cells (data not shown). Other dETV1 fusion transcripts (Fig. 
3A) gave identical results in this assay (data not shown). In a competition assay, dETV1 
diminished the activity of full length ETV1 (Fig. 4D). So, full length ETV1 and N-truncated 
ETV1 possess different transcription regulation functions, suggesting that prostate 
cancers overexpressing full length ETV1 and those expressing N-truncated ETV1 are not 
identical. dETV1 might compete with full length ETV1 for the ETS binding sites in the 
reporter construct or form heterodimers with full length ETV1, thereby weakening the 
much stronger transactivation of full length ETV1 (see also (18)). 
Next we compared the properties of full length ETV1 and dETV1 in various in vitro 
biological assays. First, lentiviruses expressing either full length ETV1 or dETV1 were 
generated, and PNT2C2 cells were infected with these viruses. Pools of stable-transfected 
cells overexpressing ETV1 or dETV1, PNT2C2-ETV1 and PNT2C2-dETV1, respectively, 
were propagated and ETV1 protein expression was verified by Western blotting (Fig. 
5A). PNT2C2 cells infected with a GFP-lentivirus were used as controls. Overexpression 
of full length ETV1 or truncated ETV1 had no effect on proliferation of PTN2C2 cells as 
determined in a standard MTT assay (data not shown). Compared to infected control 
cells (Fig. 5B, C) and uninfected parental cells (data not shown), both PTN2C2-ETV1 and 
PTN2C2-dETV1 showed increased migration and invasion (Fig. 5B, C). So, we did not ob-
serve a significant difference between both PNT2C2 sublines in these assays. However, 
overexpression of full length ETV1 strongly stimulated anchorage-independent growth 
of PTN2C2 cells, whereas dETV1 had no effect (Fig. 5D). 
QPCR experiments were done to assess the expression of endogenous ETS target 
genes that are presumed to mediate migration, invasion or anchorage-independent 
growth (1-3). Genes studied encoded matrix metalloproteinases (MMP), uPA, uPAR and 
integrins (Fig. 6 and unpublished data). First, we confirmed overexpression of ETV1 and 
dETV1 mRNA in the PNT2C2-ETV1 and PNT2C2-dETV1 lines, respectively (Fig 6A). Next, 
we studied expression of members of the MMP family. Highest induction was detected 
for MMP1 (Fig. 6B) and MMP7 (data not shown). MMP3 was also induced, but MMP9 
was not (data not shown). In none of the experiments a significant difference between 
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PNTC2-ETV1 and PNTC2-dETV1 was detected. Similarly, expression of uPAR was induced 
in both cell types, the effect of ETV1 and dETV1 on uPA expression was limited (Fig. 
6C).   ITGAV and ITGB3 expression were induced in PTN2C2-ETV1 and PTN2C2-dETV1 
cells (Fig. 6D). However, particularly the expression of ITGB3 was strongly stimulated 
in PNT2C2-ETV1 cells, but much less in cells overexpressing dETV1.  Neither ETV1 nor 
dETV1 affected the expression of ITGB1 and ITGB5 mRNA (data not shown). 
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Figure 5 Biological properties of PNT2C2 epithelial prostate cells overexpressing full length ETV1 or N-truncated ETV1 (A) 
Western blot of PNT2C2 cells infected with lentiviruses expressing either full length ETV1, truncated ETV1 or GFP (control). 
Actin is shown as a loading control. (B) Migration of PNT2C2-ETV1 cells, PNT2C2-dETV1 cells and control PNT2C2-GFP cells was 
determined in a standard assay as described in Materials and Methods. 10% FCS was used as attractant. Pictures below the bar 
figure show migratory cells. (C) Invasion of PNT2C2-ETV1, PNT2C2-dETV1 and PNT2C2-GFP control cells. Experiments were done 
as described in Materials and Methods. Pictures of invaded cells are shown below the bar figure. (D) Anchorage-independent 
growth of PNT2C2-ETV1, PNT2C2-dETV1 and PNT2C2-GFP (control) cells, as assessed by a soft-agar assay. Representative 
pictures of colonies are shown. Bars show mean values plus SD of experiments in triplicate.
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Discussion
The results presented in this study reveal several important aspects of prostate cancer. 
First, it is increasingly becoming clear that the prostate-specific and androgen-regulated 
expression of many ETV1 fusion partners, as shown here for EST14 and HERVK17, and 
previously for TMPRSS2 (11) is an important determinant in fusion gene selection. In 
agreement with this observation, recently, for three other ETV1 fusion partners, SLC45A3, 
HERVK22q11.23 and C15orf21, preferential expression in prostate cancer has been docu-
mented (19). SLC45A3 and HERVK22q11.23 are upregulated by androgens, but C15orf21 
is downregulated. Similarly, prostate-specific and androgen-regulated KLK2 and CANT1 
are novel ETV4 fusion partners (20). An explanation for this remarkable selection would 
be a co-localization of prostate-specific genes in particular chromosome territories or 
prostate-specific transcription factories, favoring their selective interactions with part-
ner oncogenes (21-23). Alternatively, it can be postulated that certain regions in the 
genome, involved in regulation of prostate-specific gene expression, are preferentially 
unstable at the shift in cellular programming from proliferation (DNA replication) to 
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Figure 6 Expression of ETV1 target genes. Expression of ETV1 target genes was assayed by standard QPCR in PNT2C2-ETV1, 
PNT2C2-dETV1, and PNT2C2-GFP control cells. Bars represent mean QPCR data plus SD of duplicate experiments relative to 
PBGD expression. (A) ETV1 and dETV1  (p<0.05, paired samples T-test) (B) MMP1 (p< 0.05) (C) uPAR (p<0.05) and 
uPA (D) ITGB3 (p<0.05) and ITGVA .
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differentiation (expression of prostate-specific genes) during development or at tissue 
renewal (24). These unstable regions could be targets for gene fusions and if fused to 
oncogenes, be involved in tumor development.
In the LNCaP prostate cancer cell line, the complete ETV1 locus is translocated from 
chromosome 7 to chromosome 14, and integrated into the last intron of MIPOL1 (19). 
Remarkably, MIPOL1 is a directly flanking gene of EST14, which was found as ETV1 fusion 
partner in this study. Also evidence exists that in the MDA-PC2A cell line, which shows 
a (7;14) chromosomal translocation, ETV1 is linked to the same chromosome 14 region 
(19). Combined these findings indicate that chromosome 14 contains a small region that 
favours integrations and rearrangements of full length ETV1 or ETV1 fusion genes not 
only in cell lines, but also in clinical prostate cancer. It remains to be established whether 
or not overexpression of full length ETV1 in other clinical samples is the result of genomic 
rearrangement of the complete ETV1 locus. Elucidation of the chromatin structure of 
the chromosome 14 genomic region might shed more light on the mechanism of gene 
rearrangement in prostate cancer.
A further aspect of this study concerns the role of repeat sequences in prostate cancer. 
From the eight ETV1 fusion partners ((8, 19), and this study) two are members of the HERVK 
subfamily of endogenous retroviral repeat sequences, HERVK17 and HERVK22q11.23. 
Previously, only one similar gene fusion has been reported, HERVK19-FGFR1 in a myelo-
proliferative disorder (25). The finding of a role of common repeats, encoding apparently 
insignificant defective transcripts, in a frequent disease like prostate cancer urges to re-
consider the role of such repeats in disease. In this regard, the HERVK retroviral subfamily 
is of particular interest, because many members possess active promoters (26, 27). 
In transient reporter assays full length ETV1 is a strong transactivator, whereas dETV1 
is not or hardly active (Fig. 4 and (18)). However, dETV1 can stimulate expression of 
endogenous target genes (Fig. 6). So, it seems that the acidic N-terminal region, which 
functions as a dominant TAD in transient transfections, is less important for activation of 
endogenous ETV1 target genes. This finding implies that ETV1 possesses additional TADs 
that remain to be defined in more detail.  Moreover, it is of high interest to identify genes 
that are preferentially regulated by ETV1, and which are responsible for anchorage-
independent growth of prostate cells overexpressing full length ETV1. In this regard, 
ITGB3 is an attractive candidate. 
The large family of ETS transcription factors displays a wide variety of biological 
activities, including cellular proliferation, apoptosis, differentiation, tissue remodeling, 
migration, invasion and angiogenesis (2, 28). The effects might depend on the cellular 
context and on the expression levels of the individual ETS factors. In most tumor types a 
role of overexpressed wild type ETS factors, including ETV1, has been described (2, 28). 
Although clinical prostate cancers can overexpress full length ETV1 (this study) most 
prostate cancers show overexpression of N-truncated ETS transcription regulators. It is 
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tempting to speculate that the combination of prostate-specificity and protein trunca-
tion is a unique prerequisite for initial oncogenic properties of a weaker, more specific 
ETS in prostate cancer. 
Previously, the biological and molecular effects of overexpression of full length ETV1 
in prostate cancer, as shown here, have not been studied. However, recently, the effects 
of dERG, as expressed from TMPRSS2-ERG (29, 30) and of  dETV1, as expressed from 
TMPRSS2-ETV1 (19), on cell growth, migration and invasion have been described. Some 
differences in proliferation and migration were found (this study and (29)), which might 
be due to differences between dERG and dETV1 or to the different cellular context. In 
agreement with our findings, in all studies the fusion proteins were able to stimulate in-
vasion of the target cells. Like shown here, stimulation of invasive growth correlated with 
upregulation of genes known to stimulate tumor invasion and metastasis. The unique 
differences between full length ETV1 and dETV1 warrant further in depth investigation 
of the mechanism of prostate cancer growth.
We propose that overexpression of truncated ETV1 or other members of the ETS 
transcription family is most important in earlier stages of prostate cancer, whereas 
overexpression of wild type ETS transcription factors combined with downregulation 
of fusion gene expression comes into play at late stages of the disease (Supplementary 
Fig. 6). This hypothesis is supported by several observations. (i) The soft agar growth 
of PNT2C2-ETV1 cells indicates that full length ETV1 is more oncogenic than dETV1 
(Fig. 5). (ii) In prostate cancer xenografts, overexpression of fusion genes is detected 
in hormone-dependent samples, whereas in hormone-independent xenografts fusion 
gene expression is shut off, and overexpression of a full length ETS factor is turned on 
(5). (iii) Our limited clinical data indicate that full length ETV1 is expressed in the two 
recurrent tumors (Fig 1A). Moreover, the two patients with overexpression of full length 
ETV1 in primary tumors had a remarkable short survival time (50 and 19 months), as 
compared to the three patients with primary tumors with ETV1 fusion gene expression 
(99, 141, >172 months, respectively), and with patients with TMPRSS2-ERG fusion or 
without gene fusion (data not shown). Obviously, these clinical data should be validated 
in a larger patient cohort.   
In conclusion, the data presented in this study show that ETS genes play a pivotal role 
in prostate cancer, probably affecting many stages of tumor growth. Investigation of the 
mechanism of gene fusion and translocation, and the function of the various truncated 
and full length ETS transcription factors will contribute to a much broader knowledge of 
prostate tumor development and to the identification of novel therapeutic targets.
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suPPLementary information
supplementary table s1. Primer sequences
   
 forward (5’->3’) reverse (5’->3’)
rt-Pcr, QPcr, race
PBGD CATGTCTGGTAACGGCAATG GTACGAGGCTTTCAATGTTG
ETV1 E11-12 CATACCAACGGCGAGGATCA TGGAGAAAAGGGCTTCTGGA
ETV1 E1-2 AGCTGAGATTTGCGAAGAGC CTGCTCATCATTGTCAGGTAC
ETV1 E6 GGTTTCGGTGTATGAGTTGA
HERVK17 TGAAGTTACACCTGAGCGTG
HERVK17 RT CAGACAAACCTGGAGATGAG AGGCTCCAAGCTACATTGCT
Chr 17 tr 2 TGAAGTTACACCTGAGCGTG TCGCCATAAGCAACTTCCAC
EST14 AGAGGAGAAAGAGTGCTCTA
EST14 RT TCTCCAGGCTTTTTCATCTC AGAGGAGAAAGAGTGCTCTA
FOXP1 E11 TCTGACCACGACATGTGTCT
ALOX15B RT CTCTCTGGTTGCTGAGCAAG CTGGGATTTAGATGGAGACG
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ALOX12B RT GGAATCCACCGATTCAGACT AGTGAATGTCCGGGAAGTGT
FOXA1 RT ATGGAAGGGCATGAAACCAG CATAGGACATGTTGAAGGAC
MIPOL1 RT AGGAACTGGCTACTCAACTG CAGATCACTGTCCTCATGGT
MMP1 RT CTGCTTACGAATTTGCCGAC GTTCTAGGGAAGCCAAAGGA
MMP7 RT CCTCTGATCCTAATGCAGTG GAATGGATGTTCTGCCTGAAG
MMP3 RT GCTGAAGACTTTCCAGGGAT TGGGTCAAACTCCAACTGTG
MMP9 RT TTCGACGTGAAGGCGCAGAT TCCACCTGGTTCAACTCACT
uPAR RT GAAGAACAGTGCCTGGATGT CGGCAGATTTTCAAGCTCCA
uPA RT CACTACTACGGCTCTGAAGT CCAGCTCACAATTCCAGTCA
ITGB3 RT CTGGAAACTCCTCATCACCA AGGTAGACGTGGCCTCTTTA
ITGAV RT AGGATTGTTGCTACTGGCTG CTTGTTCTTCTTGAGGTGGC
ITGB5 RT TGGAAGCTGCTTGTCACCAT CGTGGAGATAGGCTTTCTGT
ITGB1 RT CATGACAGAAGGGAGTTTGC CACAGTTGTTACGGCACTAT
Breakpoint mapping
ETV1 I4AR AGCCAATTGAAGGGCAGGAG
ETV1 I4BR GCATGATCCATGCTAGTGGA
ETV1 I4CR ACAGCTTTGGTTGAGGGTAG
ETV1 I4C1R CACACCTGGCTGAGAATATG
ETV1 I4DR GACCTCAATTAGTGCTCAGT
ETV1 I4ER CTGAAGGACTTCTGGTAAGC
ETV1 I4FR ATATGCCTGTCATGGCTTTG
ETV1 I4GR GTAACTAGGTAGCAGTGGTG
ETV1 I4HR ACCACGGTTACCTGGTTATC
ETV1 I4IR GACCCACAAATTAGGGTGTC
ETV1 I4JR GGCTGTTGTGTTCATGAGGA
ETV1 I4KR CATAAGCTCCATGATAGCAG
ETV1 I4LR TGGGTCATCAATGCCTTGGC
ETV1 I4MR TGGGACTTATGCACACTCCT
ETV1 I4NR GGCTGAGAAAGACTTCAGTG
ETV1 I4OR TGGTCAGTAGCAGCAGTTAG
ETV1 I5R CTGTATAGCGATGGAAGTAC
EST14 E1F GTTACTCAGTTCTTTACCCT
EST14 I1AF GAGCTTTACAGGTGATGAGA
HERVK17 F TGAAGTTACACCTGAGCGTG
mouse QPcr
Hprt TCCCTGGTTAAGCAGTACAG TTCCAGTTTCACTAATGACAC
mTmprss2 GAATGGGATCTGGTGGCTGA GGGAGCACAGTCAAACAAGT
mEst14 ACCATCAGTGGACGGCATCA CTTCTGCGGTAACAATGTAGA
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etV1 expression constructs
ETV1 AGATTTGCGAAGAGCAGCAG CCCTGCTTGACTGTCACTTG
dETV1 ATCAGAAGCCACAAGTGGGA CCCTGCTTGACTGTCACTTG
HERVK17-ETV1 GCCTTTGCAATCTCCACGTTG CCCTGCTTGACTGTCACTTG
EST14-ETV1 GATAGCACATCAGTGAAGAC CCCTGCTTGACTGTCACTTG
FOXP1-ETV1 TCTGCACCTTCCAAGACCTC CCCTGCTTGACTGTCACTTG
foXP1 exon 11
accc ccct aaca ctag gctt tgtt tact gact cttt gatt taat tgct gttt gaag agga cgga atta gctg ttaa ttga ttta atta tcca attt gttt gttt 
cagG CATG ATTC CAAC AGAA CTGC AGCA GCTC TGGA AAGA AGTG ACAA GTGC TCAT ACTG CAGA AGAA ACCA CAGG CAAC 
AATC ACAG CAGT TTGG ATCT GACC ACGA CATG TGTC TCCT CCTC TGCA CCTT CCAA GACC TCCT TAAT AATG AACC CACA TGCC 
TCTA CCAA TGGA CAGC TCTC AGTC CACA CTCC CAAA AGGG AAAG gtag gaac cagc cact gaga tggg tcca aaac tgcc ttta acat 
gaga gggg tggg tggc cctg cctc gtca tatc tcag tgat ccct aatt ggat ccat gtga cttg aatg tgca tata atta ctga ggaa tgta tt
Figure S2.  Sequence of the FOXP1 exon in the FOXP1-ETV1 fusion gene.
Sequence of FOXP1 exon 11 is shown in capitals.
In grey: sequence present in FOXP1C transcripts and in FOXP1-ETV1 fusion transcripts.
Italic: splice acceptor/donor site.
ATG translation initiation codon is underlined.
Breakpoints HERVK17-ETV1:
     fusion point
116: ...AGTATTACTTGGGGGAGGGG ↓ GCCTGGGCAACAAGAGCGAG…
  CHR 17 (HERV-K)  ETV1 intron 5 (Alu Sp)
     fusion point
104: …AGTTAGAAGATTTGAATCAA ↓ TGTTTTCAATGTAAGGATAC…
  CHR17 (HERV-K)  ETV1 intron 4
Breakpoint EST14-ETV1:
    117kb deletion
342: …TAAAAAATATAGACAAGAAT ↓ CTATGCATTGATCTTGGACA… 
  EST14 intron 1   (L3) C14orf25 intron 4 
   fusion point to etV1
342:  …GAAAAAGAAAACTACAGGCC ↓ AATGTGAATGACCTTTTTAA…
           C14orf25 intron 4 (L1MA2)   ETV1 intron 4
Figure S1. Sequences of genomic fusion points. Fusion points were mapped by long range PCR and sequencing in samples 
116,104 and 342. The sequence of the fusionpoint formed by the 117 kbp deletion  (sample 342) was determined by the same 
approach. PCR primers are given in Supplementary Table 1.
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HerVK17
ctat gctc accc aatg atca cctc acca tcag ccca ccct cagc ctat agga tcaa agga actg tact caat aaat atca gtgg aacc caga gctc ctgg 
CCTT TGCA ATCT CCAC GTTG CGAT GGAT CCTT GGAC CCAC TTTT GTTA ACTC TTAA ACTT TGTG TCTT TGTC TTTA TTTC TTTT 
CTCA TTCC CTCG TCTC CACC GGGA AGGG GAGA GCCT GCGG GTGG TGTA TCAG GCAG GTTC CCCT ACAT CTTT GGCA CCCA 
ACAC GGTC TCCT TGAA CCCA GGTG AAGT TACA CCTG AGCG TGGT CGTT GTGA AGAA CGGT CTGT CCAG GAAC TCCC GAGA 
ACGT GTGG TCGG CCTT GCGG TAAG CTTG TGCA CTCG GAGC ATTC CAGG GACA CCAT GGGA CAAT CCAA AAGT AAAC ATTC 
TGCA TATT TACA TTTT ATTA AGCT CCTC TTAA AGAG GGCA GGAA TTAA GGCT AGCA CAGA AAAT TTGA TTAC TCTG TTTC CAAC 
AGTA GAGC AATA TCGT CCTT GGTT TCCT GAAC ATGG TACC ATGG ACTT CAAA GATT GGGA ACAG GTGG GAAT TGCC TTAA 
AACA AGTT TGTA……
Figure S5. HERVK17 sequence present in HERVK17-ETV1 fusion transcripts.
The 5’-region of FLJ35294 is depicted in capitals.
In grey: exon 1 of HERVK17 present in HERVK17-ETV1 fusion transcripts.
TATA box is underlined.
Italic: splice donor site.
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Figure S4. Tissue-specific expression of EST14 and HERVK17 flanking genes.
(A) Expression of MIPOL1 and FOXA1, which flank EST14 and (B) expression of ALOX15B and ALOX12B, flanking 
HERVK17 as assessed by QPCR on a cDNA panel from 16 different normal tissues. QPCR data are presented relative to PBGD 
expression.
est14 exon 1 (Bf673302)
ctaa cagc ctgt agat ctag attt tttt ctct ctaa aaca tctt catt gacc atga ccat taat attt actc ataa atgg attt gtac acag gctc aacc ATAG 
CACA TCAG TGAA GACA AAAA GAGT TGTT ACTC AGTT CTTT ACCC TAGA ATAA ATCA AATC AACA AATA TTTA TTGA ATGT CTAC 
TATG TGCA AATA GCCC TGGA CTGT TCAG CTTT TAAA AGCC ATCC AACT TTTC ACAT TAAC AAAT CAAA GCAT TATT ATTT CAAG 
CATT GCAG AAGC TGCT TCCA TGTC CTTA AGGT GACA AAGC ATAT GAGG ACTT TGCA AGTA CTTG GAGT AAAG GAAG AGAA 
GAGA ATTC ACAG AGTG AAAA GAGG AGAA AGAG TGCT CTAA AATA TCAC CAAT GGAC TGCA ACAT gtat gtat gtac acat aagt 
ttat gtgt atgt gtct atat tatg tatg tgtt tata tatg tgta taca taca atga gaag aatg agtg aatt tgga gaga aata gcct tcgt taaa gtac aata 
ggaa tagg ca
Figure S3. Sequence of the EST14 exon in the EST14-ETV1 fusion gene.
Published sequence of EST14 exon 1 is shown in capitals (Unigene Hs.229997).
In grey: EST14 exon 1 sequence present in EST14-ETV1 fusion transcripts.
TATA box is underlined.
Italic: splice donor site.
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Normal Prostate Early Prostate cancer Late Prostate cancer
ETSTAD ETS
ETSTAD
ETS
Figuur S6
Figure S6. Model of sequential expression of ETS genes in prostate cancer.
In prostate cancer, first expression of prostate-specific truncated ETS is necessary for ncogenesis. In late stage prostate cancer 
fusion gene expression is down regulated. Instead, overexpression of wild type ETS is favored. Blue box indicates own promoter, 
orange box indicates prostate-specific promoter, hatched blue box indicates either own promoter and/or other promoter
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GeneraL Discussion
Prostate cancer is the most frequently diagnosed tumor in men in countries with a West-
ern lifestyle (1). Although our knowledge of molecular mechanisms underlying prostate 
cancer development and progression has rapidly increased over the past few years, 
there are still many questions that remain to be addressed. A better understanding of 
the molecular mechanisms is essential for the development of targeted therapies and 
for predicting the clinical course of the disease. The aim of this thesis was to unravel the 
major genetic alterations in prostate cancer. The main focus of this discussion will be on 
the recently identified ETS fusion genes in prostate cancer, which are the most frequent 
genetic alteration detected to date.
Genome-WiDe stuDies for iDentification of canDiDate oncoGenes 
anD tumour suPPressor Genes
Genome-wide array CGH studies can be used as a basis for the search of novel tumour 
suppressor genes and oncogenes in cancer (2, 3). Depending on the platform used, 
BAC, cDNA or oligonucleotide arrays, and on the distance between the probes, a high 
resolution can be reached. Nowadays, SNP arrays are frequently used to obtain detailed 
information on genetic alterations. An advantage of SNP arrays over BAC and cDNA ar-
rays is that SNP arrays also provide allelotypic information. However, this information 
is not used to identify the classical tumour suppressor genes or oncogenes in sporadic 
cancer.
In our search for novel tumour suppressor genes we used 1 Mbp spaced genome-wide 
BAC arrays to identify genomic alterations in human prostate cancer xenografts. Xeno-
grafts are powerful tools to investigate genetic alterations. They lack contamination of 
normal cells and are available in unlimited quantities. This simplifies the identification 
of high-level amplifications and homozygous deletions. Moreover, they represent dif-
ferent stages of clinical disease, ranging from primary tumours to distant metastases 
and locally recurrent disease, and from androgen-dependent to androgen-independent 
tumours. However, one has to keep in mind that these xenografts may be biased in that 
they probably represent the more aggressive tumours and that they may have acquired 
additional genetic alterations during propagation on immuno-deficient mice. 
Genomic alterations were characterized in eleven human prostate cancer xenografts 
(Chapters 2, 3 and 4) and eleven homozygous deletions were identified, one on chromo-
some 2q, one on 8p, three involving the tumour suppressor gene PTEN on 10q, two on 
13q, two on 16q and two on 17p. The two homozygous deletions on 17p were further 
characterized. This led to the discovery of N-COR as a novel tumour suppressor gene 
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in prostate cancer. However, with the arrays used several homozygous deletions were 
missed: a small previously identified homozygous deletion of exon 5 of PTEN (4), one 
homozygous deletion on 8p involving WRN (5), and two homozygous deletions on 17p, 
one involving MKK4 and the other involving N-COR (Chapter 2). All these homozygous 
deleted regions are located between two BACs. Use of a tilling path genome-wide 
BAC array or a high-density oligo array would have detected most of these alterations. 
The question remains how many more homozygous deleted regions were missed and 
whether they contain genes that are relevant in prostate cancer.
Very recently, genomic DNA from ten xenografts was investigated by oligonucleotide 
arrays containing over 1 million data points. Preliminary results showed overall the same 
genomic alterations as detected on the BAC arrays. However, on oligonucleotide arrays 
many additional small regions of (homozygous) loss and a few additional regions of gain 
were detected. The question can be raised whether all these alterations are relevant in 
tumorigenesis or whether they are an insignificant consequence of acquired genomic 
instability. Parts of these alterations were detected in multiple samples, including nor-
mal DNA. Most likely, many of the small regions of gain or loss are structural natural 
occurring copy number variations (6, 7). It remains to be investigated whether these 
structural variants contribute to disease, including cancer. 
The homozygous deletions missed on the BAC arrays were detected on the oligo-
nucleotide arrays. Also, in the DNA of the xenografts five larger specific homozygous 
deletions were detected, located on chromosome arms 4q, 5q, 10q, 13q (Figure 1), and 
17q. The homozygous deleted region detected in xenograft PC339 on 4q (~310 kbp) 
contained seven genes, but none of these genes has been described as candidate tu-
mour suppressor gene. A homozygous deleted region in DNA of xenograft PC339 was 
located on 5q (~300 kbp), FBXL17 maps in this region. Whether this gene is a potential 
tumour suppressor gene needs to be established. In xenograft PC374 a homozygous 
deletion of ~100 kbp was detected on 10q. There are no known genes located in this 
fragment, however, this region is located between BRWD2 and FGFR2, and it is a cancer-
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Figure 1. Comparison of the BAC array and SNP array data of chromosome 13q of DNA from xenograft PC324.
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related recombination hot spot (8). On 13q a homozygous deletion of ~630 kbp in the 
DNA of xenograft PC324 was detected (Figure 1). In this region seven genes are located. 
Four of these, ARL11, KPNA3, C13ORF1 and KNCRG, have been described as candidate 
tumour suppressor genes (9-12). In DNA of xenograft PC133 a ~130 kbp homozygous 
deleted region was detected on 17q. In this region kinase suppressor of RAS (KSR1) is 
located as candidate tumour suppressor gene (13). The most promising regions should 
be subjected to further study to identify true genes involved in prostate cancer.
In conclusion, oligonucleotide arrays detected many small additional alterations com-
pared to the BAC arrays. However, many of these alterations were detected both in tu-
mour and in normal DNA. Part of the homozygous deletions detected, overlapped with 
already known homozygous deletions, however, others were new. All new homozygous 
deletions were unique, which might indicate that genes that map in these fragments are 
of importance in a low percentage of tumours. Thus, high-density oligonucleotide ar-
rays, although more sensitive, seem not essential in the search for frequently inactivated 
tumour suppressor genes. However, sensitive oligonucleotide arrays might be helpful in 
specific mapping of chromosomal breakpoints (see below). 
searcH for neW fusion Genes in cancer
The first chromosomal translocation identified in human cancer was t(9;22), the Phila-
delphia chromosome (14). This translocation was discovered by classical cytogenetic 
techniques and led to the identification of the BCR-ABL1 fusion gene in the early 1980’s. 
Following this finding, many more fusion genes have been discovered, mainly in malig-
nant haematological disorders and in childhood sarcomas (15), using molecular cytoge-
netic techniques as a tool to pinpoint gene rearrangements. In epithelial tumours fusion 
genes have hardly been detected, although many chromosomal aberrations have been 
identified. In a few rare subtype epithelial tumours fusion genes were described, includ-
ing ETV6-NTRK3 in secretory breast cancer, PAX-PPARG in follicular thyroid carcinoma, 
and RET/NTRK1 rearrangements in papillary thyroid carcinomas (15). These fusion genes 
have been identified by cytogenetic techniques or by overexpression and subsequent 
gene walking.
As described in Chapter 2, we detected a unique situation of loss of a small region, en-
compassing four BACs on chromosome 21q in three human prostate cancer xenografts. 
The resolution of the BAC arrays did not allow precise mapping of the breakpoints. 
However, on the oligonucleotide arrays we could pinpoint the breakpoints to ERG and 
TMPRSS2, resulting in an interstitial deleting and the forming of the TMPRSS2-ERG fu-
sion gene. The detection of this fusion gene by array CGH was only possible because of 
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the location of the fusion partners within 3 Mbp on the same chromosome. For direct 
detection of gene fusions array CGH is not suitable, but high-density oligo arrays can in 
some cases, where parts of chromosomes are gained or lost following chromosomal re-
arrangement, more precisely map chromosomal breakpoints. If such a breakpoint is in a 
gene, it might indicate the forming of a fusion gene. However, the partner, if there is one, 
remains to be identified. Also note that the initial discovery of the TMPRSS2-ERG fusion 
gene made use of a bio-informatics approach, denoted cancer outlier profile analysis 
(COPA) (16), searching for genes with marked overexpression in a subset of samples.  
Recently, a functional approach resulted in the identification of a fusion gene in an 
epithelial cancer, making use of a retroviral cDNA library from a lung adenocarcinoma 
specimen. Infection of mouse 3T3 cells by the retroviral library led to the formation of 
many transformed foci (17). Sequencing of recovered cDNAs resulted in the identifica-
tion of the EML4-ALK fusion transcript. EML4-ALK gene fusion turned out to be present 
in ~5% of non-small cell lung cancers (18, 19). Recently, genome-wide massive parallel 
paired-end sequencing has been developed as technological tool to characterize rear-
rangements in genomic DNA from healthy individuals and in cancer genomes (20, 21). 
Ruan et al used cDNA of cancer cell lines as template for massive parallel paired-end 
sequencing, denoted paired-end diTag analysis (22), allowing a comprehensive charac-
terization of (cancer) transcriptomes, which is able to identify novel fusion transcripts. 
These novel genome-wide techniques seem very promising in the identification of 
previously unknown fusion genes, (fusion) transcripts and other rearrangements that 
underlie cancer development and progression.
TMPRSS2-ERG Gene fusion anD ProGnosis of cLinicaL Prostate 
cancer
Several groups have attempted to correlate TMPRSS2-ERG fusion with clinical status 
of prostate cancer and tried to find out if TMPRSS2-ERG fusion is of prognostic value. 
This has resulted in confusing outcomes: no association with prognosis, association 
with good prognosis or with poor prognosis. These observations suggest that the role 
of TMPRSS2-ERG in prostate cancer is complex. However, it is not easy to compare the 
different studies because 1) Different techniques were used to determine TMPRSS2-ERG 
fusion status, i.e. FISH, RT-PCR or QPCR. 2) The origins of tumour materials, biopsies, 
radical prostatectomy samples, lymph node metastasis or transurethral resections of 
the prostate (TUR-Ps) were different. 3) Different patient cohorts; length of follow up; 
availability of clinical data; number of patient samples were included in the studies. This 
made it difficult to draw conclusions from the available data for the prognostic signifi-
cance of TMPRSS2-ERG fusion in clinical prostate cancer.
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Two studies (23, 24) reported on TMPRSS2-ERG fusion in watchful-waiting cohorts by 
FISH analysis on tissue microarrays constructed from TUR-Ps. Both studies concluded 
that presence of TMPRSS2-ERG fusion is associated with shorter cancer-specific survival. 
However, in one of the studies this was only true if the mechanism of fusion was by in-
terstitial deletion. The percentage of TMPRSS2-ERG fusion gene positive specimens (De-
michelis et al 15% and Attard et al 30%) was rather low in both studies, possibly because 
both cohorts consisted of patients with low-stage disease. Moreover, both studies used 
FISH analysis on paraffin-embedded material, which can be technically challenging on 
samples with low tumour volume. Perner et al and Attard et al found that TMPRSS2-ERG 
fusion by deletion in primary tumors was correlated with earlier biochemical recurrence 
(23, 25). Loss of one or more of the genes in the genomic fragment between TMPRSS2 
and ERG with tumour suppressor potential may influence oncogenic potential and 
might explain a worse clinical outcome. The best candidate gene that maps between 
TMPRSS2 and ERG might be HMGN1. HMGN1 alters the compaction of chromatin and has 
previously been described as a candidate tumour suppressor gene (26). Interestingly, 
ETS2, an ETS family member, also maps between TMPRSS2 and ERG. Recently, it has been 
reported that ETS2 is downregulated in prostate cancer (27). It has also been shown that 
ERG competes with ETS2 in a transcriptional complex including c-FOS and c-JUN (28). 
Not only the loss of the genomic region between TMPRSS2 and ERG has been impli-
cated in poor prognosis of prostate cancer, also the presence of specific TMPRSS2-ERG 
splice variants has been described in this regard. Wang et al reported that the presence 
of an in frame native ATG of either TMPRSS2 or ERG in TMPRSS2-ERG fusion transcripts is 
correlated with more aggressive disease (29).
In contrast to manuscripts describing an association between TMPRSS2-ERG and poor 
prognosis, Petrovics et al associated high ERG mRNA expression levels with a favourable 
prognosis (30). Also Saramäki et al correlated TMPRSS2-ERG fusion with longer time to 
PSA progression (31). We found no difference in biochemical progression-free survival 
between the TMPRSS2-ERG fusion positive and fusion-gene negative patients (Chapter 
5). However, by separation of the fusion-gene positive group in TMPRSS2(exon 0)-ERG 
transcript positive samples and TMPRSS2(exon 0)-ERG transcript negative samples we 
observed that patients with TMPRSS2(exon 0)-ERG expression had a better biochemical 
progression-free survival compared to patients not expressing this transcript.
Apparently, different aspects of TMPRSS2-ERG fusion are important in determining its 
prognostic value. It is clear that for accurate establishment of the prognostic value of 
theTMPRSS2-ERG fusion gene large well-defined patient cohorts with a long follow-up 
are needed. Fusion gene status should be determined both by QPCR and FISH analysis. 
A next issue that remains to be addressed concerns the question whether patients 
with other ETS fusion genes have the same prognosis as patients harbouring TMPRSS2-
ERG fusion genes. ERG on the one hand and ETV1, ETV4 and ETV5 on the other hand 
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are members of different subgroups of the ETS transcription factor family, with different 
structural and functional properties. So, at determining prognostic value of TMPRSS2-
ERG, other ETS fusion genes should also be taken into account and considered as 
separate groups.
function of ets fusion Genes in Prostate cancer
ETS transcription factors are involved in multiple biological processes, like apoptosis, 
cellular proliferation, differentiation, angiogenesis, tissue remodelling, metastasis and 
transformation (32, 33). To determine the functional role of ETS factors in prostate and 
prostate cancer, recently several in vitro and in vivo studies have been performed (34-39). 
Translation from most ETS fusion transcripts will result in the synthesis of an N-truncated 
ETS protein (dETS), but sometimes also full length ETS proteins will be synthesized (see 
also above). We found overexpression of full length ETV1 and of dETV1 (Chapter 7). Full 
length ETV1 protein possesses an N-terminal transactivation domain (TAD) and in the 
C-terminal half the DNA binding ETS domain (ETS) (40). In dETV1 protein the TAD is 
absent. Two other fusion gene partners, ETV4 and ETV5, are members of the same ETS 
subfamily as ETV1. Most likely their function is closely related to that of ETV1. ERG is 
member of a different ETS subfamily and might have different properties (40-42). Be-
cause overexpression of both truncated and full length ETS factors has been found, it is 
important to investigate whether both proteins possess the same biological properties 
in prostate cancer. In vitro biological assays showed that both truncated and full length 
ETS factors are able to induce migration and invasion of immortalized, non-tumorigenic 
epithelial prostate cells. However, we also showed that full length ETV1 is capable of 
stimulating anchorage-independent growth in a soft agar assay, whereas dETV1 is not. 
It still needs to be established whether the other full length ETS factors have the same 
properties. Because ETV4 and ETV5 belong to the same ETS subfamily as ETV1 and share 
high homology in their structural domains it is to be expected that similar results will be 
obtained. ERG, on the other hand belongs to a different subfamily. 
In Ewing sarcomas the same ETS genes are found in EWS-ETS fusion genes. In all these 
fusion genes the N-terminal TAD of the ETS factor is replaced by the more potent TAD of 
EWS. At first it was thought that all EWS-ETS fusion proteins would behave similarly as 
aberrant transcription factors. However, it has been shown that there are differences in 
oncogenic potential between the different EWS-ETS fusion proteins (43). Whether there 
are differences in oncogenic potential between the different ETS fusion genes detected 
in prostate cancer needs further research. 
Many ETS target genes have been identified to date, including invasion-associated 
matrix metalloproteinases (MMPs) and uPAR/uPA. Expression analysis of ETS target genes 
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has shown that MMPs and uPAR/uPA indeed are induced by full length ETS, but also by 
N-truncated ETS. However, we have shown a difference in stimulation of genes involved 
in integrin signalling (ITGA3 and ITGAV) (35). Integrins are known to play a role in mul-
tiple processes, including metastasis, survival, proliferation and motility (44). Aberrant 
integrin signalling is thought to be involved in mediating the detachment of tumour 
cells from their neighbouring cells while providing enhanced survival and proliferative 
capabilities. This allows disseminating tumour cells to grow in a new, foreign, microen-
vironment
Thus, full-length ETS factors seem more oncogenic than truncated ETS factors 
in prostate cells (Chapter 7). In Chapter 4 we have shown that overexpression of full 
length ETS factors is detected in late stage AR negative disease, when expression of the 
TMPRSS2-ERG fusion gene is downregulated in these tumours. This indicates a role for 
truncated ETS factors in early stages of prostate cancer and that full length ETS factors 
are more important in late stages of prostate cancer progression. This hypothesis is 
summarized in the model depicted in Figure 2. Overexpression of full length ETS factors 
is also frequently detected in advanced stages and linked to metastasis of other type 
tumours (45, 46).
cHaracteristics of ets fusion Partners
The most common fusion partner of ETS genes in prostate cancer is TMPRSS2. TMPRSS2 
is a prostate-specific and androgen-regulated gene (47). Recently, it has been shown 
that ETV1, ETV4 and ETV5 have, besides TMPRSS2, multiple fusion partners (34, 38, 48, 49) 
(Chapters 6 and 7). Most fusion partners have a prostate-specific and androgen-regulated 
expression pattern. It seems that prostate-specificity is a more important determinant 
Figuur 2
Figure 2. Model of the sequential expression of ETS genes in prostate cancer. The blue box indicates expression from the 
ETS promoter, the orange box a prostate-specific promoter and a hatched blue box ETS or prostate-specific promoter. TAD: 
transactivation domain. ETS: DNA binding domain.
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of the fusion partners than androgen upregulation, because some fusion partners are 
weakly induced by androgens (EST14 and CANT1) or downregulated by androgens 
(C15orf21). Moreover, it is known that many prostate-specific genes are androgen-
regulated, whereas many androgen-regulated genes are not prostate-specific.
Two ETS gene fusion partners, HNRPA2B1 and DDX5, have a ubiquitous expression 
pattern (38, 50, 51). Especially the genomic locus between HNRPA2B1 and the flank-
ing gene, CBX3, is of interest. This locus contains a methylation-free CpG island, which 
encompasses the divergently transcribed promoters of HNRPA2B1 and CBX3 and pos-
sesses a dominant ubiquitously acting chromatin-opening element (52). This results in 
an open chromatin structure and a high and stable expression of the genes, because the 
promoters are resistant to transcriptional silencing. The genomic locus of DDX5 and its 
flanking gene CCDC45 seems structurally similar, containing closely spaced dual diver-
gently transcribed promoters embedded within a large CpG island. Whether, this CpG 
island has the same properties as the HNRPA2B1-CBX3 locus needs to be investigated. 
However, since both DDX5 and CCDC45 are ubiquitously expressed genes, it is tempting 
to speculate that this is the case. 
mecHanism of ets Gene fusion
As stated above, the most important characteristics of the fusion partners of ETS genes 
in prostate cancer are prostate-specificity and androgen-regulation. This common 
expression pattern is suggestive for a similar mechanism of gene fusion. In the last few 
years accumulating evidence has been published that gene transcription is not random 
in the nucleus but that specific nuclear compartments are being formed, the so-called 
transcription factories (53-56). In these specific nuclear compartments genes might be 
expressed that are regulated by the same mechanisms. Possibly, there exist specialized 
prostate-specific, androgen-regulated transcription factories. Recently, it has been 
shown that the fusion partners in Burkitt lymphoma and plasmacytoma, IgH and cMYC, 
are preferentially expressed in the same nuclear regions upon in vitro B cell stimulation 
(57). In line with this observation, ETS transcription factors and the prostate-specific 
genes might also be preferentially expressed in the same nuclear compartments. 
Because ETS fusion genes are detected in 40-70% of prostate cancer samples and in 
~20% of high-grade PIN lesions (58, 59), they most likely occur early in prostate tum-
origenesis and may even be an initiating event. Based on the stem cell/progenitor cell 
concept of tumour development (60, 61), a model for prostate cancer development is 
proposed (Figure 3). 
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In this model, upon differentiation of stem/progenitor cells expression of prostate-
specific genes is induced. This will lead to a more open chromatin structure of these 
genes, which might be more vulnerable to DNA damage. Aberrant repair of the dam-
aged DNA can lead to gene fusions. If these fusions are with ETS genes an important 
step of prostate tumour development is initiated. An important issue in this model that 
remains to be addressed concerns the selection of ETS genes. Why are these genes 
selected as fusion partners? Are ETS genes selectively sensitive for DNA damage during 
certain stages of prostate development (renewal)? Are ETS genes indeed expressed in 
the same nuclear compartments as prostate-specific genes? Is fusion with ETS genes the 
only possibility for tumour development? Why are ETV1, ETV4 and ETV5 (and ERG) the 
fusion partners and not one of the other ETS family members?
Preliminary data obtained from transgenic mouse models indicate that overexpres-
sion of a (truncated) ETS protein is not sufficient for the formation of prostate tumours, 
although precursor stages are induced in some models (36, 38, 39). Additional altera-
tions seem necessary for development of prostate carcinoma. This might also be true 
for human prostate cancer. An important next question that remains to be addressed 
is whether aberrant ETS signalling has preferential co-occurring genetic alterations in 
generation of prostate cancer. 
Figuur 3
Figure 3. Model of formation of fusion genes and their role in prostate cancer development. Blue: prostate-specific gene; 
green: ETS gene. Red dot: transcription factory.
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Summary
Prostate cancer is the most common malignancy in men in countries with a Western 
lifestyle. Our knowledge of the molecular mechanisms underlying prostate cancer 
development and progression has rapidly increased over the past few years, however, 
many questions remain to be addressed. In this thesis the major genetic defects under-
lying prostate cancer development and progression are characterized. 
In Chapter 1 a general introduction on genetic alterations in prostate cancer is given. 
By a genome-wide screen of the DNA of eleven human prostate cancer xenografts ge-
nomic alterations were identified (Chapter 2). The main focus was on the detection and 
characterization of novel homozygous deletions, because these are reliable landmarks 
of tumour suppressor genes. Eleven homozygous deletions were identified in eight 
xenografts, part of these deletions contain genes implicated in tumorigenesis, such as 
PTEN, RB1 and MKK4. Moreover, further structural and functional analysis showed N-COR 
as a novel candidate tumor suppressor gene in prostate cancer.
In Chapter 3, chromosome 10 alterations were studied in more detail in eleven pros-
tate cancer xenografts and four prostate cancer cell lines. We identified five homozygous 
deletions of the tumour suppressor gene PTEN and loss of one PTEN allele and mutation 
of the second allele in four samples. Loss of one copy of PTEN was observed in four 
samples. Loss of one or two copies of PTEN was always accompanied by loss of the distal 
flanking gene FLJ11218 and often by loss of the proximal flanking genes MINPP1, PAPSS2, 
and FLJ14600.
One of the major discoveries in prostate cancer research during the last years was the 
detection of recurrent gene fusions. In Chapter 4, the identification and characterization 
of TMPRSS2-ERG and TMPRSS2-ETV1 fusion genes in prostate cancer xenografts are de-
scribed. TMPRSS2-ERG fusion transcripts were detected in five androgen-dependent xe-
nografts and TMPRSS2-ETV1 fusion transcripts were detected in one androgen-sensitive 
xenograft. TMPRSS2-ERG fusion was the result of an interstitial deletion or translocation 
as shown by array CGH and FISH analysis. Moreover, TMPRSS2-ERG gene fusion was 
detected in three androgen receptor negative xenografts, however, the fusion gene was 
not expressed. Instead overexpression of wild type ETV4, ETV1 or FLI1 was detected.
Transcription of TMPRSS2 can start from two alternative first exons, exon 0 and exon 
1. In Chapter 5, we determined the specific characteristics of transcripts starting at 
either TMPRSS2 exon 0 or TMPRSS2 exon 1. Both transcripts were regulated by andro-
gens. However, TMPRSS2 (exon 0) transcripts were more prostate-specific compared to 
TMPRSS2(exon 1) transcripts. Levels of TMPRSS2(exon1)-ERG transcripts in clinical prostate 
cancer samples were comparable, but TMPRSS2(exon 0)-ERG transcripts were present at 
very variable levels. Expression of TMPRSS2(exon 0)-ERG transcripts was detected in 55% 
of fusion-gene positive primary tumors, but, at a much lower level, in only 15% of fusion-
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gene positive recurrences. In primary tumors, expression of TMPRSS2(exon 0)-ERG was an 
independent predictor of longer biochemical progression-free survival.
Besides the initial discovery of fusion of TMPRSS2 to ETS genes, other fusion-gene 
combinations were discovered. In Chapter 6, the identification and characterization of 
unique novel ETV4 fusion genes, KLK2-ETV4 and CANT1-ETV4, is described. Both fusion 
partners showed androgen-regulated and prostate-specific characteristics. Overexpres-
sion of full length ETV1 and novel ETV1 fusion genes was detected in 10% of clinical pros-
tate cancer samples (Chapter 7). Novel fusion partners identified were FOXP1, a spliced 
EST (EST14) and an endogenous retroviral repeat element (HERVK17). Both EST14 and 
HERVK17 had an androgen-regulated and prostate-specific expression pattern. Further 
functional characterization of full length ETV1 and N-truncated ETV1 (dETV1) protein 
revealed full length ETV1 as a strong transactivator, but dETV1 was not. Moreover, stable 
overexpression in immortalized non-tumorigenic prostate epithelial cells (PNT2C2) 
showed that both full length ETV1 and dETV1 were able to stimulate migration or inva-
sion. However, full length ETV1 was able to induce anchorage-independent growth of 
PNT2C2 cells, whereas dETV1 was not. Furthermore, gene expression analysis showed 
upregulation of target genes involved in invasion/metastasis, like uPa/uPAR and MMPs, 
both by full length ETV1 and dETV1. In contrast, integrin β3 was clearly upregulated by 
full length ETV1, but much less by dETV1.
In Chapter 8 the results described in Chapters 2-7 are discussed in more detail and 
gaps in our knowledge are indicated. Moreover, novel concepts of molecular genetic 
mechanisms of prostate cancer development are proposed and future directions of 
research are suggested.  
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Prostaatkanker is de meest voorkomende vorm van kanker bij mannen in landen met 
een westerse levensstijl. Onze kennis van de moleculaire mechanismen die ten grond-
slag liggen aan de ontwikkeling en progressieve groei van prostaatkanker is sinds de 
laatste paar jaar snel toegenomen, maar er zijn nog vele vragen die beantwoord moeten 
worden. In dit proefschrift zijn de meest belangrijke genetische veranderingen die een 
rol spelen bij prostaatkanker gekarakteriseerd.
In Hoofdstuk 1 wordt een algemene introductie gegeven van de genetische ver-
anderingen die gevonden zijn in prostaatkanker. Door middel van een genoomwijde 
analyse  zijn de veranderingen in het DNA van elf humane prostaatkankers, die gegroeid 
werden op immunodeficiënte muizen (zogenaamde xenografts), bepaald (Hoofdstuk 2). 
De focus was op het identificeren van nieuwe homozygote deleties in het DNA, omdat 
dit betrouwbare herkenningspunten voor tumor suppressor genen zijn. Er werden elf 
homozygote deleties gedetecteerd in acht xenografts, waarvan de meeste genen bevat-
ten waarvan in meer of mindere mate duidelijk is dat ze een rol spelen in tumorigenese, 
zoals PTEN, RB1 en MKK4. Verdere structurele en functionele analyses hebben N-COR als 
een nieuw kandidaat tumor suppressorgen in prostaatkanker geïdentificeerd.
In Hoofdstuk 3, werden veranderingen van chromosoom 10 in meer detail bestudeerd 
in elf prostaatkanker xenografts en in vier prostaatkanker cellijnen. We hebben vijf ho-
mozygote deleties van het tumorsuppressorgen PTEN geïdentificeerd. Verlies van een 
PTEN allel en mutatie van het tweede allel werd in vier monsters gevonden. Verlies van 
één kopie van PTEN in vier monsters gevonden. Verlies van een of twee kopieën van 
PTEN werd altijd gevonden in combinatie met verlies van het distaal flankerende gen 
FLJ11218 en vaak ook met verlies van de proximaal flankerende genen MINPP1, PAPSS2 
en FLJ14600.
Een van de belangrijkste ontdekkingen van het genetisch onderzoek naar prostaat-
kanker van de laatste jaren is de detectie van fusiegenen. In Hoofdstuk 4, wordt de 
identificatie en karakterisering van TMPRSS2-ERG en TMPRSS2-ETV1 fusiegenen in pros-
taatkanker xenografts beschreven. TMPRSS2-ERG fusietranscripten werden gedetecteerd 
in vijf xenografts, waarvan de groei afhankelijk is van androgenen, en TMPRSS2-ETV1 
fusietranscripten werden gevonden in een androgeen-gevoelig xenograft. Fusie van 
TMPRSS2 met ERG is het gevolg van een interstitiële deletie of van een translocatie, zoals 
aangetoond door middel van array CGH en FISH analyse. Bovendien werd TMPRSS2-ERG 
fusie gedetecteerd in drie xenografts, die de androgeenreceptor niet tot expressie 
brachten, maar waarin het fusiegen niet tot expressie kwam. In plaats hiervan werd 
overexpressie van het nornale (wild type) ETV4, ETV1 of FLI1 gedetecteerd.
Transcriptie van TMPRSS2 kan vanaf twee alternatieve eerste exonen, exon 0 en exon 
1, beginnen. In Hoofdstuk 5 werden de specifieke karakteristieken van transcripten 
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beginnend vanaf of TMPRSS2 exon 0 of exon 1 bepaald. Beide transcripten werden gere-
guleerd door androgenen, maar het niveau van expressie van transcripten, die TMPRSS2 
exon 1 bevatten, was veel hoger. TMPRSS2(exon 0) transcripten waren meer prostaat-
specifiek vergeleken met TMPRSS2(exon 1) transcripten. Het niveau van transcripten van 
TMPRSS2(exon 1)-ERG was niet veel verschillend in klinische humane prostaatkanker 
monsters, maar TMPRSS2(exon 0)-ERG transcripten waren aanwezig in sterk variabele 
hoeveelheden. Expressie van TMPRSS2(exon 0)-ERG transcripten werd gedetecteerd in 
55% van de primaire tumoren die het fusiegen bevatten en, met een veel lager expres-
sieniveau, in 15% van de fusiegen positieve terugkerende tumoren, die resistent waren 
geworden tegen de hormonale therapie. Expressie van TMPRSS2(exon 0)-ERG in primaire 
tumoren voorspelde een langere overleving zonder biochemische progressie, onafhan-
kelijk van andere parameters.
Naast de oorspronkelijke ontdekking van TMPRSS2 fusie met ETS genen werden an-
dere fusiegenen gevonden. In Hoofdstuk 6 wordt de identificatie en karakterisering van 
unieke, nieuwe ETV4 fusiegenen, KLK2-ETV4 en CANT1-ETV4, beschreven. Beide fusie-
partners hebben net als TMPRSS2 als eigenschappen dat ze androgeen-gereguleerde en 
prostaatspecifieke tot expressie komen. Overexpressie van  het gehele ETV1 gen of van 
nieuwe ETV1 fusiegenen werd in 10% van klinische prostaatkanker monsters gevonden 
(Hoofdstuk 7). Als nieuwe fusiepartners van ETV1 werden FOXP1, een twee exon EST 
(EST14) en een endogeen retroviraal repeat element (HERVK17) ontdekt. Zowel EST14 
als HERVK17 vertoonden ook een androgeen-gereguleerd en prostaatspecifiek expres-
siepatroon. Verdere functionele karakterisering van het volledige ETV1 eiwit en het 
verkorte  ETV1 (dETV1) eiwit toonde aan dat ETV1 een sterke activator van transcriptie 
was zoals gemeten met een reportergen, terwijl dat niet het geval was voor dETV1. 
Daarnaast liet stabiele overexpressie van het volledige ETV1 eiwit en het verkorte eiwit 
in geïmmortaliseerde niet-tumorigene epitheliale prostaatcellen (PNT2C2) geen verschil 
zien in de stimulering van migratie en invasie. ETV1 was echter in staat om “anchorage” 
onafhankelijke groei van PNT2C2 cellen te stimuleren, terwijl dETV1 dat niet kon. ETS 
doelwitgenen betrokken bij invasieve celgroei en metastase, zoals uPa/uPAR en MMP’s, 
werden gestimuleerd door zowel ETV1 als dETV1. In tegenstelling hiermee werd een 
ander gen betrokken bij deze processen, integrinβ3, duidelijk opgereguleerd door ETV1, 
maar veel minder door dETV1.
In Hoofdstuk 8 worden de resultaten beschreven in hoofdstukken 2 tot en met 7 in 
meer detail bediscussieerd en lacunes in onze huidige kennis aangegeven. Daarnaast 
worden in dit hoofdstuk nieuwe modellen voor moleculaire mechanismen van prostaat-
kanker gepostuleerd en  toekomstige richtingen van onderzoek aangegeven.
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Dankwoord
De laatste loodjes….. het dankwoord. Een promotieonderzoek doe je niet alleen, daarom 
is dit het moment om iedereen te bedanken die hier op wat voor manier dan ook aan 
bijgedragen heeft. Ik wil beginnen met het bedanken van alle patiënten voor het afstaan 
van het weefsel voor onderzoek en natuurlijk alle mensen die er voor zorgen dat dit 
materiaal uiteindelijk ook netjes gedocumenteerd opgeslagen wordt. Want zonder dit 
materiaal kun je geen onderzoek doen. Dan wil ik nu een aantal mensen in het bijzonder 
bedanken.
In de eerste plaats wil ik graag mijn promotor, Prof. Dr. Ir. Jan Trapman bedanken. 
Beste Jan, bedankt voor alles wat je me de laatste 11 jaar geleerd hebt, eerst in de tijd als 
research analist en daarna in mijn tijd als aio. Ik wil je ook erg bedanken voor je inzet om 
mijn proefschrift leescommissie af te krijgen voor mijn vertrek naar Toronto. En ik weet 
heus wel dat ik eigenwijs ben….
Vervolgens wil ik ook Guido Jenster bedanken voor de prettige samenwerking en 
leerzame adviezen. Je overweldigende enthousiasme voor het onderzoek is een grote 
inspiratie.
Daarnaast wil ik natuurlijk alle leden van de leescommissie en grote commissie be-
danken. Bedankt voor jullie interesse in mijn promotieonderzoek en voor al het advies 
en goed raad!
Joris Veltman, Ad Geurts van Kessel en de mensen in het lab in Nijmegen, bedankt dat 
jullie mij de ins en outs van array CGH bijgebracht hebben.
Hetty, bedankt dat je m’n paranimf wilt zijn, ondanks dat je altijd hebt geroepen dat 
je het niet meer doet. Verder, wil ik je enorm bedanken voor je hulp en steun zeker het 
laatste jaar! We waren een goed team.
Delila, tak! We have only been together in the lab for one year, but it was a fun time. 
Thanks for being my ‘paranimf’. Good luck and I know you can do it!
Ook wil ik Angelique even noemen, na de 11 jaar die we samen in het lab ‘rondgehan-
gen’ hebben. Bedankt voor de hulp en gezelligheid! Verder wil ik alle mensen van lab 
Be320, die ik door de jaren heen heb zien komen en gaan, bedanken voor alle hulp en 
gezelligheid.
Dan wil ik iedereen van het JNI bedanken. Bij veel van jullie ben ik wel eens langs 
geweest voor advies, hulp, of om iets te lenen/gebruiken. Dit geldt zelfs voor een aantal 
mensen uit de ‘hoogbouw’. Waar zou ik zijn zonder jullie! Bedankt!
Ik wil mijn ‘treinmaatjes’ bedanken voor de gezellige treinritjes naar Rotterdam elke 
ochtend, geen tijd voor een ochtendhumeur. Helaas, geen treinritjes meer hier in 
Toronto...., maar een wandeling van vijf minuten naar het werk heeft ook z’n voordelen.
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Vervolgens wil ik ook mijn familie en vrienden bedanken voor hun interesse in mijn 
promotieonderzoek. Hoewel, het meestal nogal moeilijk te begrijpen was wat ik nu 
precies deed. Ik hoop dat het nu jullie mijn boekje hebben, wat duidelijker is.
Tot slot wil ik mijn ouders en zusje in het bijzonder bedanken. Bedankt voor jullie 
steun en vertrouwen in mij. Ik weet dat Canada ver weg is, maar het is niet het eind van 
de wereld. En tot nu toe geniet ik met volle teugen van mijn nieuwe avontuur hier in 
Toronto!
Dus voor de laatste keer BEDANKT iedereen!!!!!
-x- Karin
